

CITATION REPORT

List of articles citing

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States

DOI: 10.1158/0008-5472.can-14-0155
Cancer Research, 2014, 74, 2913-21.

Source: <https://exaly.com/paper-pdf/57691121/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2226	Sociodemographic trends in the incidence of pancreatic and biliary tract cancer in UK primary care. 2014 , 9, e108498		6
2225	Standardized Thyroid Cancer Mortality in Korea between 1985 and 2010. 2014 , 29, 530-5		32
2224	CD109 Overexpression in Pancreatic Cancer Identified by Cell-Surface Glycoprotein Capture. 2014 , Suppl 10, S10003		9
2223	Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. <i>Cancer Research</i> , 2014 , 74, 2913-21	10.1	3795
2222	Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen. 2014 , 5, e62		22
2221	Upgrading gemcitabine with recycled kinase inhibitors. 2014 , 13, 2810-1		1
2220	Desmoplasia and chemoresistance in pancreatic cancer. 2014 , 6, 2137-54		85
2219	Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells. 2014 , 5, 357		43
2218	MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors. 2014 , 106,		4
2217	Correction: Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. <i>Cancer Research</i> , 2014 , 74, 4006-4006	10.1	8
2216	Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma. 2014 , 13, 4878-88		31
2215	Protein breakdown precedes pancreatic tumor development. 2014 , 20, 1097-9		5
2214	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. 2014 , 120, 3627-34		379
2213	Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. 2014 , 159, 80-93		650
2212	Risk determination and prevention of breast cancer. 2014 , 16, 446		180
2211	Pancreatic cancer stroma: friend or foe?. 2014 , 25, 711-2		134
2210	Integration and comparison of different genomic data for outcome prediction in cancer. 2015 , 8, 32		10

2209	Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression. 2015 , 17, 770-6	21
2208	Training the next generation of hepatologist: What will they need to know?. 2015 , 5, 129-131	6
2207	Significance of what is not sampled: Characteristics of thyroid nonmicrocarcinomas (>1.0 cm) that were not targeted. 2015 , 123, 678-83	1
2206	Constructing a molecular interaction network for thyroid cancer via large-scale text mining of gene and pathway events. 2015 , 9 Suppl 6, S5	8
2205	Internet-based physical activity intervention for women with a family history of breast cancer. 2015 , 34S, 1296-304	14
2204	Pancreatic Cancer: Progress in Systemic Therapy. 2014 , 1, 167-79	7
2203	Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies. 2015 , e52801	12
2202	Health Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care?. 2015 , 221, 1015-22	38
2201	[Metastasis of pancreatic tumors]. 2015 , 36 Suppl 2, 176-80	
2200	The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells. 2015 , 14, 203	80
2199	Therapie des metastasierten Pankreaskarzinoms. 2015 , 21, 1044-1053	
2198	The Clinical Relevance of Psammoma Body and Hashimoto Thyroiditis in Papillary Thyroid Carcinoma: A Large Case-control Study. 2015 , 94, e1881	13
2197	Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research. 2015 , 8 Suppl 2, S5	44
2196	The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. 2015 , 15, 783	33
2195	Patient experiences living with pancreatic cancer risk. 2015 , 13, 13	10
2194	Targeting c-Met in Cancer by MicroRNAs: Potential Therapeutic Applications in Hepatocellular Carcinoma. 2015 , 76, 357-67	17
2193	Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrences in orthotopic xenograft models of pancreatic cancer. 2015 , 137, 1035-46	74
2192	Early detection of sporadic pancreatic cancer: strategic map for innovation--a white paper. 2015 , 44, 686-92	30

2191	Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. 2015 , 112, 66-71	2
2190	External assessment of the Early Mortality Risk Score in patients with adenocarcinoma undergoing pancreaticoduodenectomy. 2015 , 17, 605-10	3
2189	Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study. 2015 , 44, 1259-65	29
2188	Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. 2016 , 9, 75-86	4
2187	Pancreatic cancer: gradual rise, increasing relevance. 2015 , 202, 401-2	4
2186	Hepatocellular carcinoma ablation and possible immunity in the age of nanosecond pulsed electric fields. 2015 , 2, 49-55	
2185	Chronic Liver Disease and the Detection of Hepatocellular Carcinoma by [(18)F]fluorocholine PET/CT. 2015 , 5, 189-99	11
2184	Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. 2015 , 9, 1561-72	8
2183	Molecular Mechanisms by Which a Fucus vesiculosus Extract Mediates Cell Cycle Inhibition and Cell Death in Pancreatic Cancer Cells. 2015 , 13, 4470-91	20
2182	Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer. 2015 , 2, 10	14
2181	2014 Publications of the Baylor Health Care System Medical and Scientific Staff. 2015 , 28, 266-285	
2180	Dual role of cAMP in the transcriptional regulation of multidrug resistance-associated protein 4 (MRP4) in pancreatic adenocarcinoma cell lines. 2015 , 10, e0120651	15
2179	Body Mass Index Genetic Risk Score and Endometrial Cancer Risk. 2015 , 10, e0143256	8
2178	Update on the management of pancreatic cancer: surgery is not enough. 2015 , 21, 3157-65	111
2177	Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. 2015 , 7, 833-42	19
2176	A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma. 2015 , 2015, 587250	20
2175	TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. 2015 , 6, 7504-21	36
2174	Pancreatic cancer vaccine: a unique potential therapy. 2015 , 1	

2173	Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract. 2015 , 13, 115			48
2172	A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. 2015 , 46, 201-11			143
2171	Maximal stiffness evaluation by real-time ultrasound elastography, an improved tool for the differential diagnosis of thyroid nodules. 2015 , 21, 474-81			8
2170	Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer. 2015 , 22, 593-607			41
2169	Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. 2015 , 29, 717-26			6
2168	Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. 2015 , 185, 1297-303			75
2167	INPP4B Is a PtdIns(3,4,5)P3 Phosphatase That Can Act as a Tumor Suppressor. 2015 , 5, 730-9			60
2166	Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer. <i>Cancer Research</i> , 2015 , 75, 2629-40	10.1		90
2165	The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. 2015 , 64, 1936-48			100
2164	Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancer. 2015 , 132, 138-45			71
2163	Anaplastic thyroid cancer – an overview of genetic variations and treatment modalities. 2015 , 43			4
2162	Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma. 2015 , 11			4
2161	Diagnostik bei Pankreas- und Cholangiokarzinomen. 2015 , 21, 1019-1031			
2160	Multimodal imaging of harmonophores and application of high content imaging for early cancer detection. 2015 , 1, 10-20			4
2159	Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. 2015 , 4, 1224-39			12
2158	Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction. 2015 , 21, 299-306			55
2157	microRNA: Cancer. 2015 ,			1
2156	Identification of genetic risk for pancreatic adenocarcinoma. 2015 , 208, 559-63			2

2155	Iodine intake as a risk factor for thyroid cancer: a comprehensive review of animal and human studies. 2015 , 8, 8	118
2154	MYB is a novel regulator of pancreatic tumour growth and metastasis. 2015 , 113, 1694-703	35
2153	Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy. 2015 , 889, 71-87	36
2152	Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. 2015 , 158, 1545-55	30
2151	Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. 2015 , 112, 15850-5	71
2150	Le point sur hENT1, autres biomarqueurs. 2015 , 17, 528-534	
2149	Cancers du pancréas : articulation entre la recherche fondamentale et la recherche clinique. 2015 , 17, 541-544	
2148	Organoid models of human and mouse ductal pancreatic cancer. 2015 , 160, 324-38	1072
2147	Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). 2015 , 26, 287-296	31
2146	Pancreatic cancer-associated diabetes is an "exosomopathy". 2015 , 21, 1508-10	18
2145	Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. 2015 , 358, 59-66	37
2144	ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis. 2015 , 29, 171-83	48
2143	The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. 2015 , 34, 97-114	51
2142	Expression of vitamin D receptor as a potential prognostic factor and therapeutic target in pancreatic cancer. 2015 , 67, 386-97	22
2141	Pancreatic cancer genomics: where can the science take us?. 2015 , 88, 213-9	10
2140	Biomarkers for early diagnosis of pancreatic cancer. 2015 , 9, 305-15	29
2139	Multireader evaluation of lesion conspicuity in small pancreatic adenocarcinomas: complimentary value of iodine material density and low keV simulated monoenergetic images using multiphasic rapid kVp-switching dual energy CT. 2015 , 40, 1230-40	64
2138	Long-term Survival After Pancreatic Cancer: Hope Has Arrived. 2015 , 150, 710-1	1

2137	Bioorthogonal labeling cell-surface proteins expressed in pancreatic cancer cells to identify potential diagnostic/therapeutic biomarkers. 2015 , 16, 1557-65	18
2136	Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial. 2015 , 51, 1546-54	35
2135	Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. 2015 , 21, 3512-21	120
2134	Diagnosis: A step closer to screening for curable pancreatic cancer?. 2015 , 12, 431-2	7
2133	Epidemiology and Inherited Predisposition for Sporadic Pancreatic Adenocarcinoma. 2015 , 29, 619-40	24
2132	Mouse Models of Pancreatic Ductal Adenocarcinoma. 2015 , 29, 609-17	7
2131	Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. 2015 , 8, 196-203	21
2130	Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma. 2015 , 14, 2798-809	13
2129	Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. 2015 , 29, 761-76	8
2128	Gremlin is a key pro-fibrogenic factor in chronic pancreatitis. 2015 , 93, 1085-1093	29
2127	[Pancreatic adenocarcinoma: 10 years of progress]. 2015 , 102, S62-71	1
2126	Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. 2015 , 214, 76-84	44
2125	Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer. 2015 , 110, 1233-9	36
2124	Molecular biology: Salvaging the genome. 2015 , 524, 40-1	2
2123	Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. 2015 , 16, 6677-93	131
2122	Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. 2015 , 29, 1576-85	154
2121	Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. <i>Cancer Research</i> , 2015 , 75, 3355-64	10.1 106
2120	Pathophysiological role of microRNA-29 in pancreatic cancer stroma. 2015 , 5, 11450	47

2119	KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. 2015 , 13, 963-9.e4	59
2118	Approach to patients with pancreatic cancer without detectable metastases. 2015 , 33, 1770-8	101
2117	Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. 2015 , 33, 1779-86	57
2116	Cancer vaccines. 2015 , 350, h988	156
2115	Dietary phenolics against colorectal cancer--From promising preclinical results to poor translation into clinical trials: Pitfalls and future needs. 2015 , 59, 1274-91	65
2114	A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. 2015 , 141, 1653-60	15
2113	Improving both aqueous solubility and anti-cancer activity by assessing progressive lead optimization libraries. 2015 , 25, 1971-5	6
2112	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. 2015 , 3, 399-411	289
2111	The role of SPARC expression in pancreatic cancer progression and patient survival. 2015 , 50, 1170-4	33
2110	Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. 2015 , 275, 177-87	24
2109	Risk-stratified screening for detection of melanoma. 2015 , 313, 616-7	9
2108	Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells. 2015 , 14, 1395-403	37
2107	Distribution of cholecystokinin-B receptor genotype between patients with pancreatic cancer and controls and its impact on survival. 2015 , 44, 236-42	8
2106	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. 2015 , 12, 319-34	404
2105	The changing epidemiology of thyroid cancer: why is incidence increasing?. 2015 , 27, 1-7	174
2104	Optimal differentiated thyroid cancer management in the elderly. 2015 , 32, 283-94	8
2103	Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer. 2015 , 13, 1509-19	31
2102	[Neoadjuvant therapy may allow unresectable tumors becoming resectable]. 2015 , 102, S113-6	2

2101	⌘Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy. 2015 , 12, 3999-4010	30
2100	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. 2015 , 21, 1163-71	275
2099	Periductal stromal collagen topology of pancreatic ductal adenocarcinoma differs from that of normal and chronic pancreatitis. 2015 , 28, 1470-80	78
2098	Radioimmunotherapy--a potential novel tool for pancreatic cancer therapy?. 2015 , 36, 4053-62	9
2097	Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation. 2015 , 33, 2893-902	26
2096	Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer. 2015 , 64, 1553-63	19
2095	Pancreatic cancer: Classifying pancreatic cancer using gene expression profiling. 2015 , 12, 613-4	6
2094	Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. 2015 , 14, 269-76.e1	17
2093	Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole. 2015 , 113, 864-71	45
2092	A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. 2015 , 8, 1201-11	11
2091	Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. 2015 , 22 Suppl 3, S1212-20	61
2090	[Therapy in pancreatic cancer - and still it moves along!]. 2015 , 140, 508-11	2
2089	Initial Misdiagnosis of Proximal Pancreatic Adenocarcinoma Is Associated with Delay in Diagnosis and Advanced Stage at Presentation. 2015 , 19, 1813-21	12
2088	Cancer Genetics and Implications for Clinical Management. 2015 , 95, 919-34	5
2087	Dual Energy CT in Oncology. 2015 ,	5
2086	The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women. 2015 , 24, 1407-15	114
2085	Radiographic Sarcopenia and Self-reported Exhaustion Independently Predict NSQIP Serious Complications After Pancreaticoduodenectomy in Older Adults. 2015 , 22, 3897-904	38
2084	The 8q24 rs6983267G variant is associated with increased thyroid cancer risk. 2015 , 22, 841-9	14

2083	State of the art and future directions of pancreatic ductal adenocarcinoma therapy. 2015 , 155, 80-104	66
2082	MYC/PGC-1 β Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. 2015 , 22, 590-605	423
2081	Hereditary Pancreatic Cancer Syndromes. 2015 , 24, 733-64	23
2080	Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. 2015 , 15, 1525-9	21
2079	Vitamin D and pancreatic cancer. 2015 , 368, 1-6	21
2078	Thyroid cancer mortality and incidence: a global overview. 2015 , 136, 2187-95	563
2077	Multi-target stool DNA test: a new high bar for noninvasive screening. 2015 , 60, 623-33	44
2076	BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. 2015 , 17, 569-77	175
2075	Restoration of Brain Acid Soluble Protein 1 Inhibits Proliferation and Migration of Thyroid Cancer Cells. 2016 , 129, 1439-46	15
2074	Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by Hras and Pten Loss. 2016 , 7,	9
2073	ADVANCES IN TUMOR MARKERS FOR THE EARLY DIAGNOSIS OF PAPILLARY THYROID CARCINOMA. 2016 , 8, 47	3
2072	SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells. 2016 , 7, 34890-906	18
2071	Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. 2016 , 9, 4681-6	7
2070	Next-generation sequence detects as a novel oncogene in papillary thyroid carcinoma. 2016 , 9, 7161-7167	7
2069	Current Role of Proteomics in Pancreatic Cancer Biomarkers Research. 2016 , 13, 68-75	4
2068	Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. 2016 , 11, 1225-35	23
2067	Biomarkers in pancreatic adenocarcinoma: current perspectives. 2016 , 9, 7459-7467	49
2066	Thyroid Cancer and Tumor Collaborative Registry (TCCR). 2016 , 15, 73-9	3

2065	Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer. 2016 , 7, 51840-51853	28
2064	Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma. 2016 , 7, 81110-81122	45
2063	Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol. 2016 , 6, e010491	6
2062	Pancreatic Cancer Genetics. 2016 , 12, 314-25	73
2061	Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer. 2016 , 11, 376-383	0
2060	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. 2016 , 7, 66328-66343	66
2059	The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. 2016 , 7, 48265-48279	79
2058	Is There Efficacy Beyond Cytotoxic Chemotherapy for Pancreatic Cancer?. 2016 , 12, 806-7	
2057	Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. 2016 , 7, 52993-53004	28
2056	The Past, Present, and Future of Pancreatic Cancer Clinical Trials. 2016 , 35, e205-15	16
2055	Clinical outcomes of pancreaticoduodenectomy in octogenarians: a surgeon's experience from 2007 to 2015. 2016 , 7, 540-6	7
2054	Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer. 2016 , 7, 547-55	35
2053	Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?. 2016 , 7, 738-749	11
2052	Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. 2016 , 11, 155-162	7
2051	Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. 2016 , 1,	79
2050	Frequency and Significance of Abnormal Pancreatic Imaging in Patients with BRCA1 and BRCA2 Genetic Mutations. 2016 , 2016, 5619358	3
2049	Pancreatic Cancer: 80 Years of Surgery-Percentage and Repetitions. 2016 , 2016, 6839687	12
2048	MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer. 2016 , 12, 326-37	59

2047	Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma. 2016 , 6, 1393-402	24
2046	Autophagy Induced during Pancreatitis Promotes -Dependent Transformation in the Pancreas. 2016 , 6, 226	6
2045	Chromatin Remodeling and Epigenetic Reprogramming in Chronic Disease and Cancer in the Liver and Pancreas. 2016 , 365-385	1
2044	KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. 2016 , 8,	106
2043	The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies. 2016 , 12, 283-91	36
2042	The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. 2016 , 12, 273-82	70
2041	Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. 2016 , 7, 85785-85797	76
2040	Metastatic Pancreatic Adenocarcinoma After Total Pancreatectomy Islet Autotransplantation for Chronic Pancreatitis. 2016 , 16, 2747-52	17
2039	Endometrial cancer: Not your grandmother's cancer. 2016 , 122, 2787-98	90
2038	Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. 2016 , 114, 451-5	8
2037	Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma. 2016 , 103, 1200-8	16
2036	Early pancreatic carcinogenesis - risk factors, early symptoms, and the impact of antidiabetic drugs. 2016 , 28, e19-25	3
2035	Robust Early Inflammation of the Peripancreatic Visceral Adipose Tissue During Diet-Induced Obesity in the KrasG12D Model of Pancreatic Cancer. 2016 , 45, 458-65	34
2034	Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. 2016 , 122, 1757-65	166
2033	Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence. 2016 , 151, 234-7	4
2032	LncRNA UCA1-miR-507-FOXM1 axis is involved in cell proliferation, invasion and G0/G1 cell cycle arrest in melanoma. 2016 , 33, 88	71
2031	Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma. 2016 , 64, 828-42	18
2030	Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group. 2016 , 45, 601-5	17

2029	Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study. 2016 , 16, 873-81	10
2028	Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening. 2016 , 45, 1062-6	19
2027	Stage scoring of liver fibrosis using Mueller matrix microscope. 2016 ,	2
2026	Familial Pancreatic Cancer. 2016 , 1-20	
2025	Laparoscopic Staging in Patients with Newly Diagnosed Pancreatic Cancer. 2016 , 1-17	
2024	Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. 2016 , 94, 222-229	15
2023	New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. 2016 , 3, 14	86
2022	Epidemiology and Prospects for Prevention of Pancreatic Cancer 2nd ed. 2016 , 1-16	
2021	Targeting Cancer Stem Cells by Functional Foods and Their Constituents. 2016 , 433-460	1
2020	Measles virus selectively blind to signaling lymphocyte activity molecule has oncolytic efficacy against nectin-4-expressing pancreatic cancer cells. 2016 , 107, 1647-1652	19
2019	The micropapillary/hobnail variant of papillary thyroid carcinoma: A review of series described in the literature compared to a series from one southern Italy pathology institution. 2016 , 17, 521-527	27
2018	A panel of four genes accurately differentiates benign from malignant thyroid nodules. 2016 , 35, 169	23
2017	Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinoma. 2016 , 12, 4961-4968	4
2016	Esculetin induces antiproliferative and apoptotic response in pancreatic cancer cells by directly binding to KEAP1. 2016 , 15, 64	44
2015	Surveillance for neoplasia in the pancreas. 2016 , 30, 971-986	16
2014	Chemoradiation of pancreatic carcinoma. 2016 , 2, 43-47	
2013	PATZ1 is a target of miR-29b that is induced by Ha-Ras oncogene in rat thyroid cells. 2016 , 6, 25268	9
2012	Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer. 2016 , 16, 37	17

2011	Breast parenchymal patterns in processed versus raw digital mammograms: A large population study toward assessing differences in quantitative measures across image representations. 2016 , 43, 5862	20
2010	Utility of 18 Fludeoxyglucose in Preoperative Positron-Emission Tomography-Computed Tomography (PET-CT) in the Early Diagnosis of Exocrine Pancreatic Cancer: A Study of 139 Resected Cases. 2016 , 94, 511-517	1
2009	Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. 2016 , 1, 226-237	181
2008	Delineating the Role of β -Tubulins in Pancreatic Cancer: β -Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. 2016 , 18, 753-764	13
2007	PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. 2016 , 30, 2669-2683	62
2006	Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model. 2016 , 29, 366-372	3
2005	The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. 2016 , 18, 339-47	5
2004	Modeling pancreatic cancer with organoids. 2016 , 2, 176-190	134
2003	Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. 2016 , 114, 737-43	124
2002	Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis. 2016 , 101, 108-120	22
2001	A novel small-molecule YLT256 inhibits proliferation and induces apoptosis both in vitro and in vivo in solid tumors. 2016 , 81, 482-490	1
2000	A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer. 2016 , 16, 640-5	28
1999	Standardization of surgical care in a high-volume center improves survival in resected pancreatic head cancer. 2016 , 212, 195-201.e1	16
1998	Pancreatic cancer. 2016 , 34, 282-291	5
1997	Experiences with a low-iodine diet: A qualitative study of patients with thyroid cancer receiving radioactive iodine therapy. 2016 , 23, 43-50	7
1996	The ever-changing landscape of pancreatic cancer stem cells. 2016 , 16, 489-96	17
1995	Lin28 and let-7: roles and regulation in liver diseases. 2016 , 310, G757-65	19
1994	Dietary total antioxidant capacity and pancreatic cancer risk: an Italian case-control study. 2016 , 115, 102-7	20

1993	Volume-outcome relationships in pancreatoduodenectomy for cancer. 2016 , 18, 317-24	85
1992	Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown. 2016 , 18, 265-272	25
1991	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. 2016 , 25, 1185-91	22
1990	Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. 2016 , 34, 1787-94	241
1989	Downregulation of B7-H4 in the MHCC97-H hepatocellular carcinoma cell line by arsenic trioxide. 2016 , 13, 2032-8	8
1988	Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. 2016 , 142, 1353-60	30
1987	Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. 2016 , 33, 37	1
1986	Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. 2016 , 16, 593-8	46
1985	Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. 2016 , 160, 136-144	74
1984	Surgical Oncology Manual. 2016 ,	
1983	[Resection for advanced pancreatic cancer following multimodal therapy]. 2016 , 87, 406-12	
1982	Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer. 2016 , 17, 1413-20	15
1981	Adenocarcinoma of the Pancreas. 2016 , 251-266	
1980	Transcriptome Analysis of Piperlongumine-Treated Human Pancreatic Cancer Cells Reveals Involvement of Oxidative Stress and Endoplasmic Reticulum Stress Pathways. 2016 , 19, 578-85	17
1979	Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. 2016 , 186, 1537-46	23
1978	A Review of Scientific Topics and Literature in Abdominal Radiology in Germany--Part 2: Abdominal Parenchymal Organs. 2016 , 188, 245-52	1
1977	Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy. 2016 , 44, 856-65	39
1976	Hepatocellular Carcinoma and Viral Hepatitis in New York City. 2016 , 63, 1577-1583	11

1975	Functional characterization of a chr13q22.1 pancreatic cancer risk locus reveals long-range interaction and allele-specific effects on DIS3 expression. 2016 , 25, 4726-4738	17
1974	The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes Kras(G12D)-mediated pancreatic cancer initiation. 2016 , 7, e2295	20
1973	TGF- β -induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. 2016 , 37, 1041-1051	48
1972	Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. 2016 , 209, 567-581	26
1971	Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions. 2016 , 143, 287-293	50
1970	Utility of 18 fludeoxyglucose in preoperative positon-emission tomography-computed tomography (PET-CT) in the early diagnosis of exocrine pancreatic cancer: A study of 139 resected cases. 2016 , 94, 511-517	2
1969	Watson for Genomics: Moving Personalized Medicine Forward. 2016 , 2, 392-395	12
1968	Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. 2016 , 115, 188-94	52
1967	Global profiling of alternative RNA splicing events provides insights into molecular differences between various types of hepatocellular carcinoma. 2016 , 17, 683	28
1966	Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. 2016 , 23, T57-67	12
1965	Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. 2016 , 97, 1225-1232	24
1964	Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. 2016 , 9, 539-545	3
1963	Cancer du pancr�s et traitement n�adjuvant : Valuation de la r�ponse en imagerie. 2016 , 97, 501-508	
1962	Pancreatic Cytopathology. 2016 , 9, 661-676	6
1961	In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5-MYC Axis. 2016 , 2, 391-392	2
1960	Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer. 2016 , 122, 3175-3182	30
1959	Familial pancreatic cancer. 2016 , 43, 548-553	71
1958	The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma. <i>Cancer Research</i> , 2016 , 76, 5092-102	10.1 27

1957	Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer. 2016 , 26, 320-37	15
1956	Modelling of pancreatic ductal adenocarcinoma in vitro with three-dimensional microstructured hydrogels. 2016 , 6, 54226-54235	24
1955	Locally advanced pancreatic duct adenocarcinoma: pancreatectomy with planned arterial resection based on axial arterial encasement. 2016 , 401, 1131-1142	20
1954	Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. 2016 , 1866, 163-176	20
1953	Hepatocellular Carcinoma as a Paradigm for a Systemic Evolutionary Approach to Cancer. 2016 , 157-161	1
1952	The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. 2016 , 115, 887-94	31
1951	Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database. 2016 , 160, 1080-1096	56
1950	Pancreatic cancer tissue banks: where are we heading?. 2016 , 12, 2661-2663	7
1949	Molecular Detection of Gastrointestinal Neoplasia: Innovations in Early Detection and Screening. 2016 , 45, 529-42	8
1948	Pancreatic carcinoma: Key-points from diagnosis to treatment. 2016 , 97, 1207-1223	19
1947	Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. 2016 , 113, E5328-36	140
1946	Why is pancreatic adenocarcinoma not screened for earlier?. 2016 , 16, 1003-4	3
1945	A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies. 2016 , 14, 57	30
1944	Pigment Epithelium-derived Factor (PEDF) Blocks Wnt3a Protein-induced Autophagy in Pancreatic Intraepithelial Neoplasms. 2016 , 291, 22074-22085	8
1943	Tbx3 fosters pancreatic cancer growth by increased angiogenesis and activin/nodal-dependent induction of stemness. 2016 , 17, 367-378	19
1942	Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. 2016 , 5, 2649-56	106
1941	Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition. 2016 , 15, 4476-4489	13
1940	Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. 2016 , 1866, 177-188	15

1939 L  dibocarcinome du pancr  s: du diagnostic au traitement. **2016**, 97, 483-500

1938 Prognostic value of occult tumor cells obtained by peritoneal lavage in patients with resectable pancreatic cancer and no ascites: A systematic review. **2016**, 114, 743-751 9

1937 Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?. **2016**, 114, 587-596 29

1936 Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. **2016**, 143, 46-53 94

1935 Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. **2016**, 22, 5992-6001 25

1934 A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. **2016**, 34, 733-739 20

1933 ZNRF3 is downregulated in papillary thyroid carcinoma and suppresses the proliferation and invasion of papillary thyroid cancer cells. **2016**, 37, 12665-12672 12

1932 A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer. **2016**, 78, 541-5 15

1931 Concepts to Target MYC in Pancreatic Cancer. **2016**, 15, 1792-8 54

1930 mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. *Cancer Research*, **2016**, 76, 6911-6923 10.1 49

1929 Paternal programming of breast cancer risk in daughters in a rat model: opposing effects of animal- and plant-based high-fat diets. **2016**, 18, 71 29

1928 Endoscopic Evaluation in the Workup of Pancreatic Cancer. **2016**, 96, 1257-1270 8

1927 Management of Metastatic Pancreatic Adenocarcinoma. **2016**, 96, 1391-1414 9

1926 Genetics of Pancreatic Cancer and Its Implications on Therapy. **2016**, 96, 1207-1221 9

1925 Assessment of different 3D culture systems to study tumor phenotype and chemosensitivity in pancreatic ductal adenocarcinoma. **2016**, 49, 243-52 10

1924 Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. *Cancer Research*, **2016**, 76, 7049-7058 10.1 27

1923 Necroptosis DAMPs anti-tumor immunity. **2016**, 2, 16033 1

1922 Inhibition of NF-kappa B pathway leads to deregulation of epithelial-mesenchymal transition and neural invasion in pancreatic cancer. **2016**, 96, 1268-1278 41

1921	Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. 2016 , 6, 33535	50
1920	Stiffness of pancreatic cancer cells is associated with increased invasive potential. 2016 , 8, 1232-1245	59
1919	Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. 2016 , 4, 33	9
1918	Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer. 2016 , 144, 277-320	6
1917	Human pancreatic stellate cells modulate 3D collagen alignment to promote the migration of pancreatic ductal adenocarcinoma cells. 2016 , 18, 105	27
1916	CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma. 2016 , 4, 968-982	129
1915	Pancreatic cancer. 2016 , 2, 16022	838
1914	Molecular Pathogenesis of Pancreatic Cancer. 2016 , 144, 241-275	48
1913	The Impact of Obesity on Gallstone Disease, Acute Pancreatitis, and Pancreatic Cancer. 2016 , 45, 625-637	21
1912	Systemic Therapy in Pancreatic Cancer. 2016 , 247-273	1
1911	Systemic Therapy for Metastatic Colorectal Cancer. 2016 , 275-338	
1910	Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. 2016 , 115, 1520-1529	14
1909	Association between screening and the thyroid cancer "epidemic" in South Korea: evidence from a nationwide study. 2016 , 355, i5745	103
1908	Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence. 2016 , 354, i3839	16
1907	Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma. 2016 , 95, e4006	1
1906	The confused oncologic patient: a rational clinical approach. 2016 , 29, 789-796	7
1905	New insights in the development of pancreatic cancer. 2016 , 32, 394-400	11
1904	Masitinib plus gemcitabine for personalized treatment of PDAC patients with overexpression of ACOX1. 2016 , 1, 479-485	

1903	The association between regular use of aspirin and the prevalence of prostate cancer: Results from the National Health Interview Survey. 2016 , 95, e3909	4
1902	Inpatient Burden of Pancreatic Cancer in the United States: An Analysis of National Trends in the United States From 1997 to 2012. 2016 , 45, e41-2	3
1901	Early Detection of Pancreatic Cancer-a Defined Future Using Lessons From Other Cancers: A White Paper. 2016 , 45, 1073-9	31
1900	Impact of delay between imaging and treatment in patients with potentially curable pancreatic cancer. 2016 , 103, 267-75	46
1899	Using a Delphi process to determine optimal care for patients with pancreatic cancer. 2016 , 12, 105-14	7
1898	FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. 2016 , 16, 24	33
1897	Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review. 2016 , 2, 1209-16	42
1896	Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked. 2016 , 380, 31-8	42
1895	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 2016 , 34, 2784-96	205
1894	Predicting the Risk of Melanoma. 2016 , 152, 875-7	3
1893	MYB Promotes Desmoplasia in Pancreatic Cancer through Direct Transcriptional Up-regulation and Cooperative Action of Sonic Hedgehog and Adrenomedullin. 2016 , 291, 16263-70	14
1892	Occupation and Thyroid Cancer: A Population-Based, Case-Control Study in Connecticut. 2016 , 58, 299-305	17
1891	Development of Pancreatic Cancer: Targets for Early Detection and Treatment. 2016 , 34, 525-31	4
1890	Mueller matrix microscope: a quantitative tool to facilitate detections and fibrosis scorings of liver cirrhosis and cancer tissues. 2016 , 21, 71112	72
1889	Surgical and molecular pathology of pancreatic neoplasms. 2016 , 11, 47	74
1888	CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer. 2016 , 20, 1331-42	32
1887	Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 2016 , 34, 2654-68	218
1886	A systemic evolutionary approach to cancer: Hepatocarcinogenesis as a paradigm. 2016 , 93, 132-7	8

1885	The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF- β mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF- β . 2016 , 16, 155	15
1884	A microRNA biomarker of hepatocellular carcinoma recurrence following liver transplantation accounting for within-patient heterogeneity. 2016 , 9, 18	14
1883	From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. 2016 , 4, 14	73
1882	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 2016 , 34, 2541-56	223
1881	The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology. 2016 , 12, 339-83	93
1880	Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death. 2016 , 5, e233	11
1879	Global Trends in Pancreatic Cancer Mortality From 1980 Through 2013 and Predictions for 2017. 2016 , 14, 1452-1462.e4	67
1878	DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster. <i>Cancer Research</i> , 2016 , 76, 4546-58	10.1 74
1877	Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. 2016 , 114, 1367-75	88
1876	Aberrant lymphatic drainage and risk for melanoma recurrence after negative sentinel node biopsy in middle-aged and older men. 2016 , 38 Suppl 1, E754-60	13
1875	IL-32 has differential effects on proliferation and apoptosis of human melanoma cell lines. 2016 , 113, 364-9	13
1874	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. 2016 , 166, 9-29	22
1873	Pancreatic cancer: yesterday, today and tomorrow. 2016 , 12, 1929-46	167
1872	Early Detection and Treatment Opportunities in Pancreatic Adenocarcinoma. 2016 , 12, 31-2	
1871	The HABP2 G534E variant is an unlikely cause of familial non-medullary thyroid cancer. 2016 , 10, 1098-1103	31
1870	Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss. <i>Cancer Research</i> , 2016 , 76, 1804-13	10.1 62
1869	Pancreatic cancer. 2016 , 388, 73-85	1325
1868	Changing the course of pancreatic cancer--Focus on recent translational advances. 2016 , 44, 17-25	19

1867	Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. 2016 , 22, 2848-54	223
1866	Obesity and Cancer: The Oil that Feeds the Flame. 2016 , 23, 48-62	232
1865	Pancreatic cancer in 2015: Precision medicine in pancreatic cancer--fact or fiction?. 2016 , 13, 74-5	17
1864	Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. 2016 , 114, 269-80	66
1863	Trends in early-stage hepatocellular carcinoma, California 1988-2010. 2016 , 27, 325-31	3
1862	Cancer prevention as part of precision medicine: 'plenty to be done'. 2016 , 37, 2-9	71
1861	p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling. 2016 , 370, 260-7	50
1860	Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. 2016 , 8, 449-60	51
1859	Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer. 2016 , 13, 1822-32	19
1858	The 'SPARC' of life: Analysis of the role of osteonectin/SPARC in pancreatic cancer (Review). 2016 , 48, 1765-71	15
1857	Preclinical models of pancreatic ductal adenocarcinoma. 2016 , 238, 197-204	71
1856	Molecular and Genetic Basis of Pancreatic Carcinogenesis: Which Concepts May be Clinically Relevant?. 2016 , 25, 227-38	6
1855	Laparoscopic pancreatic surgery for benign and malignant disease. 2016 , 13, 227-38	87
1854	Partnering to advance early detection and prevention efforts for pancreatic cancer: the Florida Pancreas Collaborative. 2016 , 12, 997-1000	8
1853	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. 2016 , 10, 893-905	31
1852	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. 2016 , 34, 987-1011	114
1851	Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence?. 2016 , 222, 448-56	31
1850	Long-term survival in patients with pancreatic ductal adenocarcinoma. 2016 , 159, 1520-1527	50

1849	Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. 2016 , 113, 2200-5	11
1848	Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target. 2016 , 159, 163-70	17
1847	Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. 2016 , 381, 201-10	36
1846	Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications. 2016 , 15, 24-31	9
1845	Mapping endocrine surgery: Workforce analysis from the last six decades. 2016 , 159, 102-10	12
1844	Discussion. 2016 , 159, 110-2	
1843	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. 2016 , 98, 309-24	30
1842	Current standards and new innovative approaches for treatment of pancreatic cancer. 2016 , 57, 10-22	97
1841	Genomic analyses identify molecular subtypes of pancreatic cancer. 2016 , 531, 47-52	1785
1840	The Burden of Rehospitalization for Patients With Liver Cirrhosis. 2016 , 44, 60-9	9
1839	ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. 2016 , 374, 127-135	73
1838	Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma. 2016 , 37, 4689-97	3
1837	Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. 2016 , 223, 52-65	93
1836	TAp73 loss favors Smad-independent TGF- β signaling that drives EMT in pancreatic ductal adenocarcinoma. 2016 , 23, 1358-70	29
1835	Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma. 2016 , 15, 1043-52	62
1834	Molecular Imaging of Pancreatic Cancer with Antibodies. 2016 , 13, 8-24	52
1833	Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. 2016 , 27, 184-92	6
1832	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. 2016 , 22, 2565-74	52

1831	Contribution of changes in demography and in the risk factors to the predicted pattern of cancer mortality among Spanish women by 2022. 2016 , 40, 113-8	8
1830	Integrin β acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC). 2016 , 37, 5117-31	18
1829	Germline Mutation of the CCK Receptor: A Novel Biomarker for Pancreas Cancer. 2016 , 7, e134	4
1828	Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer. 2016 , 151, 338-45	78
1827	Adherence to World Cancer Research Fund/American Institute for Cancer Research recommendations and pancreatic cancer risk. 2016 , 40, 15-21	16
1826	Key role of pancreatic stellate cells in pancreatic cancer. 2016 , 381, 194-200	76
1825	The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. 2016 , 35, 2529-41	71
1824	Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. 2016 , 25, 207-11	88
1823	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. 2016 , 150, 48-63	71
1822	Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses. 2016 , 57, 453-9	64
1821	Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells. 2016 , 38, 50-60	7
1820	Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. 2016 , 20, 341-59	24
1819	MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies. 2016 , 35, 1609-18	80
1818	Reduced risk of pancreatic cancer associated with asthma and nasal allergies. 2017 , 66, 314-322	37
1817	Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. 2017 , 265, 800-805	75
1816	Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer. 2017 , 140, 2101-2111	26
1815	Modeling Human Cancers in Drosophila. 2017 , 121, 287-309	75
1814	Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer. 2017 , 109,	33

1813	IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. 2017 , 34, 23	16
1812	Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. 2017 , 16, 76-87	49
1811	Endocrine surgery fellowship graduates past, present, and future: 8 years of early job market experiences and what program directors and trainees can expect. 2017 , 161, 289-296	15
1810	Far-Red and Near-Infrared Seminalphthofluorophores for Targeted Pancreatic Cancer Imaging. 2017 , 2, 154-163	16
1809	Pancreatic cancer: Stroma and its current and emerging targeted therapies. 2017 , 391, 38-49	101
1808	Systematic review of site distribution of bone metastases in differentiated thyroid cancer. 2017 , 39, 812-818	30
1807	Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. 2017 , 49, 367-376	250
1806	Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study. 2017 , 70, 237-243	31
1805	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. 2017 , 174, 145-172	19
1804	Design, synthesis and cytotoxic activity of water-soluble quinones with dibromo--benzoquinone cores and amino oligo(ethylene glycol) side chains against MCF-7 breast cancer cells. 2017 , 8, 662-672	4
1803	Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. 2017 , 130, 1099-1106.e1	73
1802	Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. 2017 , 9, 159-170	24
1801	A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. 2017 , 393, 86-93	201
1800	Changes in Liver Transplant Criteria for Hepatocellular Carcinoma. 2017 , 16, 33-38	
1799	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. 2017 , 2, 337-346	20
1798	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. <i>Cancer Research</i> , 2017 , 77, 2647-2660	10.1 60
1797	Targeted therapy of pancreatic cancer: biomarkers are needed. 2017 , 18, 421-422	10
1796	Mediterranean diet and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition cohort. 2017 , 116, 811-820	21

1795	Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. 2017 , 66, 1677-1687	104
1794	Moscatilin induces apoptosis of pancreatic cancer cells via reactive oxygen species and the JNK/SAPK pathway. 2017 , 15, 1195-1203	25
1793	Management of Thyroid Nodules and Differentiated Thyroid Cancer. 2017 ,	3
1792	Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. 2017 , 15, e583-e589	5
1791	The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. 2017 , 397, 94-102	40
1790	Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. 2017 , 394, 76-87	73
1789	Using an endoscopic distal cap to collect pancreatic fluid from the ampulla (with video). 2017 , 86, 1152-1156.e28	
1788	Private Funding for Pancreatic Cancer Research: More Than a Chip Shot. 2017 , 152, 918-921.e2	2
1787	Oligometastatic Disease in Pancreatic Cancer - How to Proceed?. 2017 , 33, 36-41	23
1786	Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. 2017 , 392, 83-93	69
1785	Prediction of Recurrence by Preoperative Intratumoral FDG Uptake Heterogeneity in Endometrioid Endometrial Cancer. 2017 , 10, 178-183	12
1784	Team work and cytopathology molecular diagnosis of solid pancreatic lesions. 2017 , 29, 657-666	7
1783	Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with Zr-5B1. 2017 , 14, 908-915	21
1782	Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. 2017 , 10, 82	70
1781	Diagnosis of hepatocellular carcinoma: An update on international guidelines. 2017 , 98, 379-391	30
1780	Can protein science solve the unmet needs in pancreatic cancer diagnosis and therapy?. 2017 , 14, 469-471	
1779	Endometrial Cancer Trends by Race and Histology in the USA: Projecting the Number of New Cases from 2015 to 2040. 2016 , 4, 895	19
1778	Molecular subtypes in cancers of the gastrointestinal tract. 2017 , 14, 333-342	79

1777	Comprehensive Dissection of Transcriptome Data and Regulatory Factors in Pancreatic Cancer Cells. 2017 , 118, 3976-3985	1
1776	Evaluation of Suppressive Effects of Trilast on the Invasion/Metastasis Mechanism in a Murine Pancreatic Cancer Cell Line. 2017 , 46, 567-574	1
1775	Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials. 2017 , 24, 2371-2378	9
1774	Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer. 2017 , 6, e1319044	42
1773	Diagnostic Biomarkers. 2017 , 1-22	
1772	Screening for Hepatocellular Carcinoma in Patients with Cirrhosis: A Need to Increase Awareness. 2017 , 130, 1007-1008	
1771	Discrimination of pancreatic cancer and pancreatitis by LC-MS metabolomics. 2017 , 13, 61	30
1770	Pancreatic Adenocarcinoma in the Neck of the Pancreas Involving the Celiac Trunk (Appleby Procedure). 2017 , 297-310	
1769	Differential expression of aquaporin-3 and aquaporin-5 in pancreatic ductal adenocarcinoma. 2017 , 115, 980-996	30
1768	Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. 2017 , 51, 650-655	26
1767	microRNA-7 impairs autophagy-derived pools of glucose to suppress pancreatic cancer progression. 2017 , 400, 69-78	54
1766	Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. 2017 , 4, 13-37	64
1765	Stromal SPOCK1 supports invasive pancreatic cancer growth. 2017 , 11, 1050-1064	21
1764	Molecular Events in the Natural History of Pancreatic Cancer. 2017 , 3, 336-346	45
1763	Chemoresistance in pancreatic cancer: Emerging concepts. 2017 , 13, 2507-2513	40
1762	WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma. 2017 , 13, 2531-2538	26
1761	3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. 2017 , 79, 41-49	36
1760	Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. 2017 , 123, 438-445	33

1759	90Y Liver Radioembolization Imaging Using Amplitude-Based Gated PET/CT. 2017 , 42, 373-374	5
1758	A Cohort Study of Adolescent and Midlife Diet and Pancreatic Cancer Risk in the NIH-AARP Diet and Health Study. 2017 , 186, 305-317	13
1757	Population-Based Assessment of Complications Following Surgery for Thyroid Cancer. 2017 , 102, 2543-2551	46
1756	Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease. 2017 , 17, 229	10
1755	Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. 2017 , 66, 1103-1110	178
1754	Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?. 2017 , 11, 683-694	4
1753	A circulating T2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. 2017 , 6, e1322242	23
1752	Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database. 2017 , 29, 904-908	8
1751	Early detection of sporadic pancreatic cancer: time for change. 2017 , 29, 885-891	9
1750	Prognostic Value of Molecular Subtypes in Pancreatic Cancer. 2017 , 46, e29-e31	7
1749	Pancreatic Cancer Incidence and Lethality Rates in Brazil: An Ecological Study. 2017 , 46, 699-706	11
1748	Severe Case of Tumor Lysis Syndrome Presenting Spontaneously in a Metastatic Pancreatic Adenocarcinoma Patient. 2017 , 46, e31-e32	3
1747	Alternating pH landscapes shape epithelial cancer initiation and progression: Focus on pancreatic cancer. 2017 , 39, 1600253	35
1746	MicroRNA-21 as a prognostic biomarker in patients with pancreatic cancer - A systematic review and meta-analysis. 2017 , 214, 515-524	21
1745	Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. 2017 , 44, 43-59	59
1744	Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent - a multicenter survey in Germany and review of the literature. 2017 , 55, 657-666	3
1743	A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. 2017 , 40, 132-139	4
1742	Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. 2017 , 116, 1462-1469	16

1741	Molecular Genetics of Endometrial Carcinoma. 2017 ,	1
1740	Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences. 2017 , 943, 3-46	48
1739	Tetrabromobisphenol A activates the hepatic interferon pathway in rats. 2017 , 266, 32-41	15
1738	Adenylyl cyclase 3/adenylyl cyclase-associated protein 1 (CAP1) complex mediates the anti-migratory effect of forskolin in pancreatic cancer cells. 2017 , 56, 1344-1360	16
1737	Diagnosis and staging of pancreatic ductal adenocarcinoma. 2017 , 19, 1205-1216	8
1736	Identification of potent cholecystokinin-B receptor antagonists: synthesis, molecular modeling and anti-cancer activity against pancreatic cancer cells. 2017 , 8, 1561-1574	5
1735	IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma. 2017 , 16, 1898-1908	63
1734	Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics. 2017 , 313, L664-L676	44
1733	Association of lysosomal protein transmembrane 4 beta gene polymorphism with pancreatic carcinoma susceptibility in the Chinese population. 2017 , 39, 1010428317705518	3
1732	Direct interaction between caffeic acid phenethyl ester and human neutrophil elastase inhibits the growth and migration of PANC-1 cells. 2017 , 37, 3019-3025	13
1731	Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors. 2017 , 116, 55-62	31
1730	Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?. 2017 , 46, 143-150	8
1729	Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. 2017 , 49, 1325-1335	19
1728	Incidence and mortality of pancreatic cancer on a rapid rise in Taiwan, 1999-2012. 2017 , 49, 75-84	12
1727	Metabolic syndrome and in-hospital outcomes among pancreatic cancer patients. 2017 , 11 Suppl 2, S643-S650	4
1726	Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1 β pathway. 2017 , 137, 45-62	24
1725	Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. 2017 , 141, 905-915	42
1724	Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. 2017 , 179, 158-170	92

1723	Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis. 2017 , 110, 19-25	27
1722	RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion. 2017 , 8, e2835	12
1721	Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus. 2017 , 91,	21
1720	The pancreatic cancer microenvironment: A true double agent. 2017 , 116, 7-15	44
1719	Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Human Disease. 2017 , 46, 813-819	28
1718	What is the impact of neoadjuvant chemoradiation on outcomes in gastro-intestinal cancer?. 2017 , 154, 185-195	6
1717	Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer. 2017 , 90, 20170165	9
1716	Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. 2017 , 44, 153-169	39
1715	Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. 2017 , 28, 985-995	77
1714	Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma". 2017 , 23, 1629-1637	33
1713	Personalized Management of Pancreatic Ductal Adenocarcinoma Patients through Computational Modeling. <i>Cancer Research</i> , 2017 , 77, 3325-3335	10.1 9
1712	Current and Emerging Therapies in Metastatic Pancreatic Cancer. 2017 , 23, 1670-1678	84
1711	Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. 2017 , 109,	27
1710	CAR T-cell therapy for pancreatic cancer. 2017 , 116, 63-74	47
1709	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. 2017 , 34, 331-357	6
1708	Drug resistance in pancreatic cancer: Impact of altered energy metabolism. 2017 , 114, 139-152	123
1707	Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. 2017 , 12, 309-321	27
1706	Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. 2017 , 116, 1247-1253	21

1705	SIRT1 promotes the proliferation and metastasis of human pancreatic cancer cells. 2017 , 39, 1010428317691180	
1704	Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX. 2017 , 10, 559-565	16
1703	Incidence and Epidemiology. 2017 , 1-10	1
1702	Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocarcinoma patients: A preliminary report. 2017 , 17, 438-444	9
1701	Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer. 2017 , 34, 229-239	16
1700	Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. 2017 , 7, 44686	36
1699	Mailed Outreach Program Increases Ultrasound Screening of Patients With Cirrhosis for Hepatocellular Carcinoma. 2017 , 152, 608-615.e4	59
1698	Bioengineered tumoral microtissues recapitulate desmoplastic reaction of pancreatic cancer. 2017 , 49, 152-166	41
1697	A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. 2017 , 161, 930-938	28
1696	Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. 2017 , 23, 3129-3138	127
1695	Helicobacter pylori infection, chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort: A nested case-control study. 2017 , 140, 1727-1735	15
1694	Underestimation of pancreatic cancer in the national cancer registry - Reconsidering the incidence and survival rates. 2017 , 72, 186-191	37
1693	CXCR2 inhibition in pancreatic cancer: opportunities for immunotherapy?. 2017 , 9, 9-12	9
1692	Aspirin Use and Reduced Risk of Pancreatic Cancer. 2017 , 26, 68-74	50
1691	New developments in the early diagnosis of pancreatic cancer. 2017 , 11, 149-156	17
1690	ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. 2017 , 36, 3094-3103	47
1689	Sanguinarine inhibits pancreatic cancer stem cell characteristics by inducing oxidative stress and suppressing sonic hedgehog-Gli-Nanog pathway. 2017 , 38, 1047-1056	45
1688	Ruthenium arene complexes with triphenylphosphane ligands: cytotoxicity towards pancreatic cancer cells, interaction with model proteins, and effect of ethacrynic acid substitution. 2017 , 41, 14574-14588 ³²	

1687	Alteration of Blood Circulation in the Upper Limb Before and After Surgery for Breast Cancer Associated with Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy. 2017 , 15, 343-348	
1686	Use of minimally invasive spine surgical instruments for the treatment of bone tumors. 2017 , 14, 881-890	3
1685	N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2. 2017 , 14, 2101-2107	6
1684	Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. 2017 , 24, 107327481772924535	5
1683	DCPP1 is the mouse ortholog of human PAUF that possesses functional analogy in pancreatic cancer. 2017 , 493, 1498-1503	0
1682	Fractalkine/CX3CR1 axis modulated the development of pancreatic ductal adenocarcinoma via JAK/STAT signaling pathway. 2017 , 493, 1510-1517	15
1681	Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers. 2017 , 46, 1238-1241	16
1680	A genetic roadmap of pancreatic cancer: still evolving. 2017 , 66, 2170-2178	32
1679	Algorithm guided outlining of 105 pancreatic cancer liver metastases in Ultrasound. 2017 , 7, 12779	2
1678	Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer. 2017 , 10, 136-140	5
1677	4-1BB Agonist Focuses CD8 Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. 2017 , 23, 7263-7275	29
1676	TGF- β and IL-6 family signalling crosstalk: an integrated model. 2017 , 35, 100-124	6
1675	NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF- κ B activation. 2017 , 411, 44-56	7
1674	Current Standards of Chemotherapy for Pancreatic Cancer. 2017 , 39, 2125-2134	45
1673	Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. 2017 , 7, 13024	30
1672	Long non-coding RNA PCAT-1 contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer. 2017 , 95, 1112-1118	64
1671	Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure. 2017 , 11, 422-427	4
1670	Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy. 2017 , 36, 338-351	10

1669	Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. 2017 , 60, 32-43	93
1668	ONTD induces growth arrest and apoptosis of human hepatoma Bel-7402 cells through a peroxisome proliferator-activated receptor β -dependent pathway. 2017 , 45, 44-53	6
1667	Genomics in Primary and Secondary Prevention of Pancreatic Cancer. 2017 , 20, 92-99	2
1666	Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. 2017 , 10, 631-645	26
1665	Analysis on survival and prognostic factors in patients with resectable pancreatic adenocarcinoma. 2017 , 37, 612-620	4
1664	Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. 2017 , 9,	137
1663	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. 2017 , 17, 951-964	1
1662	Commentary: Pancreatic cancer: is the worst to come?. 2017 , 46, 1774-1775	9
1661	TRPC6 channels modulate the response of pancreatic stellate cells to hypoxia. 2017 , 469, 1567-1577	22
1660	The NQO1 bioactivatable drug, β -lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. 2017 , 292, 18203-18216	41
1659	Critical role for arginase 2 in obesity-associated pancreatic cancer. 2017 , 8, 242	47
1658	Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. 2017 , 24, 3674-3682	22
1657	Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. 2017 , 46, 1152-1157	38
1656	A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. 2017 , 22, 1427-e129	26
1655	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. 2017 , 114, 10202-10207	303
1654	Non-thermal plasma-treated solution demonstrates antitumor activity against pancreatic cancer cells in vitro and in vivo. 2017 , 7, 8319	84
1653	Pancreatic cancer: Exosomes for targeting KRAS in the treatment of pancreatic cancer. 2017 , 14, 636-638	9
1652	Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. 2017 , 117, 572-582	18

1651	Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. 2017 , 96, e6769	18
1650	MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer. 2017 , 23, 5881-5891	39
1649	Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma. 2017 , 243, 148-154	50
1648	Pancreatic cancer screening: Still a delusion?. 2017 , 17, 754-765	14
1647	High-grade pancreatic intraepithelial lesions: prevalence and implications in pancreatic neoplasia. 2017 , 16, 202-208	2
1646	The use of negative pressure wound therapy to prevent post-operative surgical site infections following pancreaticoduodenectomy. 2017 , 19, 825-831	22
1645	What is the right dose of modern medicine?. 2017 , 20, 185-186	
1644	Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. 2017 , 11, 1413-1429	16
1643	Value of contrast-enhanced ultrasound in differential diagnosis of solid lesions of pancreas (SLP): A systematic review and a meta-analysis. 2017 , 96, e7463	15
1642	Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. 2017 , 123, 4158-4167	50
1641	iTRAQ-coupled 2D LC/MS-MS analysis of CXCR7-transfected papillary thyroid carcinoma cells: A new insight into CXCR7 regulation of papillary thyroid carcinoma progression and identification of potential biomarkers. 2017 , 14, 3734-3740	6
1640	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. 2017 , 23, 6094-6100	107
1639	A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. 2017 , 31, 43-51	31
1638	Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer. 2017 , 17, 782-787	5
1637	BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer. 2017 , 7, 1184-1199	36
1636	[Branch duct intraductal papillary mucinous neoplasm - surgical approach]. 2017 , 88, 927-933	1
1635	Nelumbo nucifera leaf extract treatment attenuated preneoplastic lesions and oxidative stress in the livers of diethylnitrosamine-treated rats. 2017 , 32, 2327-2340	13
1634	The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system. 2017 , 43, 2112-2118	12

1633	The Safety and Efficacy of an Alcohol-Free Pancreatic Cyst Ablation Protocol. 2017 , 153, 1295-1303	52
1632	Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk. 2017 , 141, 2423-2429	19
1631	A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. 2017 , 109,	40
1630	Slicing and Dicing Pancreatic Cancer Into Actionable Nuggets. 2017 , 15, 649-650	
1629	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. 2017 , 32, 185-203.e13	896
1628	Incidence of pancreatic cancer in Denmark: 70 years of registration, 1943-2012. 2017 , 56, 1763-1768	7
1627	Classification, Morphology, Molecular Pathogenesis, and Outcome of Premalignant Lesions of the Pancreas. 2017 , 141, 1606-1614	18
1626	Silencing of semaphorin 3C suppresses cell proliferation and migration in MCF-7 breast cancer cells. 2017 , 14, 5913-5917	13
1625	Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. 2017 , 49, e406	75
1624	Berries and other natural products in the pancreatic cancer chemoprevention in human clinical trials. 2017 , 7, 147-161	37
1623	Clinical Management: Metastatic Disease. 2017 , 23, 355-361	
1622	Advances in the Genetics and Biology of Pancreatic Cancer. 2017 , 23, 315-320	14
1621	The Pancreatic Cancer Microenvironment. 2017 , 23, 321-325	85
1620	Oral Health and the Oral Microbiome in Pancreatic Cancer: An Overview of Epidemiological Studies. 2017 , 23, 310-314	25
1619	Abnormal alterations of miR-1 and miR-214 are associated with clinicopathological features and prognosis of patients with PDAC. 2017 , 14, 4605-4612	6
1618	Upregulation of Tyrosine Kinase FYN in Human Thyroid Carcinoma: Role in Modulating Tumor Cell Proliferation, Invasion, and Migration. 2017 , 32, 320-326	13
1617	How to suction pancreatic juice from the duodenum: Endoscope, catheter, or cap-assisted?. 2017 , 86, 1157-1159	
1616	Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. 2017 , 13, 2931-2952	10

1615	Glycogen synthase kinase-3 β ablation limits pancreatitis-induced acinar-to-ductal metaplasia. 2017 , 243, 65-77	21
1614	Surgery for pancreatic ductal adenocarcinoma. 2017 , 19, 1303-1311	6
1613	Quel impact de la radiochimiothérapie avant une chirurgie pour cancer digestif?. 2017 , 154, 192-203	
1612	Posttranscriptional Regulation of mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. <i>Cancer Research</i> , 2017 , 77, 5011-5025	10.1 40
1611	HMGA1 expression levels are elevated in pancreatic intraepithelial neoplasia cells in the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer. 2017 , 117, 639-647	9
1610	Extended Pancreatectomy: Does It Have a Role in the Contemporary Management of Pancreatic Adenocarcinoma?. 2017 , 34, 441-446	5
1609	Advances in nanomicelles for sustained drug delivery. 2017 , 55, 21-34	30
1608	Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease. 2017 , 95, 33-38	6
1607	Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel. 2017 , 7, 4851	3
1606	Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. 2017 , 123, 3725-3731	51
1605	PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. 2017 , 74, 4231-4243	14
1604	Implications of the lysophosphatidic acid signaling axis in liver cancer. 2017 , 1868, 277-282	17
1603	Value of lymph node positivity in treatment planning for early stage pancreatic cancer. 2017 , 162, 557-567	24
1602	Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts. 2017 , 56, 1754-1762	18
1601	Imaging in pancreatic disease. 2017 , 14, 97-109	44
1600	Enhancement of gemcitabine against pancreatic cancer by loading in mesoporous silica vesicles. 2017 , 28, 531-536	27
1599	Cholestyramine as a promising, strong anion exchange resin for direct capture of genetic biomarkers from raw pancreatic fluids. 2017 , 114, 934-938	1
1598	Post-treatment cognitive dysfunction in women treated with thyroidectomy for papillary thyroid carcinoma. 2017 , 25, 915-923	11

1597	High cardiovascular disease mortality after endometrial cancer diagnosis: Results from the Surveillance, Epidemiology, and End Results (SEER) Database. 2017 , 140, 555-564	51
1596	Targeting reactive oxygen species in development and progression of pancreatic cancer. 2017 , 17, 19-31	35
1595	A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. 2017 , 112, 172-183	72
1594	Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways. 2017 , 150, 310-322	63
1593	A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma. 2017 , 27, 23-35	22
1592	Differences in Brain Glucose Metabolism During Preparation for I Ablation in Thyroid Cancer Patients: Thyroid Hormone Withdrawal Versus Recombinant Human Thyrotropin. 2017 , 27, 23-28	3
1591	An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. 2017 , 65, 1196-1205	123
1590	[F]Fluorocholine PET/CT Imaging of Liver Cancer: Radiopathologic Correlation with Tissue Phospholipid Profiling. 2017 , 19, 446-455	17
1589	NO and Pancreatic Cancer: A Complex Interaction with Therapeutic Potential. 2017 , 26, 1000-1008	5
1588	miR-216 and miR-217 expression is reduced in transgenic mouse models of pancreatic adenocarcinoma, knockout of miR-216/miR-217 host gene is embryonic lethal. 2017 , 17, 203-212	23
1587	Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. 2017 , 36, 1770-1778	391
1586	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?. 2017 , 123, 372-381	271
1585	HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. 2017 , 36, 1804-1815	62
1584	Predicted Increases in Incidence of Colorectal Cancer in Developed and Developing Regions, in Association With Ageing Populations. 2017 , 15, 892-900.e4	38
1583	Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. <i>Cancer Research</i> , 2017 , 77, 672-683	10.1 18
1582	Clinicopathological features of thyroid cancer in the elderly compared to younger counterparts: single-center experience. 2017 , 40, 471-479	4
1581	Polymeric micelles of suberoylanilide hydroxamic acid to enhance the anticancer potential in vitro and in vivo. 2017 , 12, 43-58	12
1580	Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. 2017 , 23, 1607-1620	23

1579	[Criteria for resectability of pancreatic cancer and postoperative imaging]. 2017 , 57, 1075-1090	2
1578	In-depth assessment of an interactive graph-based approach for the segmentation for pancreatic metastasis in ultrasound acquisitions of the liver with two specialists in Internal Medicine. 2017 ,	1
1577	Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. 2017 , 7, e018175	20
1576	MiR-629 promotes human pancreatic cancer progression by targeting FOXO3. 2017 , 8, e3154	31
1575	On the significance of Tim-3 expression in pancreatic cancer. 2017 , 24, 1754-1757	13
1574	The Pancreatic Expression Database: 2018 update. 2018 , 46, D1107-D1110	5
1573	Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells. 2017 , 12, 1177271917715443	10
1572	Diagnostic du carcinome hépatocellulaire : échographie de contraste et les agents hépatospcifiques intégrés dans les nouvelles recommandations internationales. 2017 , 1, S84-S97	
1571	Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer: A case report. 2017 , 96, e9338	0
1570	TGF-β in pancreatic cancer initiation and progression: two sides of the same coin. 2017 , 7, 39	60
1569	[Autophagy contributes to the initiation of pancreatic cancer]. 2017 , 33, 335-339	2
1568	Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. 2017 , 8, 82144-82155	32
1567	TLE1 function and therapeutic potential in cancer. 2017 , 8, 15971-15976	11
1566	The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. 2017 , 8, 381	21
1565	Targeting Activated Platelets: A Unique and Potentially Universal Approach for Cancer Imaging. 2017 , 7, 2565-2574	28
1564	Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?. 2017 , 18,	26
1563	Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs). 2017 , 5,	8
1562	Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine. 2017 , 22,	4

1561	Expression Profiling Identifies the Noncoding Processed Transcript of HNRNPU with Proliferative Properties in Pancreatic Ductal Adenocarcinoma. 2017 , 3,	9
1560	Nutritional and Metabolic Derangements in Pancreatic Cancer and Pancreatic Resection. 2017 , 9,	96
1559	The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients. 2017 , 18,	46
1558	Selective cytotoxicity of vanadium complexes on human pancreatic ductal adenocarcinoma cell line by inducing necroptosis, apoptosis and mitotic catastrophe process. 2017 , 8, 60324-60341	28
1557	Targeted Molecular Imaging of Pancreatic Cancer with a Miniature Endoscope. 2017 , 7,	3
1556	KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. 2017 , 9,	119
1555	Pancreatic Cancer Chemoresistance to Gemcitabine. 2017 , 9,	205
1554	Cadmium and Cadmium/Zinc Ratios and Tobacco-Related Morbidities. 2017 , 14,	70
1553	The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy. 2017 , 18,	12
1552	Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. 2017 , 18,	25
1551	Natural Anticancer Compounds and Their Derivatives in Clinical Trials. 2017 , 51-104	3
1550	Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis. 2017 , 2017, 3276806	10
1549	Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. 2017 , 2017, 8282391	11
1548	Insurance Status Is Related to Receipt of Therapy and Survival in Patients with Early-Stage Pancreatic Exocrine Carcinoma. 2017 , 2017, 4354592	8
1547	Adjuvant chemoradiotherapy (gemcitabine-based) in pancreatic adenocarcinoma: the Pisa University experience. 2017 , 103, 577-582	1
1546	Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. 2017 , 5,	49
1545	Drug pricing should depend on shared values. 2017 , 552, S78	4
1544	Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: a population-based study. 2017 , 9, 471-479	17

1543	A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. 2017 , 10, 2115-2126	40
1542	Overdiagnosis and overtreatment of thyroid cancer: A population-based temporal trend study. 2017 , 12, e0179387	80
1541	A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express Hsp epitopes. 2017 , 12, e0184901	9
1540	Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers. 2017 , 12, e0185687	12
1539	"Stealth dissemination" of macrophage-tumor cell fusions cultured from blood of patients with pancreatic ductal adenocarcinoma. 2017 , 12, e0184451	31
1538	A new panel of SNPs to assess thyroid carcinoma risk: a pilot study in a Brazilian admixture population. 2017 , 18, 140	3
1537	Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer. 2017 , 17, 495	8
1536	Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. 2017 , 16, 169	153
1535	Validation and comparison of the molecular classifications of pancreatic carcinomas. 2017 , 16, 168	21
1534	Array comparative genomic hybridization of 18 pancreatic ductal adenocarcinomas and their autologous metastases. 2017 , 10, 560	5
1533	Collaborations across disciplines: MU thyroid nodule electronic database (MU-TNED), a multidisciplinary informatics approach. 2017 ,	
1532	What questions are most important to pancreatic cancer patients soon after diagnosis? A multicenter survey. 2017 , 37,	1
1531	Electron microscopic analysis of different cell types in human pancreatic cancer spheres. 2018 , 15, 2485-2490	17
1530	Postablation Endometrial Carcinoma. 2017 , 21,	12
1529	Prospective validation of patient fatigue questionnaire (FACIT-F) for fatigue assessment in nab-paclitaxel plus gemcitabine therapy. 2018 , 8, 121-126	4
1528	Hereditary Pancreatic Cancer. 2017 ,	
1527	The Improvement of Care in Patients with Pancreatic Cancer. 2017 ,	
1526	Mathematical modelling of liver cancer in western Kenya. 2017 , 11, 2855-2875	1

1525	Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas. 2017 , 2017, 7834702	4
1524	Paeoniflorin suppresses pancreatic cancer cell growth by upregulating HTRA3 expression. 2017 , 11, 2481-249128	
1523	Nanotherapy: a next generation hallmark for combating cancer. 2017 , 811-830	2
1522	The Effects of Multi-Growth Factors-Containing Cream on Post-Thyroidectomy Scars: A Preliminary Study. 2017 , 29, 314-320	3
1521	Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene. 2017 , 8, 33393-33404	23
1520	Comparative effectiveness and resource utilization of -paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting. 2017 , 9, 141-148	25
1519	Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic. 2017 , 8, 513-522	20
1518	Pancreatic Cancer in Lynch Syndrome Patients. 2017 , 8, 3667-3674	23
1517	Mortality assessment of patients with pancreatic cancer in Mexico, 2000-2014. 2017 , 11, 788	4
1516	Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts. 2017 , 8, 19074-19088	18
1515	Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. 2017 , 37, 301-310	10
1514	Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. 2017 , 35, 3382-3390	207
1513	Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. 2017 , 13, 265-269	31
1512	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. 2017 , 13, 261-264	16
1511	A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. 2017 , 8, 83446-83456	38
1510	Correlation of Gankyrin oncoprotein overexpression with histopathological grade in prostate cancer. 2017 , 64, 732-737	7
1509	Does gender affect self-perceived pain in cancer patients? -A meta-analysis. 2017 , 6, S177-S184	11
1508	Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature. 2017 , 8, 379-386	14

1507	Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. 2017 , 8, 387-404	18
1506	Yes-associated protein and immunosuppressive microenvironment in pancreatic cancer development: a new strategy to improve immunotherapy efficacy?. 2017 , 9, 1798-1801	
1505	Pylorus preservation pancreatectomy or not. 2017 , 2, 100	6
1504	Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response. 2017 , 8, 556-565	17
1503	Coadministration of Polymeric Conjugates of Docetaxel and Cycloamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis. 2018 , 35, 17	3
1502	Leukocyte Telomere Length and Pancreatic Cancer Risk: Updated Epidemiologic Review. 2018 , 47, 265-271	7
1501	Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. 2018 , 6, 389-401	42
1500	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. 2018 , 118, 947-954	23
1499	Autocrine activation of platelet-derived growth factor receptor β in metastatic papillary thyroid cancer. 2018 , 75, 146-153	4
1498	Chiroptical spectroscopy and metabolomics for blood-based sensing of pancreatic cancer. 2018 , 30, 581-591	10
1497	Tumor-Induced Myeloid Cells Are Reduced by Gemcitabine-Loaded PAMAM Dendrimers Decorated with Anti-Flt1 Antibody. 2018 , 15, 1526-1533	13
1496	Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. 2018 , 27, 205-212	105
1495	Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar). 2018 , 17, 655-671	11
1494	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. 2018 , 110, 1067-1074	103
1493	Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. 2018 , 1869, 248-255	16
1492	Mahanine drives pancreatic adenocarcinoma cells into endoplasmic reticular stress-mediated apoptosis through modulating sialylation process and Ca-signaling. 2018 , 8, 3911	7
1491	Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival. 2018 , 3, 11	82
1490	Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth. <i>Cancer Research</i> , 2018 , 78, 3321-3336	10.1 43

1489	Young age is associated with increased rates of residual and recurrent paediatric differentiated thyroid carcinoma. 2018 , 89, 212-218	9
1488	A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras. 2018 , 57, 1130-1143	12
1487	The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells. 2018 , 9, 445	19
1486	Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model. 2018 , 8, 5899	23
1485	Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis. 2018 , 8, e017249	10
1484	The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. 2018 , 13, 333-351	9
1483	Mutations in the pancreatic secretory enzymes and are associated with pancreatic cancer. 2018 , 115, 4767-4772	34
1482	Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. 2018 , 287, 374-390	71
1481	Towards Prevention of Breast Cancer: What Are the Clinical Challenges?. 2018 , 11, 255-264	5
1480	Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. 2018 , 115, E3769-E3778	71
1479	Management of hyperbilirubinaemia in pancreatic cancer patients. 2018 , 94, 26-36	3
1478	Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival. 2018 , 14, 326-336	11
1477	Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions. 2018 , 109, 1135-1146	22
1476	Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer. 2018 , 27, 1711-1718	6
1475	Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. 2018 , 18, 420-428	23
1474	IL23 and TGF- β diminish macrophage associated metastasis in pancreatic carcinoma. 2018 , 8, 5808	10
1473	Isovitexin (IV) induces apoptosis and autophagy in liver cancer cells through endoplasmic reticulum stress. 2018 , 496, 1047-1054	30
1472	Pancreatic cancer screening in high-risk individuals with germline genetic mutations. 2018 , 87, 1443-1450	31

1471	Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. 2018 , 20, 563-572	11
1470	Membrane progesterone receptors μ and δ have potential as prognostic biomarkers of endometrial cancer. 2018 , 178, 303-311	17
1469	Clinical implementation of contrast-enhanced four-dimensional dual-energy computed tomography for target delineation of pancreatic cancer. 2018 , 129, 105-111	12
1468	Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma. 2018 , 20, 573-581	16
1467	Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. 2018 , 52, 221-228	2
1466	Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?. 2018 , 188, 107-118	13
1465	Investigation of radiomic signatures for local recurrence using primary tumor texture analysis in oropharyngeal head and neck cancer patients. 2018 , 8, 1524	69
1464	Noninvasive Optical Imaging Techniques in Clinical Application. 2018 , 497-508	2
1463	Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?. 2018 , 268, 1-8	98
1462	A look at the progress of treating pancreatic cancer over the past 20 years. 2018 , 18, 295-304	15
1461	Racial/ethnic differences in thyroid cancer incidence in the United States, 2007-2014. 2018 , 124, 1483-1491	25
1460	Patient-derived organoid models help define personalized management of gastrointestinal cancer. 2018 , 105, e48-e60	71
1459	Porous Polymer Bearing Polyphenolic Organic Building Units as a Chemotherapeutic Agent for Cancer Treatment. 2018 , 3, 529-535	10
1458	Comparative assessment of texture features for the identification of cancer in ultrasound images: a review. 2018 , 38, 275-296	19
1457	Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues. 2018 , 112, 33-45	15
1456	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. 2018 , 9, 556	103
1455	A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. 2018 , 226, 596-603	5
1454	Epidemiology of Pancreatic Cancer. 2018 , 665-672	

1453 Molecular Understanding of Development of Ductal Pancreatic Cancer. **2018**, 679-687

1452 Pathology of Exocrine Pancreatic Tumors. **2018**, 693-704

1451 Screening of Patients with Hereditary Pancreatic Cancer. **2018**, 745-754

1450 Effect of Implementing Community of Practice Modified Thyroid Imaging Reporting and Data System on Reporting Adherence and Number of Thyroid Biopsies. **2018**, 25, 915-924 3

1449 Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. **2018**, 115, E1147-E1156 84

1448 Obesity and Pancreatic Cancer: Overview of Epidemiology and Potential Prevention by Weight Loss. **2018**, 47, 158-162 46

1447 The Static Magnetic Field Remotely Boosts the Efficiency of Doxorubicin through Modulating ROS Behaviors. **2018**, 8, 990 17

1446 Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle. **2018**, 47, 142-157 16

1445 Impact of Integrated Health Care Delivery on Racial and Ethnic Disparities in Pancreatic Cancer. **2018**, 47, 221-226 10

1444 Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. **2018**, 554, 62-68 192

1443 Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. **2018**, 24, 1326-1336 198

1442 LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. *Cancer Research*, **2018**, 78, 909-921 10.1 51

1441 [Epidemiology of pancreatic cancer]. **2018**, 105, 63-69 18

1440 LAG-3 in Non-Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival. **2018**, 19, 249-259.e2 31

1439 Pancreatic HIF2 α Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm. **2018**, 5, 169-185.e2 7

1438 Pancreas 3D Organoids: Current and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer. **2018**, 5, 289-298 57

1437 CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. **2018**, 24, 1415-1425 52

1436 Identification of genes highly downregulated in pancreatic cancer through a meta-analysis of microarray datasets: implications for discovery of novel tumor-suppressor genes and therapeutic targets. **2018**, 144, 309-320 10

1435	Medical oncology and pancreatic cancer: what the radiologist needs to know. 2018 , 43, 383-392	1
1434	Genetic testing for indeterminate thyroid cytology: review and meta-analysis. 2018 , 25, R163-R177	50
1433	Noninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine. 2018 , 154, 485-487.e1	44
1432	Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. 2018 , 154, 820-838	118
1431	Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. 2018 , 7, 525-535	71
1430	Atopic allergic conditions and pancreatic cancer risk: Results from the Multiethnic Cohort Study. 2018 , 142, 2019-2027	8
1429	Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. 2018 , 47, 427-439	96
1428	MiR-137 functions as a tumor suppressor in pancreatic cancer by targeting MRGBP. 2018 , 119, 4799-4807	20
1427	Laparoscopic versus open pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. 2018 , 53, 243-256	8
1426	The significance of intertumor and intratumor heterogeneity in liver cancer. 2018 , 50, e416	89
1425	Plasma protein profiling of patients with intraductal papillary mucinous neoplasm of the pancreas as potential precursor lesions of pancreatic cancer. 2018 , 477, 127-134	5
1424	Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. 2018 , 110, 460-466	13
1423	Delivery of Hydrophobic Anticancer Drugs by Hydrophobically Modified Alginate Based Magnetic Nanocarrier. 2018 , 57, 822-832	31
1422	Thy1-Targeted Microbubbles for Ultrasound Molecular Imaging of Pancreatic Ductal Adenocarcinoma. 2018 , 24, 1574-1585	21
1421	Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance. 2018 , 24, 2963-2974	42
1420	CSF1R Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype. 2018 , 23, 1448-1460	105
1419	The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. 2018 , 47, 516-525	28
1418	Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer. 2018 , 17, 66	44

1417	Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma. 2018 , 16, 66	6
1416	Radiotherapy-induced cell death activates paracrine HMGB1-TLR2 signaling and accelerates pancreatic carcinoma metastasis. 2018 , 37, 77	24
1415	Liver resection for non-colorectal metastases. 2018 , 50, 113-116	6
1414	Mutant Kras Dosage and Chromothripsis: The Right Ingredients for a Pancreatic Cancer Catastrophe. 2018 , 4, 399-401	4
1413	Extracellular vesicles released in response to respiratory exposures: implications for chronic disease. 2018 , 21, 142-160	27
1412	PIK3R3 Promotes Metastasis of Pancreatic Cancer via ZEB1 Induced Epithelial-Mesenchymal Transition. 2018 , 46, 1930-1938	11
1411	Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology. 2018 , 144, 1205-1217	9
1410	Epidemiology and Prospects for Prevention of Pancreatic Cancer. 2018 , 3-18	2
1409	CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. 2018 , 500, 691-697	30
1408	Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer. 2018 , 6, 17-32	13
1407	Immunotherapy and Prevention of Pancreatic Cancer. 2018 , 4, 418-428	146
1406	PET imaging of Hsp90 expression in pancreatic cancer using a new Cu-labeled dimeric Sansalvamide A decapeptide. 2018 , 50, 897-907	6
1405	Therapeutic developments in pancreatic cancer: current and future perspectives. 2018 , 15, 333-348	423
1404	Smad4-TGF- β Signaling Pathways in Pancreatic Cancer Pathogenesis. 2018 , 431-455	0
1403	Adjuvant Chemotherapy in Pancreatic Cancer. 2018 , 1039-1071	
1402	Diagnostic Biomarkers. 2018 , 659-680	4
1401	Secondary Screening for Inherited Pancreatic Ductal Adenocarcinoma. 2018 , 1401-1434	
1400	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. 2018 , 1577-1611	0

1399 Mouse Models of Pancreatic Exocrine Cancer. **2018**, 509-538

1398 Familial Pancreatic Cancer. **2018**, 553-572

1

1397 Laparoscopic Staging in Patients with Newly Diagnosed Pancreatic Cancer. **2018**, 753-769

1396 Role of Tumor-Stromal Interactions in Pancreatic Cancer Invasion and Metastases. **2018**, 539-552

1395 Pancreatic Adenocarcinoma: CT and PET/CT. **2018**, 681-710

1394 Symptom experiences in patients with advanced pancreatic cancer as reported during healthcare encounters. **2018**, 27, e12838

5

1393 Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection. **2018**, 98, 69-74

5

1392 Pancreaticoduodenectomy is justified in a subset of elderly patients with pancreatic ductal adenocarcinoma: A population-based retrospective cohort study of 4,283 patients. **2018**, 53, 262-268

7

1391 Long non-coding RNA XIST exerts oncogenic functions in pancreatic cancer via miR-34a-5p. **2018**, 39, 1591-1600

42

1390 The advanced glycation end-product N -carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention. **2018**, 245, 197-208

33

1389 The spatio-temporal distribution and risk factors of thyroid cancer during rapid urbanization-A case study in China. **2018**, 630, 1436-1445

7

1388 Radioiodine refractory differentiated thyroid cancer. **2018**, 125, 111-120

39

1387 A Changing Landscape in Pancreatic Cancer. **2018**, 268, 9-10

7

1386 Obesity and breast cancer in premenopausal women: Current evidence and future perspectives. **2018**, 230, 217-221

35

1385 Current Concepts in the Treatment of Resectable Pancreatic Cancer. **2018**, 20, 39

9

1384 [Hepatocellular carcinoma: Increase in incidence or future plague?]. **2018**, 105, 502-507

1

1383 Thyroid Disease Around the World. **2018**, 51, 631-642

27

1382 [Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy]. **2018**, 89, 510-515

6

1381	Management of Borderline Resectable Pancreatic Cancer. 2018 , 100, 1155-1174	20
1380	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. 2018 , 10,	110
1379	Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'. 2018 , 94, 95-103	20
1378	The prognostic value of B7-H4 in pancreatic cancer: Systematic review and meta-analysis. 2018 , 97, e0088	7
1377	Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood. 2018 , 12, 3311-3320	157
1376	Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults. 2018 , 40, 512-525	21
1375	Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells. 2018 , 122, 84-92	4
1374	p16, p21, and p53 proteins play an important role in development of pancreatic intraepithelial neoplastic. 2018 , 187, 629-637	7
1373	Keep Quiet and Stay in Line! Smart Polymers to Keep an Eye on Pancreatic Tumors. 2018 , 26, 940-941	1
1372	Lifetime and baseline alcohol intakes and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition study. 2018 , 143, 801-812	24
1371	Distinctive Desmoplastic 3D Morphology Associated With BRAFV600E in Papillary Thyroid Cancers. 2018 , 103, 1102-1111	6
1370	PAK4 pathway as a potential therapeutic target in pancreatic cancer. 2018 , 14, 579-582	10
1369	Design, synthesis and biological evaluation of anti-pancreatic cancer activity of plinabulin derivatives based on the co-crystal structure. 2018 , 26, 2061-2072	12
1368	IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. 2018 , 67, 320-332	255
1367	A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. 2018 , 7, e1303584	26
1366	Metastatic Pancreatic Cancer. 2018 , 31, 151-152	4
1365	Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. 2018 , 67, 128-137	142
1364	Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. 2018 , 67, 497-507	114

1363	Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer. 2018 , 267, 775-781	15
1362	Characterising -regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. 2018 , 67, 521-533	16
1361	Management of unresectable, locally advanced pancreatic adenocarcinoma. 2018 , 20, 113-118	3
1360	Sonodynamic therapy combined with novel anti-cancer agents, sanguinarine and ginger root extract: Synergistic increase in toxicity in the presence of PANC-1 cells in vitro. 2018 , 40, 72-80	11
1359	A metabolomics-based biomarker signature discriminates pancreatic cancer from chronic pancreatitis. 2018 , 67, 2-3	15
1358	Non-coding regulatory variations: the dark matter of pancreatic cancer genomics. 2018 , 67, 399-400	3
1357	Relationship between pancreatic intraepithelial neoplasias, pancreatic ductal adenocarcinomas, and single nucleotide polymorphisms in autopsied elderly patients. 2018 , 57, 12-18	4
1356	Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. 2018 , 20, 119-127	74
1355	Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer. 2018 , 34, 284-291	21
1354	Human biliverdin reductase regulates the molecular mechanism underlying cancer development. 2018 , 119, 1337-1345	8
1353	Comparison of laparoscopic to open pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. 2018 , 32, 2239-2248	44
1352	Trichostatin A alters cytoskeleton and energy metabolism of pancreatic adenocarcinoma cells: An in depth proteomic study. 2018 , 119, 2696-2707	23
1351	An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). 2018 , 94, 39-46	10
1350	A Novel Therapeutic Strategy for Pancreatic Cancer: Targeting Cell Surface Glycan Using rBC2LC-N Lectin-Drug Conjugate (LDC). 2018 , 17, 183-195	30
1349	Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms. 2018 , 23, 121-127	9
1348	A prognostic 4-lncRNA expression signature for lung squamous cell carcinoma. 2018 , 46, 1207-1214	22
1347	Low-fat Dietary Pattern and Pancreatic Cancer Risk in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. 2018 , 110,	27
1346	Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. 2018 , 118, 555-567	55

1345	Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice. 2018 , 8, 8-20	9
1344	GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. 2018 , 32, 1170-1183	47
1343	Organoids: An intermediate modeling platform in precision oncology. 2018 , 414, 174-180	42
1342	Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. 2018 , 142, 1322-1331	15
1341	Clinical outcome of portal vein thrombosis in patients with digestive cancers: A large AGEO multicenter study. 2018 , 50, 285-290	6
1340	Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. <i>Cancer Research</i> , 2018 , 78, 246-255	10.1 86
1339	Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. 2018 , 1864, 607-617	26
1338	The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study. 2018 , 148, 154-160	25
1337	Overcoming immune evasion in pancreatic cancer: the combination matters. 2018 , 67, 997-999	10
1336	Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. 2018 , 14, 165-175	16
1335	Lnc RNA SNHG20 participated in proliferation, invasion, and migration of breast cancer cells via miR-495. 2018 , 119, 7971-7981	49
1334	Emerging trends in the immunotherapy of pancreatic cancer. 2018 , 417, 35-46	61
1333	KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. 2018 , 8,	296
1332	Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. 2018 , 33, 75-90.e7	147
1331	Rs4705342 polymorphism is involved in the tumorigenesis of HBV positive HCC by altering the binding affinity of HBV induced NF-kB with the promoter region of microRNA-143. 2018 , 119, 5233-5242	7
1330	Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer. 2018 , 57, 799-806	18
1329	Improving prognosis and reducing decision regret for pancreatic cancer treatment using artificial neural networks. 2018 , 106, 110-118	41
1328	Pancreatic cancer: A critical review of dietary risk. 2018 , 52, 1-13	28

1327	Intratumoural leukocyte infiltration is a prognostic indicator among pancreatic cancer patients with type 2 diabetes. 2018 , 18, 85-93	3
1326	Xanthohumol inhibits angiogenesis by suppressing nuclear factor- κ B activation in pancreatic cancer. 2018 , 109, 132-140	58
1325	Targeting both tumour-associated CXCR2 neutrophils and CCR2 macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. 2018 , 67, 1112-1123	197
1324	Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis. 2018 , 43, 163-169	11
1323	Lysine methylation signaling in pancreatic cancer. 2018 , 30, 30-37	8
1322	The role of imaging in the clinical practice of radiation oncology for pancreatic cancer. 2018 , 43, 393-403	4
1321	Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. 2018 , 49, 1-8	9
1320	Life after endometrial cancer: A systematic review of patient-reported outcomes. 2018 , 148, 403-413	23
1319	Preoperative optimization for major hepatic resection. 2018 , 403, 23-35	16
1318	Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma. 2018 , 118, 546-557	9
1317	Locally advanced pancreatic cancer: An emerging entity. 2018 , 42, 12-25	9
1316	ETV4 Facilitates Cell-Cycle Progression in Pancreatic Cells through Transcriptional Regulation of Cyclin D1. 2018 , 16, 187-196	22
1315	Erlotinib conjugated gold nanocluster enveloped magnetic iron oxide nanoparticles: A targeted probe for imaging pancreatic cancer cells. 2018 , 257, 1035-1043	19
1314	The Symptom Experience of Patients With Advanced Pancreatic Cancer: An Integrative Review. 2018 , 41, 33-44	25
1313	Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious Mutation. 2018 , 2018,	78
1312	Ethyl acetate extract from <i>Inula helenium</i> L. inhibits the proliferation of pancreatic cancer cells by regulating the STAT3/AKT pathway. 2018 , 17, 5440-5448	3
1311	Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline or Mutations.. 2018 , 2, 1-9	11
1310	Can computational modeling help in personalizing the care of patients with pancreatic ductal adenocarcinoma?. 2018 , 1,	

1309	Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. 2018 , 36, 2887-2894	76
1308	Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center. 2018 , 9, 1074-1083	1
1307	Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation. 2018 , 3, 80	20
1306	Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. 2018 , 9, 1014-1026	25
1305	The relationship between aspirin use and mortality in colorectal cancer. 2018 , 9, 1133-1137	6
1304	Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma. 2018 , 9, 1027-1036	4
1303	The preoperative modified Glasgow prognostic score for the prediction of survival after pancreatic cancer resection following non-surgical treatment of an initially unresectable disease. 2018 , 22, 229-235	4
1302	Quantifying temporal trends of age-standardized rates with odds. 2018 , 16, 18	1
1301	Liquid biopsy-based biomarkers for early detection of pancreatic cancer. 2018 , 1, 19-19	
1300	Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. 2018 , 9, 29820-29841	65
1299	Ultrasonic cavitation induces necrosis and impairs growth in three-dimensional models of pancreatic ductal adenocarcinoma. 2018 , 13, e0209094	4
1298	Dissected peripancreatic tissue margin is a critical prognostic factor and is associated with a gene mutation in pancreatic ductal adenocarcinoma. 2019 , 17, 2141-2150	1
1297	MU thyroid nodule electronic database (MU-TNED), a multidisciplinary informatics approach to long-term thyroid nodule and thyroid cancer follow-up. 2018 , 21, 32	1
1296	Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence. 2018 , 1,	1
1295	Enhanced Electric Pulse Technology for the Ablation of Pancreatic Cancer. 2018 ,	2
1294	Pancreatic Cancer, Leptin, and Chemoresistance: Current Challenges. 2018 ,	3
1293	HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. 2018 , 7,	35
1292	Relationship between type 2 diabetes and pancreatic cancer. 2018 , 2,	

1291	Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes. 2018 , 2,	16
1290	Utilizing cell line-derived organoids to evaluate the efficacy of a novel LIFR-inhibitor, EC359 in targeting pancreatic tumor stroma. 2019 , 10, 1-10	11
1289	Reflex Testing for Germline , , , and Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries.. 2018 , 2, 1-16	10
1288	Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients in China. 2018 , 6, e4893	10
1287	Large database utilization in health outcomes research in pancreatic cancer: an update. 2018 , 9, 996-1004	5
1286	Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer. 2018 , 8, 16389	27
1285	Model to Stratify Risk of Pancreatic Cancer in Patients Diagnosed as New-onset Diabetes. 2018 , 72, 159	
1284	MicroRNA-195: a review of its role in cancers. 2018 , 11, 7109-7123	43
1283	Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. 2018 , 155, 1999-2013.e3	189
1282	The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. 2018 , 6,	5
1281	Identification of hub genes with diagnostic values in pancreatic cancer by bioinformatics analyses and supervised learning methods. 2018 , 16, 223	18
1280	ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. 2018 , 7, 87	27
1279	New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer. 2018 , 13, 691-704	5
1278	Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [¹¹ C]PBR28. 2018 , 232, 570-577	10
1277	miR-21 promotes EGF-induced pancreatic cancer cell proliferation by targeting Spry2. 2018 , 9, 1157	37
1276	Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. 2018 , 9, 4945	93
1275	Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells. 2018 , 18, 1157	25
1274	Dehydroabiatic oximes halt pancreatic cancer cell growth in the G1 phase through induction of p27 and downregulation of cyclin D1. 2018 , 8, 15923	8

1273	Hyperglycemia aggravates microenvironment hypoxia and promotes the metastatic ability of pancreatic cancer. 2018 , 16, 479-487	23
1272	ASO Author Reflections: Distal Pancreatectomy with Celiac Axis Resection for Locally Advanced Pancreatic Cancer-Patient Selection and Surgical Experience are Key. 2018 , 25, 828-829	1
1271	Surgery for Pancreatic Cancer after neoadjuvant treatment. 2018 , 2, 413-418	29
1270	A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. 2018 , 18, 986	6
1269	KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer. 2018 , 29, 2280-2282	4
1268	Patterns and predictors of end-of-life care in older patients with pancreatic cancer. 2018 , 7, 6401-6410	12
1267	Thyroid Cancer and Iodine Deficiency Status: A 10-Year Review at a Single Cancer Center in Tanzania. 2018 , 2, 2473974X18777238	3
1266	Serum level of co-expressed hub miRNAs as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. 2018 , 9, 3991-3999	21
1265	Murine Models of Pancreatitis Leading to the Development of Pancreatic Cancer. 2018 , 83, e48	4
1264	Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer: From Concept to Reality. 2018 , 47, 1208-1212	18
1263	Development of Parvifloron D-loaded Smart Nanoparticles to Target Pancreatic Cancer. 2018 , 10,	16
1262	Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. 2018 , 18, 1298	44
1261	Pankreaskarzinom: Chirurgische Konzepte zur kompletten Tumorentfernung. 2018 , 16, 80-86	
1260	Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. 2018 , 9, 19396-19405	28
1259	Metabolic Dependencies in Pancreatic Cancer. 2018 , 8, 617	36
1258	Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine. 2018 , 19,	11
1257	Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification. 2018 , 47, 1350-1356	6
1256	Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. 2018 , 8, 17914	34

1255	A Glimmer of Hope for Pancreatic Cancer. 2018 , 379, 2463-2464	26
1254	FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. 2018 , 379, 2395-2406	1047
1253	Comparative Transcriptomics Unravels Prodigiosin's Potential Cancer-Specific Activity Between Human Small Airway Epithelial Cells and Lung Adenocarcinoma Cells. 2018 , 8, 573	6
1252	Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. 2018 , 10, 1758835918816281	16281
1251	Survival of Patients with Oligometastatic Pancreatic Ductal Adenocarcinoma Treated with Combined Modality Treatment Including Surgical Resection: A Pilot Study. 2018 , 4, 88-94	19
1250	Unveiling the Potential of Repurposing FDA-Approved Drugs in Pancreatic Cancer. 2018 , 09,	
1249	Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. 2018 , 9, 21613-21627	29
1248	Advancement of NF- κ B Signaling Pathway: A Novel Target in Pancreatic Cancer. 2018 , 19,	67
1247	PANCREATIC CANCER IN BRAZIL: MORTALITY TRENDS AND PROJECTIONS UNTIL 2029. 2018 , 55, 230-236	7
1246	Targeted Therapies for Pancreatic Cancer and Hurdles Ahead. 2018 , 38, 6591-6606	40
1245	Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. 2018 , 24, 4846-4861	559
1244	ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF- β signalling. 2018 , 9, 5083	29
1243	Wireless, battery-free, flexible, miniaturized dosimeters monitor exposure to solar radiation and to light for phototherapy. 2018 , 10,	59
1242	Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death. 2018 , 39, 1984-1990	7
1241	Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. 2018 , 5, 42-49	3
1240	TEKT4 Promotes Papillary Thyroid Cancer Cell Proliferation, Colony Formation, and Metastasis through Activating PI3K/Akt Pathway. 2018 , 29, 310-316	14
1239	The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. 2018 , 9, 573	8
1238	Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. 2018 , 8, 14008	15

1237	The Role of Neoadjuvant Therapy in Surgical Treatment of Pancreatic Cancer. 2018,	
1236	The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma. 2018, 144, 2419-2431	9
1235	Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers. 2018, 17, 2495-2506	7
1234	FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. 2018, 118, 1021-1026	14
1233	Advanced pancreatic cancer: The standard of care and new opportunities. 2018, 12, 370	7
1232	Decreased trend in hospital mortality from pancreatic cancer despite increase in number of hospital admissions. 2018, 13, e0199909	6
1231	Precursor Lesions of Pancreatic Cancer. 2018, 41, 603-610	15
1230	Proteomic Identification of FLT3 and PCBP3 as Potential Prognostic Biomarkers for Pancreatic Cancer. 2018, 38, 5759-5765	13
1229	Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with Y-Labeled Fully Human Anti-CD147 Monoclonal Antibody 059-053 in a BxPC-3 Xenograft Mouse Model of Refractory Pancreatic Cancer. 2018, 19,	13
1228	Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma. 2018, 41, 619-625	8
1227	Cold Physical Plasma Selectively Elicits Apoptosis in Murine Pancreatic Cancer Cells and. 2018, 38, 5655-5663	30
1226	The Potential of CAR T Cell Therapy in Pancreatic Cancer. 2018, 9, 2166	63
1225	Adaptive biokinetic modelling of iodine-131 in thyroid cancer treatments: implications on individualised internal dosimetry. 2018, 38, 1501-1511	3
1224	'Diseases Desperate Grown by Desperate Appliance Are Relieved, or Not at all' - Towards Finding a Cure for Pancreatic Cancer, Where Do We Stand Today?. 2018, 41, 588-589	
1223	Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma. 2018, 41, 590-594	7
1222	Novel Methylselenoesters Induce Programed Cell Death via Entosis in Pancreatic Cancer Cells. 2018, 19,	10
1221	Does Axl have potential as a therapeutic target in pancreatic cancer?. 2018, 22, 955-966	13
1220	AR regulates the expression of AKR1B1 in human pancreatic cancer cells and promotes their proliferation via the ERK1/2 pathway. 2018, 45, 1863-1871	12

1219	Ancistrololikone E, a 5,8'-Coupled Naphthylisoquinoline Alkaloid, Eliminates the Tolerance of Cancer Cells to Nutrition Starvation by Inhibition of the Akt/mTOR/Autophagy Signaling Pathway. 2018 , 81, 2282-2291	39
1218	Gene expression differences between thyroid carcinoma, thyroid adenoma and normal thyroid tissue. 2018 , 40, 3359-3369	13
1217	[Personalized cancer medicine : Biomarkers for molecular therapy stratification in pancreatic carcinoma]. 2018 , 39, 221-224	
1216	Immunohistochemical staining for S100P, SMAD4, and IMP3 on cell block preparations is sensitive and highly specific for pancreatic ductal adenocarcinoma. 2018 , 7, 318-323	8
1215	Increased Risk of Hepatocellular Carcinoma Associated With Neighborhood Concentrated Disadvantage. 2018 , 8, 375	4
1214	Projection of cancer incidence rates and case numbers until 2030: A probabilistic approach applied to German cancer registry data (1999-2013). 2018 , 57, 110-119	10
1213	The Falciform Ligament for Mesenteric and Portal Vein Reconstruction in Local Advanced Pancreatic Tumor: A Surgical Guide and Single-Center Experience. 2018 , 2018, 2943879	11
1212	Gene Therapy for Pancreatic Diseases: Current Status. 2018 , 19,	8
1211	Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy. 2018 , 35, 158	6
1210	Feasibility assessment of yttrium-90 liver radioembolization imaging using amplitude-based gated PET/CT. 2018 , 39, 222-227	1
1209	A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of poor prognosis. 2018 , 18, 1032	29
1208	Disruption of C1galt1 Gene Promotes Development and Metastasis of Pancreatic Adenocarcinomas in Mice. 2018 , 155, 1608-1624	37
1207	The interaction between miR-148a and DNMT1 suppresses cell migration and invasion by reactivating tumor suppressor genes in pancreatic cancer. 2018 , 40, 2916-2925	17
1206	Radiation Therapy in Pancreatic Cancer. 2018 , 1-11	
1205	Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with clinical outcome. 2018 , 18, 945-953	6
1204	Integrated analysis of long noncoding RNA interactions reveals the potential role in progression of human papillary thyroid cancer. 2018 , 7, 5394-5410	13
1203	Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. 2018 , 119, 1208-1214	111
1202	CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. 2018 , 9, 4275	34

1201	Currently available first-line drug therapies for treating pancreatic cancer. 2018 , 19, 1927-1940	3
1200	In vitro evaluation of the antitumor effect of bismuth lipophilic nanoparticles (BisBAL NPs) on breast cancer cells. 2018 , 13, 6089-6097	19
1199	Genetic determination of pancreatic cancer. 2018 , 34, 178-182	
1198	Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. 2018 , 9, 1065	58
1197	Screening for Pancreatic Cancer in Individuals With New-onset Diabetes Mellitus. 2018 , 14, 657-662	1
1196	The Microbiome and Pancreatic Cancer: An Evidence-based Association?. 2018 , 52 Suppl 1, Proceedings from t, S82-S85	13
1195	Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. 2018 , 10,	10
1194	Endoscopic Ultrasound-Based Pancreatic Cancer Screening of High-Risk Individuals: A Prospective Observational Trial. 2018 , 47, 586-591	17
1193	The Effect of Pancreatic Juice Collection Time on the Detection of KRAS Mutations. 2018 , 47, 35-39	8
1192	Demographic, clinical, and pathological features of early onset pancreatic cancer patients. 2018 , 18, 139	16
1191	Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis. 2018 , 9, 3156-3167	34
1190	Omega-3 Fatty Acids Prevent Early Pancreatic Carcinogenesis via Repression of the AKT Pathway. 2018 , 10,	18
1189	Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance. 2018 , 11, 1307-1322 ⁹	
1188	Steroid Receptor Coactivator-2 Controls the Pentose Phosphate Pathway through RPIA in Human Endometrial Cancer Cells. 2018 , 8, 13134	2
1187	Combining Bulk Temperature and Nanoheating Enables Advanced Magnetic Fluid Hyperthermia Efficacy on Pancreatic Tumor Cells. 2018 , 8, 13210	37
1186	HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. 2018 , 36, 359-366	248
1185	Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. <i>Cancer Research</i> , 2018 , 78, 6146-6158	10.1 19
1184	Focus on pancreatic cancer. 2018 , 50, 1272-1273	

1183	Cancer Progress and Priorities: Uterine Cancer. 2018 , 27, 985-994	22
1182	Hodgkin lymphoma in elderly patients. 2018 , 30, 308-316	8
1181	The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship. 2018 , 10,	119
1180	lncRNA LINC00673 induces proliferation, metastasis and epithelial-mesenchymal transition in thyroid carcinoma via Kruppel-like factor 2. 2018 , 53, 1927-1938	18
1179	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). 2018 , 50, 1257-1271	65
1178	Adjuvant Treatment in Potentially Curable Pancreatic Cancer: Need to Include Tumor Location in the Equation?. 2018 , 47, e50-e52	4
1177	Clinicopathological characteristics and prognosis of thyroid cancer in northwest China: A population-based retrospective study of 2490 patients. 2018 , 9, 1453-1460	10
1176	Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. 2018 , 10,	41
1175	Prediction of central lymph node metastasis in papillary thyroid microcarcinoma according to clinicopathologic factors and thyroid nodule sonographic features: a case-control study. 2018 , 10, 3237-3243	23
1174	Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD score). 2018 , 129, 313-318	11
1173	A novel tumor suppressor gene is correlated with progression in papillary thyroid carcinoma. 2018 , 11, 307-311	5
1172	Advanced EUS Guided Tissue Acquisition Methods for Pancreatic Cancer. 2018 , 10,	7
1171	Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. 2018 , 25, 3984-3993	13
1170	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. 2018 , 9, 1878	69
1169	Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. 2018 , 50, 979-990	20
1168	Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabilization of oncoprotein c-MYC. 2018 , 39, 1548-1559	10
1167	Characteristics and Clinical Outcomes of Individuals at High Risk for Pancreatic Cancer: A Descriptive Analysis from a Comprehensive Cancer Center. 2019 , 1, 106-119	1
1166	Irreversible Electroporation in Pancreatic Cancer. 2018 ,	1

1165	Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment. 2018 , 25, 342-350	17
1164	Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer. 2018 , 329, 31-40	20
1163	. 2018 ,	5
1162	Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer. <i>Cancer Research</i> , 2018 , 78, 4282-4291	10.1 63
1161	Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. 2018 , 32, 4022-4028	53
1160	Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. 2018 , 9, 1978	119
1159	High-Density Infiltration of V-domain Immunoglobulin Suppressor of T-cell Activation Up-regulated Immune Cells in Human Pancreatic Cancer. 2018 , 47, 725-731	15
1158	Endoscopic ultrasound-guided tissue acquisition of pancreatic masses. 2018 , 20, 30-38	1
1157	miR-301a plays a pivotal role in hypoxia-induced gemcitabine resistance in pancreatic cancer. 2018 , 369, 120-128	13
1156	Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin- α /FAK/ERK pathway. 2018 , 1864, 2538-2549	15
1155	The role of selected chemokines and their specific receptors in pancreatic cancer. 2018 , 33, 141-147	8
1154	Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases. 2018 , 37, 5248-5256	11
1153	Overcoming diagnostic issues in precision treatment of pancreatic cancer. 2018 , 3, 189-195	1
1152	MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. 2018 , 52, 124-128	13
1151	KRAS mutation and epithelial-macrophage interplay in pancreatic neoplastic transformation. 2018 , 143, 1994-2007	18
1150	Fusions in Wild-Type Pancreatic Cancer. 2018 , 8, 1087-1095	99
1149	Resveratrol Inhibits ROS-Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR-21. 2018 , 2018, 1346958	34
1148	Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways. 2018 , 2018, 9482018	44

1147	Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. 2018 , 49, 178-193.e7	287
1146	Do patients with pancreatic body or tail cancer benefit from adjuvant therapy?A cohort study. 2018 , 27, 245-250	5
1145	The Heterogeneity of Cancer Metabolism. 2018 ,	4
1144	The Intricate Metabolism of Pancreatic Cancers. 2018 , 1063, 73-81	7
1143	Pancreatic cancer stem cells: features and detection methods. 2018 , 24, 797-805	41
1142	Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. 2018 , 24, 5018-5027	101
1141	Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. 2018 , 155, 490-500.e2	79
1140	Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. 2018 , 432, 227-236	25
1139	Genomics of Peritoneal Malignancies. 2018 , 27, 463-475	5
1138	Ischemic gastropathy after distal pancreatectomy with en bloc celiac axis resection for pancreatic body cancer. 2018 , 403, 561-571	19
1137	Electroporation with Cisplatin against Metastatic Pancreatic Cancer: Study on Human Primary Cell Culture. 2018 , 2018, 7364539	12
1136	Polymeric micelles as a versatile tool in oral chemotherapy. 2018 , 293-329	4
1135	Genomic testing for pancreatic cancer in clinical practice as real-world evidence. 2018 , 18, 647-654	24
1134	Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. 2018 , 155, 730-739.e3	113
1133	Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. 2018 , 18, 693	41
1132	Serotonin uptake is required for Rac1 activation in Kras-induced acinar-to-ductal metaplasia in the pancreas. 2018 , 246, 352-365	10
1131	Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. 2018 , 211, 1010-1019	22
1130	Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. 2018 , 13, 447-459	6

1129	Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. 2018 , 109, 2841-2851	24
1128	Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells. 2018 , 18, 772	12
1127	Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. 2018 , 9, 84	11
1126	[Maintenance strategies for advanced pancreatic cancer: Rationale and issues]. 2018 , 105, 739-741	2
1125	A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers. 2018 , 6, 7	14
1124	Photoactive linear and hyperbranched polyesters based on 4-methylcyclohexanone and 4-tert-butylcyclohexanone moieties in the main chain: synthetic methodology, characterization and cytotoxicity. 2018 , 25, 1	5
1123	Guidelines for the diagnosis and treatment of pancreatic adenocarcinoma (2018 edition): A standardized procedure recommended in China. 2018 , 17, 383-384	
1122	Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. 2018 , 39, 1197-1206	4
1121	MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers. 2018 , 2018, 9740357	9
1120	Clinical effect of and its relevance to V600E mutation in papillary thyroid carcinoma: a case-control study. 2018 , 10, 1351-1358	2
1119	Expanding laparoscopic pancreaticoduodenectomy to pancreatic-head and periampullary malignancy: major findings based on systematic review and meta-analysis. 2018 , 18, 102	28
1118	Thienopyrimidine-Chalcone Hybrid Molecules Inhibit Fas-Activated Serine/Threonine Kinase: An Approach To Ameliorate Antiproliferation in Human Breast Cancer Cells. 2018 , 15, 4173-4189	28
1117	Antidiabetic adiponectin receptor agonist AdipoRon suppresses tumour growth of pancreatic cancer by inducing RIPK1/ERK-dependent necroptosis. 2018 , 9, 804	39
1116	Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset. 2018 , 2018, 8765369	13
1115	A myeloid and lymphoid infiltrate in murine pancreatic tumors exposed to plasma-treated medium. 2018 , 11, 10-17	25
1114	Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1 β . 2018 , 371, 63-71	47
1113	Race and Health Disparities in Patient Refusal of Surgery for Early-Stage Pancreatic Cancer: An NCDDB Cohort Study. 2018 , 25, 3427-3435	36
1112	TGF- β II Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727. 2018 , 10,	13

1111	Differential expression profile of CXCR3 splicing variants is associated with thyroid neoplasia. Potential role in papillary thyroid carcinoma oncogenesis?. 2018 , 9, 2445-2467	11
1110	Efficacy of surgeon-performed, ultrasound-guided lymph node fine needle aspiration in patients with thyroid pathologic conditions. 2018 , 164, 657-664	3
1109	Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma. 2018 , 9, 108	31
1108	Enhancing the Therapeutic Efficacy of Cancer Treatment With Cannabinoids. 2018 , 8, 114	18
1107	Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells. 2017 , 10,	68
1106	Recent Advances in Chromatin Mechanisms Controlling Pancreatic Carcinogenesis. 2018 , 2, 11	0
1105	Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. 2018 , 10,	22
1104	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. 2018 , 10,	14
1103	The Ever-Evolving Concept of the Cancer Stem Cell in Pancreatic Cancer. 2018 , 10,	62
1102	Nano-Pulse Stimulation Ablates Orthotopic Rat Hepatocellular Carcinoma and Induces Innate and Adaptive Memory Immune Mechanisms that Prevent Recurrence. 2018 , 10,	15
1101	Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene. 2018 , 10,	5
1100	Role of Gene Therapy in Pancreatic Cancer-A Review. 2018 , 10,	14
1099	A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. 2018 , 10,	14
1098	Pancreatic Cystic Lesions: Pathogenesis and Malignant Potential. 2018 , 6,	10
1097	How academically productive are endocrine surgeons in the United States?. 2018 , 229, 122-126	6
1096	Long non-coding RNA lnc-PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC-3. 2018 , 143, 3143-3154	25
1095	[Pancreatic ductal adenocarcinoma]. 2018 , 59, 805-822	8
1094	Overweight or Obese Individuals at Eighteen Years of Age Develop Pancreatic Adenocarcinoma at a Significantly Earlier Age. 2018 , 2018, 2380596	2

1093	A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation. 2018,	3
1092	Preventive Potential of Resveratrol in Carcinogen-Induced Rat Thyroid Tumorigenesis. 2018, 10,	21
1091	Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression. 2018, 19,	20
1090	Risk Factors for Cardiovascular Disease Among Thyroid Cancer Survivors: Findings From the Utah Cancer Survivors Study. 2018, 103, 2468-2477	16
1089	Comprehensive molecular profiling of the B7 family in gastrointestinal cancer. 2018, 51, e12468	4
1088	Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. 2018, 18, 688	122
1087	Pancreatic Cancer Related Health Disparities: A Commentary. 2018, 10,	18
1086	Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis. 2018, 14, 124-136	83
1085	PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. 2018, 81, 157-165	23
1084	Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis. 2018, 18, 534	49
1083	Populationsbasierte Studie zu zystischen Raumforderungen des Pankreas. 2018, 13, 136-139	
1082	Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. 2018, 28, 2675-2678	22
1081	Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatment. 2018, 127, 80-97	123
1080	Incidence and histological patterns of thyroid cancer in Sri Lanka 2001-2010: an analysis of national cancer registry data. 2018, 18, 163	20
1079	Facile assembly of upconversion nanoparticle-based micelles for active targeted dual-mode imaging in pancreatic cancer. 2018, 16, 7	20
1078	Comparison of anticancer effects of everolimus-gemcitabine combination with gemcitabine on pancreatic cancer using Rgs16 biomarker evaluation. 2018, 27, 1113-1117	
1077	The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. 2018, 1870, 67-75	66
1076	Hierarchical structural component modeling of microRNA-mRNA integration analysis. 2018, 19, 75	11

1075	Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. 2018 , 25, 184-195	7
1074	Designer hydrogels: Shedding light on the physical chemistry of the pancreatic cancer microenvironment. 2018 , 436, 22-27	14
1073	Pancreatic cancer survival analysis defines a signature that predicts outcome. 2018 , 13, e0201751	38
1072	[Role of radiation therapy in the management of pancreatic cancer]. 2018 , 22, 552-557	
1071	Effect of silver nanoparticles in the induction of apoptosis on human hepatocellular carcinoma (HepG2) cell line. 2018 , 93, 465-471	60
1070	Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages. 2018 , 8, 12000	33
1069	Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study. 2018 , 268, 408-420	73
1068	Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. 2018 , 24, 6204-6211	35
1067	DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer. 2018 , 10,	8
1066	Evaluation of Anti-Tumor Efficacy of Vorinostat Encapsulated Self-Assembled Polymeric Micelles in Solid Tumors. 2018 , 19, 3141-3151	7
1065	GATA4 inhibits cell differentiation and proliferation in pancreatic cancer. 2018 , 13, e0202449	8
1064	siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin. 2018 , 12, 805-816	38
1063	Pancreatic cancer circulating tumor cells: applications for personalized oncology. 2018 , 18, 809-820	16
1062	Nutritional and Environmental Factors in Thyroid Carcinogenesis. 2018 , 15,	33
1061	From somatic mutation to early detection: insights from molecular characterization of pancreatic cancer precursor lesions. 2018 , 246, 395-404	38
1060	Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It. 2018 , 22, 1804-1810	19
1059	MicroRNAs Targeting Caspase-3 and -7 in PANC-1 Cells. 2018 , 19,	18
1058	Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells. 2018 , 7, 549-561	11

1057	Ancistroyafungines A-D, 5,8'- and 5,1'-coupled naphthylisoquinoline alkaloids from a Congolese <i>Ancistrocladus</i> species, with antiausterity activities against human PANC-1 pancreatic cancer cells. 2018 , 130, 6-16	15
1056	Long non-coding RNA PVT1 promotes epithelial-mesenchymal transition via the TGF- β /Smad pathway in pancreatic cancer cells. 2018 , 40, 1093-1102	34
1055	Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine. 2018 , 8, 3824-3840	44
1054	Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional <i>Kras</i> G12D mice. 2018 , 18, 797	11
1053	lncRNA H19 predicts poor prognosis in patients with melanoma and regulates cell growth, invasion, migration and epithelial-mesenchymal transition in melanoma cells. 2018 , 11, 3583-3595	23
1052	Pancreatic Cancer-Induced Cachexia and Relevant Mouse Models. 2018 , 47, 937-945	25
1051	A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent. 2018 , 13, e0199130	4
1050	Pancreatic cancer stem cells: A state or an entity?. 2018 , 53, 223-231	45
1049	Expression of annexin II and stromal tenascin C promotes epithelial to mesenchymal transition and correlates with distant metastasis in pancreatic cancer. 2018 , 42, 821-830	20
1048	Label-free and non-invasive BS-SERS detection of liver cancer based on the solid device of silver nanofilm. 2018 , 49, 1426-1434	14
1047	The ATR Inhibitor AZD6738 Synergizes with Gemcitabine and to Induce Pancreatic Ductal Adenocarcinoma Regression. 2018 , 17, 1670-1682	54
1046	Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population. 2018 , 89, 397-407	3
1045	Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. 2018 , 48, 637-644	1
1044	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. 2018 , 8, 1096-1111	156
1043	An Array of Bioactive Compounds From Australian Eucalypts and Their Relevance in Pancreatic Cancer Therapeutics. 2018 , 47, 690-707	4
1042	The Role of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma and Preclinical Models to Study It. 2018 , 735-748	
1041	Borderline resectable pancreatic cancer. Challenges and controversies. 2018 , 68, 124-135	17
1040	Prognostic value of hsa-mir-299 and hsa-mir-7706 in hepatocellular carcinoma. 2018 , 16, 815-820	8

1039	The Role of MR Imaging in Pancreatic Cancer. 2018 , 26, 363-373	9
1038	The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. 2018 , 8, 8666	35
1037	Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis. 2018 , 6, 489-499	26
1036	LRP4 promotes proliferation, migration, and invasion in papillary thyroid cancer. 2018 , 503, 257-263	7
1035	The Emerging Roles and Clinical Potential of Exosomes in Cancer. 2018 , 285-311	1
1034	Development of [F]ALF-NOTA-NT as PET Agents of Neurotensin Receptor-1 Positive Pancreatic Cancer. 2018 , 15, 3093-3100	16
1033	Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. 2018 , 23, 3312-3326	43
1032	Characterization of an Inducible Alcoholic Liver Fibrosis Model for Hepatocellular Carcinoma Investigation in a Transgenic Porcine Tumorigenic Platform. 2018 , 29, 1194-1202.e1	7
1031	Design, synthesis and anti-inflammatory activity of pyrimidine scaffold benzamide derivatives as epidermal growth factor receptor tyrosine kinase inhibitors. 2018 , 1171, 541-550	7
1030	[Chronic Pancreatitis and Pancreatic Cancer - Tumor Risk and Screening]. 2018 , 143, 895-906	4
1029	Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. 2018 , 25, 2475-2483	46
1028	Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. 2018 , 45, 696-711.e8	70
1027	Palliation of Malignant Pancreaticobiliary Obstruction. 2019 , 734-747.e4	0
1026	Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model. 2019 , 37, 364-374	18
1025	Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer. 2019 , 21, 219-225	66
1024	Individualized Care. 2019 ,	7
1023	Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma. 2019 , 69, 639-652	44
1022	Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. 2019 , 144, 981-990	24

1021	Secular trends in liver cancer incidence from 1997 to 2014 in Taiwan and projection to 2035: An age-period-cohort analysis. 2019 , 118, 444-449	9
1020	Health Utility Book (HUB)-Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer. 2019 , 4, 2381468319852594	
1019	Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice. 2019 , 18, 1539-1547	3
1018	Neue Standards in der adjuvanten Therapie des Pankreaskarzinoms?!. 2019 , 14, 126-128	
1017	Duktales Adenokarzinom des Pankreas. 2019 , 14, 131-148	
1016	Functional and Phenotypic Characterization of Tumor-Infiltrating Leukocyte Subsets and Their Contribution to the Pathogenesis of Hepatocellular Carcinoma and Cholangiocarcinoma. 2019 , 12, 1468-1479	5
1015	Endometrial cancer and obesity. 2019 , 21, 237-245	10
1014	Expression of ANGPTL2 and its impact on papillary thyroid cancer. 2019 , 19, 204	9
1013	DNA-Methylation-Caused Downregulation of Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma. 2019 , 11,	4
1012	PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. 2019 , 38, 6662-6677	33
1011	Optineurin downregulation induces endoplasmic reticulum stress, chaperone-mediated autophagy, and apoptosis in pancreatic cancer cells. 2019 , 5, 128	13
1010	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. 2019 , 14, 141	117
1009	Analysis of microRNA expression in brush cytology specimens improves the diagnosis of pancreatobiliary cancer. 2019 , 19, 873-879	4
1008	EMT and Stemness-Key Players in Pancreatic Cancer Stem Cells. 2019 , 11,	56
1007	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. 2019 , 9, 11610	18
1006	Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. 2019 , 11,	25
1005	Molecular biomarkers predicting early development of endometrial carcinoma: A pilot study. 2019 , 28, e13137	5
1004	A seven-miRNA expression-based prognostic signature and its corresponding potential competing endogenous RNA network in early pancreatic cancer. 2019 , 18, 1601-1608	16

1003	The Loss of Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer. 2019 , 10, 4123-4131	9
1002	Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth. 2019 , 28, 1845-1859.e5	44
1001	Knockout of Acinar Enriched microRNAs in Mice Promote Duct Formation But Not Pancreatic Cancer. 2019 , 9, 11147	7
1000	Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?. 2019 , 11,	16
999	Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype. 2019 , 58, 1985-1997	18
998	Palliative Viszeralchirurgie. 2019 ,	1
997	Endoscopic ultrasound findings and pathological features of pancreatic carcinoma in situ. 2019 , 7, E585-E593	13
996	Position emission tomography imaging in pancreatic cancer: recent progress and future directions. 2019 , 2, 6-6	
995	Pancreatic cancer-A disease in need: Optimizing and integrating supportive care. 2019 , 125, 3927-3935	35
994	Early-onset pancreatic cancer: a population-based study using the SEER registry. 2019 , 404, 565-571	17
993	KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes. 2019 , 34, 403-411	1
992	Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. 2019 , 322, 438-444	95
991	Screening for Pancreatic Cancer. 2019 , 322, 407-408	13
990	Screening for Pancreatic Cancer-Is There Hope?. 2019 , 179, 1313-1315	6
989	Screening for Pancreatic Cancer Gets a D, but the Student Is Improving. 2019 , 154, 795-797	7
988	Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer. 2019 , 110, 2846-2855	17
987	lncRNA-CCHE1 is involved in migration and invasion but not in proliferation of pancreatic adenocarcinoma cells possibly by interacting with ROCK1. 2019 , 18, 1218-1224	5
986	Surveillance for pancreatic cancer in high-risk individuals. 2019 , 3, 656-665	14

985	Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF- κ B pathway in vitro/vivo. 2019 , 225, 115223	14
984	Immuno-evolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. 2019 , 9, 12286	15
983	Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. 2019 , 121, 264-270	8
982	Integrated targeted metabolomic and lipidomic analysis: A novel approach to classifying early cystic precursors to invasive pancreatic cancer. 2019 , 9, 10208	15
981	Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. 2019 , 12,	25
980	Multifunctional role of pancreatic stellate cells in pancreatic cancer. 2019 , 2, 10-10	10
979	Regional and racial variations in the utilization of endoscopic retrograde cholangiopancreatography among pancreatic cancer patients in the United States. 2019 , 8, 3420-3427	6
978	Ist nicht obligat: histologische Sicherung vor neoadjuvanter Therapie des Pankreaskarzinoms. 2019 , 25, 658-660	
977	CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis. 2019 , 20, 1290-1299	5
976	MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells and. 2019 , 2019, 8475389	9
975	Identification of a 4-miRNA signature as a potential prognostic biomarker for pancreatic adenocarcinoma. 2019 , 120, 16416-16426	9
974	Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 2019 , 11,	19
973	Magnetic Resonance Navigation for Targeted Embolization in a Two-Level Bifurcation Phantom. 2019 , 47, 2402-2415	11
972	Clinical Scenarios Emerging from Combined Immunophenotypic, Molecular and Morphologic Analysis of Pancreatic Cancer: The Good, the Bad and the Ugly Scenario. 2019 , 11,	3
971	Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumorigenicity. 2019 , 38, 6226-6239	13
970	Evaluating pre- and post-operation plasma miRNAs of papillary thyroid carcinoma (PTC) patients in comparison to benign nodules. 2019 , 19, 690	10
969	The Microbiota and Pancreatic Cancer. 2019 , 48, 447-464	20
968	Epigenome Remodeling in Cholangiocarcinoma. 2019 , 5, 335-350	18

967	Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-][1,3,4]thiadiazol-2-yl)-1-indole Derivatives Against Pancreatic Cancer Cells. 2019 , 39, 3615-3620	16
966	Obesity-Induced Adipose Tissue Inflammation as a Strong Promotional Factor for Pancreatic Ductal Adenocarcinoma. 2019 , 8,	16
965	The Analysis of The Accuracy of Measurement of Main Pigmented Skin Lesions Signs. 2019 ,	
964	Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. 2019 , 25, 1797-1816	14
963	Deprescription during last year of life in patients with pancreatic cancer: Optimization or nihilism?. 2019 , 125, 3470-3471	
962	Progressive Impairment of NK Cell Cytotoxic Degranulation Is Associated With TGF- β Deregulation and Disease Progression in Pancreatic Cancer. 2019 , 10, 1354	26
961	Healthcare expenditures among community-dwelling adults with thyroid cancer in the United States: A propensity score matched analysis. 2019 , 5, e01995	2
960	Tumor-specific delivery of gemcitabine with activatable liposomes. 2019 , 309, 277-288	25
959	Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. 2019 , 9,	3
958	Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. 2019 , 286, 3510-3539	21
957	Conductance-Based Biophysical Distinction and Microfluidic Enrichment of Nanovesicles Derived from Pancreatic Tumor Cells of Varying Invasiveness. 2019 , 91, 10424-10431	21
956	Serum deprivation response functions as a tumor suppressor gene in papillary thyroid cancer. 2019 , 96, 418-428	4
955	Projecting Cancer Incidence for 2025 in the 2 Largest Populated Cities in Vietnam. 2019 , 26, 10732748198652740	40
954	Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. 2019 , 8, 5223-5231	8
953	IGSF1: A novel oncogene regulates the thyroid cancer progression. 2019 , 37, 516-524	6
952	Overall survival in patients over 40 years old with surgically resected pancreatic carcinoma: a SEER-based nomogram analysis. 2019 , 19, 726	7
951	Molekulare Charakterisierung des Pankreaskarzinoms. 2019 , 25, 704-709	1
950	Survival Analysis of Multi-Omics Data Identifies Potential Prognostic Markers of Pancreatic Ductal Adenocarcinoma. 2019 , 10, 624	38

949	Enhanced morphological and functional differences of pancreatic cancer with epithelial or mesenchymal characteristics in 3D culture. 2019 , 9, 10871	18
948	Two Cases of Rare Pancreatic Malignancies. 2019 , 5, 26-33	3
947	Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer. 2019 , 6, 8-20	0
946	Omics Approaches in Pancreatic Adenocarcinoma. 2019 , 11,	6
945	Inhibiting PI3 kinase—in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors. 2019 , 309, 173-180	27
944	Identification of Upregulated HNRNPs Associated with Poor Prognosis in Pancreatic Cancer. 2019 , 2019, 5134050	7
943	Vitamin E Eicosatrienol sensitizes human pancreatic cancer cells to TRAIL-induced apoptosis through proteasome-mediated down-regulation of c-FLIP. 2019 , 19, 189	5
942	Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. 2019 , 11,	13
941	Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases. 2019 , 45, 1906-1911	9
940	Urinary Metabolites Diagnostic and Prognostic of Intrahepatic Cholangiocarcinoma. 2019 , 28, 1704-1711	6
939	A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. 2019 , 11, 1758835919853196	15
938	Differentiation of Pigmented Skin Lesions Based on Digital Processing of Optical Images. 2019 , 126, 503-513	1
937	Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. 2019 , 14, 114	20
936	Influence of the body mass index on postoperative outcome and long-term survival after pancreatic resections in patients with underlying malignancy. 2019 , 8, 201-210	2
935	Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. 2019 , 53, 253-269	1
934	Toward Rational Design of Novel Anti-Cancer Drugs Based on Targeting, Solubility, and Bioavailability Exemplified by 1,3,4-Thiadiazole Derivatives Synthesized Under Solvent-Free Conditions. 2019 , 24,	13
933	Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. 2019 , 11,	30
932	Myoferlin Contributes to the Metastatic Phenotype of Pancreatic Cancer Cells by Enhancing Their Migratory Capacity through the Control of Oxidative Phosphorylation. 2019 , 11,	16

931	Nerves and Pancreatic Cancer: New Insights into a Dangerous Relationship. 2019 , 11,	21
930	CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. 2019 , 44, 3148-3157	22
929	SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer. 2019 , 10, 2670-2678	13
928	Killer on the road?-cells from pancreatic preneoplastic lesions disseminate through pancreatic ducts on their way to cancer. 2019 , 8, 392-394	
927	The Role of PEDF in Pancreatic Cancer. 2019 , 39, 3311-3315	4
926	miR-486 Promotes Capan-2 Pancreatic Cancer Cell Proliferation by Targeting Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN). 2019 , 10, 541	13
925	Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis. 2019 , 38, 3109-3116	3
924	Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. 2019 , 29, 725-738	257
923	Galectin-3 and S100A9: Novel Diabetogenic Factors Mediating Pancreatic Cancer-Associated Diabetes. 2019 , 42, 1752-1759	9
922	Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment. 2019 , 12, 4585-4593	15
921	Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. <i>Cancer Research</i> , 2019 , 79, 4491-4502	10.1 18
920	Utilising network pharmacology to explore the underlying mechanism of Wumei Pill in treating pancreatic neoplasms. 2019 , 19, 158	50
919	Semi-Physical Simulation Design of UAV Simulation Training System. 2019 , 1302, 022029	
918	Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review. 2019 , 7, 1972-1976	7
917	Harms of hepatocellular carcinoma surveillance. 2019 , 18, 383-389	3
916	Circulating microRNAs as promising diagnostic biomarkers for pancreatic cancer: a systematic review. 2019 , 12, 6665-6684	6
915	Efficacy of extended versus standard lymphadenectomy in pancreatoduodenectomy for pancreatic head adenocarcinoma. An update meta-analysis. 2019 , 19, 1074-1080	17
914	An integrated epigenome and transcriptome analysis identifies PAX2 as a master regulator of drug resistance in high grade pancreatic ductal adenocarcinoma. 2019 , 14, e0223554	6

913	Metformin alters the duodenal microbiome and decreases the incidence of pancreatic ductal adenocarcinoma promoted by diet-induced obesity. 2019 , 317, G763-G772	17
912	Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer. 2019 , 9, 996	79
911	An update on treatment options for pancreatic adenocarcinoma. 2019 , 11, 1758835919875568	73
910	Percutaneous Computed Tomography-Guided Coaxial Core Biopsy for the Diagnosis of Pancreatic Tumors. 2019 , 8,	1
909	A cellular and bioinformatics analysis of the SENP1 SUMO isopeptidase in pancreatic cancer. 2019 , 10, 821-830	6
908	Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. 2019 , 2019, 7135437	3
907	Electronic Consultations to Hepatologists Reduce Wait Time for Visits, Improve Communication, and Result in Cost Savings. 2019 , 3, 1177-1182	1
906	Growth-associated protein 43 promotes thyroid cancer cell lines progression via epithelial-mesenchymal transition. 2019 , 23, 7974-7984	5
905	The Role of Exercise in the Quality of Life in Patients After Pancreatectomy: A Prospective Randomized Controlled Trial. 2019 , 11, 65-71	1
904	Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody. 2019 , 8, 7781-7792	18
903	Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992-2016. 2019 , 30, 1377-1388	5
902	Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis. 2019 , 39, 66	16
901	ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. 2019 , 18, 1899-1908	28
900	A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma. 2019 , 9, 1160	16
899	Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies. 2019 , 215, 152691	10
898	Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma. 2019 , 39, 5565-5572	3
897	Harnessing the Microbiome for Pancreatic Cancer Immunotherapy. 2019 , 5, 670-676	20
896	34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2 : National Harbor, MD, USA. 10 November 2019. 2019 , 7, 283	22

895	Targeting Epithelial Mesenchymal Plasticity in Pancreatic Cancer: A Compendium of Preclinical Discovery in a Heterogeneous Disease. 2019 , 11,	6
894	Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death. 2019 , 9, 16588	12
893	New therapeutic targets in pancreatic cancer. 2019 , 81, 101926	48
892	Imidazo[2,1-]thiazole-Coupled Natural Noscapine Derivatives as Anticancer Agents. 2019 , 4, 19382-19398	13
891	Pancreatoduodenectomy With Vascular Resections in Borderline Resectable Pancreatic Cancer. 2019 , 33, 2303-2308	1
890	Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer. 2019 , 7, 288	15
889	Silenced ZNF154 Is Associated with Longer Survival in Resectable Pancreatic Cancer. 2019 , 20,	3
888	Conversion Surgery for Advanced Pancreatic Cancer. 2019 , 8,	10
887	The role of interleukin-18 in pancreatitis and pancreatic cancer. 2019 , 50, 1-12	12
886	A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma. 2019 , 15, 2282-2295	11
885	Pathologische Standards in der Befundung von Biopsien und Operationspräparaten mit Bauchspeicheldrüsenkrebs. 2019 , 17, 94-100	
884	Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. 2019 , 11,	40
883	The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case-control study in a Korean nationwide cohort. 2019 , 8, 7419-7430	5
882	Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. 2019 , 157, 1413-1428.e11	29
881	Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells. 2019 , 24,	3
880	Targeting TGF β 2-mutant tumors exposes vulnerabilities to stromal TGF β blockade in pancreatic cancer. 2019 , 11, e10515	28
879	Maligne Tumoren der Bauchspeicheldrüse. 2019 , 16, 57-71	
878	The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 2019 , 4, 934-947	167

877	Cost-effectiveness of recurrent laryngeal nerve monitoring in thyroid surgery. 2019 , 8, 307-311	1
876	Tc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma. 2019 , 11,	7
875	Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. 2019 , 40, 544-550	7
874	Are β -TUB1, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?. 2019 , 11,	4
873	The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer. 2019 , 8,	8
872	Hypoxia-Induced Autophagy Degrades Stromal Lumican into Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma: A Mini-Review. 2019 , 3, 22-27	11
871	Expression profile of tRNA-derived fragments in pancreatic cancer. 2019 , 18, 3104-3114	12
870	Original tumour suppressor gene polycystic kidney and hepatic disease 1-like 1 is associated with thyroid cancer cell progression. 2019 , 18, 3227-3235	7
869	Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. 2019 , 13, 430	6
868	Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. 2019 , 8, 10	86
867	MCOLN1 Promotes Proliferation and Predicts Poor Survival of Patients with Pancreatic Ductal Adenocarcinoma. 2019 , 2019, 9436047	8
866	GSK343 induces autophagy and downregulates the AKT/mTOR signaling pathway in pancreatic cancer cells. 2019 , 18, 2608-2616	6
865	CA19-9 decrease and survival according to platelet level in patients with advanced pancreatic cancer. 2019 , 19, 860	7
864	Exosome-like nanoplatform modified with targeting ligand improves anti-cancer and anti-inflammation effects of imperialine. 2019 , 311-312, 104-116	29
863	Wnt/ β -Catenin Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance. 2019 , 20,	58
862	Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. 2019 , 154, 1038-1048	63
861	Statistical projection methods for lung cancer incidence and mortality: a systematic review. 2019 , 9, e028497	15
860	Risk of Hepatocellular Carcinoma Following Use of Direct Acting Antiviral Medications for Treatment of Chronic Hepatitis C. 2019 , 12, 891-902	1

859	Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism. 2019 , 17, 111	23
858	Long non-coding RNA SLNCR1 regulates non-small cell lung cancer migration, invasion and stemness through interactions with secretory phospholipase A2. 2019 , 20, 2591-2596	14
857	Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society. 2019 , 166, 997-1003	16
856	Spatial distribution and clusters of pancreatic cancer mortality in Shandong Province, China. 2019 , 9, 12917	2
855	Downregulation of thymopoietin by miR-139-5p suppresses cell proliferation and induces cell cycle arrest/apoptosis in pancreatic ductal adenocarcinoma. 2019 , 18, 3443-3452	3
854	MiR-194-5p in Pancreatic Ductal Adenocarcinoma Peritoneal Washings is Associated with Peritoneal Recurrence and Overall Survival in Peritoneal Cytology-Negative Patients. 2019 , 26, 4506-4514	4
853	Dissecting the molecular landscape of pancreatic cancer: towards a precision medicine approach. 2019 , 4, 113-119	3
852	Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience. 2019 , 11, 1758835919874650	7
851	A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas. 2019 , 9, 13396	13
850	Racial disparities of liver cancer mortality in Wisconsin. 2019 , 30, 1277-1282	3
849	Chemoresistance in Pancreatic Cancer. 2019 , 20,	129
848	Low expression of ryanodine receptor 2 is associated with poor prognosis in thyroid carcinoma. 2019 , 18, 3605-3612	6
847	Health behaviours and beliefs in individuals with familial pancreatic cancer. 2019 , 18, 457-464	2
846	Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines. 2019 , 16, 676-689	58
845	Initial Diagnosis and Staging of Pancreatic Cancer Including Main Differentials. 2019 , 40, 436-468	6
844	Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection. 2019 , 43, 3153-3160	11
843	Chondrosarcoma: the impact of comorbidity - 30 years of experience from a population-based database including 199 consecutive chondrosarcoma patients. 2019 , 11, 109-116	1
842	The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?. 2019 , 11,	6

841	The miR-141/neuropilin-1 axis is associated with the clinicopathology and contributes to the growth and metastasis of pancreatic cancer. 2019 , 19, 248	21
840	Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. 2019 , 80, 101895	22
839	Postoperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: A systematic review and meta-analysis. 2019 , 72, 59-68	14
838	Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma. 2019 , 30, 2703-2713	8
837	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. 2019 , 18, e394-e401	7
836	Pancreatic cancer screening - is it prime time yet?. 2019 , 16, 709-710	
835	Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a hereditary pancreatic cancer surveillance program. 2019 , 21, 1371-1375	3
834	Disseminated Well-Differentiated Gastro-Entero-Pancreatic Tumors Are Associated with Metabolic Syndrome. 2019 , 8,	4
833	Animal models for modeling pancreatic cancer and novel drug discovery. 2019 , 14, 127-142	9
832	Improving preoperative detection of synchronous liver metastases in pancreatic cancer with combined contrast-enhanced and diffusion-weighted MRI. 2019 , 44, 1756-1765	12
831	Enhancing Patient Outcomes while Containing Costs after Complex Abdominal Operation: A Randomized Controlled Trial of the Whipple Accelerated Recovery Pathway. 2019 , 228, 415-424	18
830	S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. 2019 , 392, 615-622	10
829	Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist?. 2019 , 135, 95-102	5
828	First results from the Swedish National Pancreatic and Periampullary Cancer Registry. 2019 , 21, 34-42	23
827	Increasing pancreatic cancer is not paralleled by pancreaticoduodenectomy volumes in Brazil: A time trend analysis. 2019 , 18, 79-86	2
826	A Phase I-II Study Using Rixin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. 2019 , 12, 56-67	19
825	A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer. 2019 , 370, 894-901	8
824	Healthcare disparities in outcomes of patients with resectable pancreatic cancer. 2019 , 217, 725-731	24

823	Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. 2019 , 35, 267-282.e7	80
822	A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. 2019 , 74, 718-730	8
821	PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells. 2019 , 38, 4325-4339	17
820	Protein Corona Fingerprints of Liposomes: New Opportunities for Targeted Drug Delivery and Early Detection in Pancreatic Cancer. 2019 , 11,	27
819	Highly Convergent Total Synthesis and Assignment of Absolute Configuration of Majusculamide D, a Potent and Selective Cytotoxic Metabolite from <i>Moorea</i> sp. 2019 , 21, 793-796	8
818	Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. 2019 , 18, 14	141
817	Pancreatic Cancer Diagnosis and Management: Has the Time Come to Prick the Bubble?. 2018 , 9, 779	18
816	Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchymal Transition. 2019 , 11,	23
815	The dark side of radiotherapy-induced cell death in cancer. 2019 , 40, 7-8	3
814	Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. 2019 , 40, 394-405	16
813	Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. 2019 , 11,	12
812	Pancreatic cancer in young adults: changes, challenges, and solutions. 2019 , 12, 3387-3400	9
811	Projected oropharyngeal carcinoma incidence among middle-aged US men. 2019 , 41, 3226-3234	20
810	Concentration changes in gemcitabine and its metabolites after hyperthermia in pancreatic cancer cells assessed using RP-HPLC. 2019 , 24, 30	2
809	Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma. 2019 , 11, 3765-3777	5
808	Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. 2019 , 191, E574-E580	11
807	Precision Medicine in Cancer Therapy. 2019 ,	1
806	LncRNA-Disease Association Prediction Using Two-Side Sparse Self-Representation. 2019 , 10, 476	9

805	A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. 2019 , 14, 1384-1391	10
804	Targeting of an antecedent proteinase by an activatable probe with deep tissue penetration facilitates early visualization and dynamic malignancy evaluation of orthotopic pancreatic ductal adenocarcinoma (PDAC). 2019 , 7, 3320-3333	5
803	Use of Precision Imaging in the Evaluation of Pancreas Cancer. 2019 , 178, 209-236	6
802	In vivo clearable inorganic nanophotonic materials: designs, materials and applications. 2019 , 11, 12742-12754	6
801	Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells. 2019 , 19, 596	39
800	Safety of radiofrequency ablation in patients with locally advanced, unresectable pancreatic cancer: A phase II study. 2019 , 45, 2166-2172	10
799	Leflunomide Synergizes with Gemcitabine in Growth Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting. 2019 , 14, 149-158	10
798	Pancreatic cancer detection and characterization-state of the art cross-sectional imaging and imaging data analysis. 2019 , 4, 35	8
797	Are Nanocarriers Effective for the Diagnosis and Treatment of Pancreatic Cancer?. 2019 , 159-174	1
796	Do changes in health reveal the possibility of undiagnosed pancreatic cancer? Development of a risk-prediction model based on healthcare claims data. 2019 , 14, e0218580	6
795	Checkpoint inhibitors in pancreatic cancer. 2019 , 78, 17-30	76
794	Transgelin-2: Biochemical and Clinical Implications in Cancer and Asthma. 2019 , 44, 885-896	14
793	Waiting time to surgery and pancreatic cancer survival: A nationwide population-based cohort study. 2019 , 45, 1901-1905	6
792	Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature. 2019 , 19, 672-680	15
791	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. 2019 , 17, 1815-1827	24
790	New Perspective in Pancreatic Cancer. 2019 , 151-161	
789	Endoscopic Ultrasound Placement of Preloaded Fiducial Markers Shortens Procedure Time Compared to Back-Loaded Markers. 2019 , 17, 2749-2758.e2	9
788	Synthesis of C4-Aminated Indoles via a Catellani and Retro-Diels-Alder Strategy. 2019 , 141, 9731-9738	42

787	Pharmacogenetics of treatments for pancreatic cancer. 2019 , 15, 437-447	15
786	Inflammatory and Senescent Phenotype of Pancreatic Stellate Cells Induced by Sqstm1 Downregulation Facilitates Pancreatic Cancer Progression. 2019 , 15, 1020-1029	6
785	Novel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimens. 2019 , 45, 1895-1900	8
784	Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma. 2019 , 3, 646-655	4
783	Pancreatic Ductal Organoids React Kras Dependent to the Removal of Tumor Suppressive Roadblocks. 2019 , 2019, 2079742	1
782	Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. 2019 , 459, 41-49	19
781	Search for Early Pancreatic Cancer Blood Biomarkers in Five European Prospective Population Biobanks Using Metabolomics. 2019 , 160, 1731-1742	12
780	Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. 2019 , 30, 1428-1436	29
779	Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi). 2019 , 9, 475	17
778	Endometrial Carcinoma: Epidemiology and Risk Factors. 2019 , 3-12	2
777	Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis. 2019 , 24, 1543-1548	11
776	Alcoholic/Non-Alcoholic Digestive Diseases. 2019 ,	
775	TMEM16A controls EGF-induced calcium signaling implicated in pancreatic cancer prognosis. 2019 , 116, 13026-13035	36
774	Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF- β /smad2/3 axis in pancreatic cancer. 2019 , 459, 204-215	21
773	Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. 2019 , 19, 569	6
772	Exploiting the 7-methylimidazo[1,5-a]pyrazin-8(7H)-one scaffold for the development of novel chemical inhibitors for Bromodomain and Extraterminal Domain (BET) family. 2019 , 90, 103044	5
771	Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. 2019 , 7, 132	27
770	Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. 2019 , 37, 1895-1908	72

769	Use of Machine-Learning Algorithms in Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse. 2019 , 11,	10
768	Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. 2019 , 8,	9
767	The Anthrax Toxin Receptor 1 (ANTXR1) Is Enriched in Pancreatic Cancer Stem Cells Derived from Primary Tumor Cultures. 2019 , 2019, 1378639	6
766	Interethnic differences in pancreatic cancer incidence and risk factors: The Multiethnic Cohort. 2019 , 8, 3592-3603	23
765	The Proteome of Pancreatic Cancer-Derived Exosomes Reveals Signatures Rich in Key Signaling Pathways. 2019 , 19, e1800394	11
764	Management of ductal pancreatic cancer. 2019 , 51, 135-138	1
763	Current Status of Immunotherapies for Treating Pancreatic Cancer. 2019 , 21, 60	24
762	HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1. 2019 , 44, 403-418	11
761	Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. 2019 , 19, 468	16
760	Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice. 2019 , 14, e0216603	16
759	Early Cancer Detection from Multianalyte Blood Test Results. 2019 , 15, 332-341	13
758	Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. 2019 , 121, 5-14	79
757	Unraveling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry. 2019 , 411, 6319-6328	6
756	Body site-dependent variations of microbiota in pancreatic cancer pathophysiology. 2019 , 56, 260-273	2
755	Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. 2019 , 8, 3314-3324	10
754	Biomaterial substrate-derived compact cellular spheroids mimicking the behavior of pancreatic cancer and microenvironment. 2019 , 213, 119202	24
753	RNA Interference and Cancer Therapy. 2019 ,	1
752	Decision Making in Indeterminate Thyroid Nodules and the Role of Molecular Testing. 2019 , 99, 587-598	5

751	Design and synthesis of functionalized coumarins as potential anti-austerity agents that eliminates cancer cells' tolerance to nutrition starvation. 2019 , 29, 1779-1784	12
750	Environmental cadmium exposure and pancreatic cancer: Evidence from case control, animal and in vitro studies. 2019 , 128, 353-361	60
749	Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions. 2019 , 51, 392-398	9
748	Carcinogenicity assessment: Addressing the challenges of cancer and chemicals in the environment. 2019 , 128, 417-429	40
747	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. 2019 , 111, 782-794	113
746	The Use of Star Polymer Nanoparticles for the Delivery of siRNA to Mouse Orthotopic Pancreatic Tumor Models. 2019 , 1974, 329-353	5
745	Fetal bovine serum enlarges the size of human pancreatic cancer spheres accompanied by an increase in the expression of cancer stem cell markers. 2019 , 514, 112-117	8
744	A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability. 2019 , 40, 1448-1456	10
743	The potential of dopamine receptor D2 (DRD2) as a therapeutic target for tackling pancreatic cancer. 2019 , 23, 365-367	6
742	Musculoskeletal neck disorders in thyroid cancer patients after thyroidectomy. 2019 , 28, e13053	2
741	Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. 2019 , 28, 1238-1245	27
740	The stem cell-specific intermediate filament nestin missense variation p.A1199P is associated with pancreatic cancer. 2019 , 17, 4647-4654	0
739	EUS-Guided Pancreatic Cyst Ablation: a Clinical and Technical Review. 2019 , 21, 19	15
738	Low CD8+ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44+/CD133+ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer. 2019 , 11,	55
737	Genetic variants in the liver kinase B1-AMP-activated protein kinase pathway genes and pancreatic cancer risk. 2019 , 58, 1338-1348	9
736	Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death. 2019 , 454, 204-214	11
735	Application of Neutrosophic Logic to Evaluate Correlation between Prostate Cancer Mortality and Dietary Fat Assumption. 2019 , 11, 330	30
734	ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis. 2019 , 33, 641-655	11

733	Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux. 2019 , 96, 13-25	12
732	Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. 2020 , 41, 44-55	10
731	Danshen Formulae for Cancer: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. 2019 , 2019, 2310639	6
730	Drug development using pancreatic and lung organoid models. 2019 , 323-342	
729	Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy. 2019 , 71, 1100-1107	6
728	Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis. 2019 , 19, 394	21
727	Chemo-prevention and interception of obesity-promoted pancreatic ductal adenocarcinoma. 2019 , 125-147	
726	Table_3.XLSX. 2019 ,	
725	DataSheet_1.pdf. 2019 ,	
724	Image_1.JPEG. 2020 ,	
723	Image_2.JPEG. 2020 ,	
722	Image_3.JPEG. 2020 ,	
721	Data_Sheet_1.docx. 2019 ,	
720	Data_Sheet_2.docx. 2019 ,	
719	Data_Sheet_1.docx. 2020 ,	
718	Image_1.TIF. 2019 ,	
717	Table_1.DOCX. 2020 ,	
716	Table_2.docx. 2020 ,	

715 Data_Sheet_1.pdf. **2020,**

714 Data_Sheet_1.PDF. **2020,**

713 Image_1.jpeg. **2020,**

712 Table_1.docx. **2020,**

711 Table_2.docx. **2020,**

710 Table_3.docx. **2020,**

709 Table_1.docx. **2020,**

708 Data_Sheet_1.PDF. **2020,**

707 Data_Sheet_2.PDF. **2020,**

706 Data_Sheet_3.xlsx. **2020,**

705 Data_Sheet_1.pdf. **2020,**

704 Table_1.DOCX. **2020,**

703 Table_2.DOCX. **2020,**

702 Data_Sheet_1.PDF. **2020,**

701 Table_1.xlsx. **2020,**

700 Table_2.xlsx. **2020,**

699 Table_3.xlsx. **2020,**

698 Presentation_1.pdf. **2018,**

697 Image_1.TIF. 2019,

696 Image_2.TIF. 2019,

695 Image_3.TIF. 2019,

694 Image_4.TIF. 2019,

693 Image_5.TIF. 2019,

692 Image_6.TIF. 2019,

691 Image_7.TIF. 2019,

690 Image_8.TIF. 2019,

689 Image_9.TIF. 2019,

688 Table_1.XLSX. 2019,

687 Table_2.XLSX. 2019,

686 Table_3.XLSX. 2019,

685 Table_4.XLSX. 2019,

684 Table_5.XLSX. 2019,

683 Table_6.XLSX. 2019,

682 Data_Sheet_1.DOCX. 2020,

681 Data_Sheet_1.pdf. 2019,

680 Data_Sheet_1.pdf. 2019,

679 Table_1.docx. **2019**,

678 Data_Sheet_1.PDF. **2019**,

677 Data_Sheet_1.xlsx. **2020**,

676 Data_Sheet_1.ZIP. **2019**,

675 Data_Sheet_1.docx. **2018**,

674 Exosomal circular RNA hsa_circ_0006220, and hsa_circ_0001666 as biomarkers in the diagnosis of pancreatic cancer.. **2022**, e24447 1

673 Single-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer.. **2022**, 8, eabm3453 3

672 Signature of m5C-Related lncRNA for Prognostic Prediction and Immune Responses in Pancreatic Cancer.. **2022**, 2022, 7467797 3

671 Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism.. **2022**, 17, e0266601 0

670 Primary Squamous Cell Carcinoma, a Rare Pathological Report of Pancreatic Cancer. **2021**, 12, S407-S412 0

669 Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?. **2022**, 12, 0

668 ATP11A promotes EMT by regulating Numb PRR in pancreatic cancer cells.. **2022**, 10, e13172 0

667 Bromelain and acetylcysteine (BromAc) alone and in combination with gemcitabine inhibit subcutaneous deposits of pancreatic cancer after intraperitoneal injection.. **2021**, 13, 13524-13539

666 Real-world outcomes of adjuvant gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma.. **2022**, 14, 17588359221097190

665 Research Progress of Collagen in Pancreatic Cancer. **2022**, 12, 3641-3647

664 Factors influencing mortality trends of pancreatic cancer in Spain, 1955-2020.. **2022**,

663 Transabdominal Ultrasound of Pancreatic Ductal Adenocarcinoma: A Multi-Centered Population-Based Study in Sensitivity, Associated Diagnostic Intervals and Survival. **2022**,

662 Pancreatic cancer - the past, the present, and the future.. **2022**, 1-9 2

661	ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer.. 2022,	0
660	Identification of an autophagy-related gene signature for predicting prognosis and immune activity in pancreatic adenocarcinoma.. 2022, 12, 7006	0
659	Burden of pancreatic cancer along with attributable risk factors in China from 1990 to 2019, and projections until 2030.. 2022,	0
658	Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [F]F-FDG PET/CT in Patients with Liver Malignancies.. 2022, 1	2
657	Statins inhibit inflammatory cytokine production by macrophages and acinar to ductal metaplasia of pancreatic cells. 2022,	
656	Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling.. 2022, e13237	
655	Machine learning in endoscopic ultrasonography and the pancreas: The new frontier?. 2022, 3, 54-65	
654	Intracellular Trafficking and Distribution of Cd and InP Quantum Dots in HeLa and ML-1 Thyroid Cancer Cells.. 2022, 12,	1
653	Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?. 2022, 11,	1
652	Enteroendocrine Cell Formation Is an Early Event in Pancreatic Tumorigenesis.. 2022, 13, 865452	0
651	Hypoxia-induced NFATc3 deSUMOylation enhances pancreatic carcinoma progression.. 2022, 13, 413	0
650	Centralisation of surgery for complex cancer diseases: a scoping review of the evidence base on pancreatic cancer. 2022, 100334	0
649	AQP5 Is a Novel Prognostic Biomarker in Pancreatic Adenocarcinoma. 2022, 12,	1
648	Identification and Validation of Apparent Imbalanced Epi-lncRNAs Prognostic Model Based on Multi-Omics Data in Pancreatic Cancer. 2022, 9,	1
647	Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.. 2022,	3
646	ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer.. 2022,	0
645	ASO Author Reflections: Constructed Scoring System Using TP53 and SMAD4 Mutations Combined with Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma.. 2022,	
644	On optimal biomarker cutoffs accounting for misclassification costs in diagnostic trilemmas with applications to pancreatic cancer.. 2022,	

643	Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer.. 2022 ,	10
642	Epithelial and Mesenchymal Features of Pancreatic Ductal Adenocarcinoma Cell Lines in Two- and Three-Dimensional Cultures. 2022 , 12, 746	0
641	Current Pathology Model of Pancreatic Cancer.. 2022 , 14,	1
640	SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine.. 2022 , 39, 110813	1
639	A Path Forward for Understanding and Addressing Multifaceted Pancreatic Cancer Disparities.. 2022 ,	
638	Focal Liver Lesion MRI Feature Identification Using Efficientnet and MONAI: A Feasibility Study.. 2022 , 11,	0
637	Nuclear GSK-3 β and Oncogenic KRas Lead to the Retention of Pancreatic Ductal Progenitor Cells Phenotypically Similar to Those Seen in IPMN. 2022 , 10,	0
636	Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.. 2022 , 11, 2066767	3
635	Radiofrequency Ablation for Thyroid Papillary Microcarcinoma. 2022 , 34, 216-218	
634	Insulin receptors in pancreatic acinar cells contribute to KrasG12D-driven cancer initiation in the context of diet-induced obesity.	
633	Modeling of cancer-related body-wide effects identifies LTB4 as a diagnostic biomarker for pancreatic cancer.. 2022 , 80, 104050	2
632	Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study.. 2022 , 169, 20-31	1
631	Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells.. 2022 , 53, 102324	2
630	SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer.. 2022 , 215693	1
629	Functional mechanism and clinical implications of miR-141 in human cancers.. 2022 , 110354	0
628	Varied effect of fortification of kale sprouts with novel organic selenium compounds on the synthesis of sulphur and phenolic compounds in relation to cytotoxic, antioxidant and anti-inflammatory activity. 2022 , 179, 107509	1
627	Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. 2022 , 14, 2429	1
626	Annotation and functional characterization of long noncoding RNAs deregulated in pancreatic adenocarcinoma.. 2022 , 1	

625	ITGBL1 transcriptionally inhibited by JDP2 promotes the development of pancreatic cancer through the TGF-beta/Smad pathway.. 2022 , 55, e11989	
624	The Role of Feedback Loops in Targeted Therapy for Pancreatic Cancer. 2022 , 12,	0
623	Dynamic Interplay between Structural Variations and 3D Genome Organization in Pancreatic Cancer.. 2022 , e2200818	0
622	Long-term outcomes of endoscopic double stenting using an anti-reflux metal stent for combined malignant biliary and duodenal obstruction.. 2022 ,	2
621	Photoimmunotherapy Retains Its Anti-Tumor Efficacy with Increasing Stromal Content in Heterotypic Pancreatic Cancer Spheroids.. 2022 ,	0
620	Transcriptional ITPR3 as potential targets and biomarkers for human pancreatic cancer.. 2022 , 14,	
619	Co-Variation of Serum Osteoprotegerin and Pigment-Epithelial Derived Factor as Biomarker of Pancreatic Cancer.. 2022 , 9,	
618	Neoadjuvant treatment in localized and resectable cancer of the pancreas: a new therapeutic paradigm. 2022 ,	
617	An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer. 2022 , 12,	0
616	Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy.	1
615	Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer. 2022 , 104095	0
614	Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. 2022 , 12,	
613	Sparstolonin B inhibits pancreatic adenocarcinoma through the NF- κ B signaling pathway. 2022 , 417, 113214	0
612	Remnant Pancreatic Cancer After Surgical Resection for Pancreatic Cancer. 2022 , 401-406	
611	Chemotherapy in Pancreatic Ductal Adenocarcinoma. 2022 , 171-176	
610	Activated Stromal Cells in the Development of Pancreatic Ductal Adenocarcinoma and Therapeutic Approaches to Stroma Remodeling. 2022 , 16, 193-202	
609	The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways. 2022 , 14, 2619	0
608	From prehab to rehab: nutritional support for people undergoing pancreatic cancer surgery.	1

607	Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. 2022 , 14, 2486	3
606	The Limits of Molecular Signatures for Pancreatic Ductal Adenocarcinoma Subtyping.	
605	Pancreatic Ductal Adenocarcinoma: Current and Emerging Therapeutic Uses of Focused Ultrasound. 2022 , 14, 2577	2
604	The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer. 12,	0
603	Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. 2022 , 14, 2588	0
602	Designing optimal allocations for cancer screening using queuing network models. 2022 , 18, e1010179	
601	The heterogeneous distribution of extracellular adenosine reveals a myeloid-dependent axis, shaping the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.	
600	Translation of a Protease Turnover Assay for Clinical Discrimination of Mucinous Pancreatic Cysts. 2022 , 12, 1343	
599	The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer.	0
598	FL118, acting as a ß-molecular glue degrader, binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy. 2022 , 12,	3
597	Pyroptosis-related genes regulate proliferation and invasion of pancreatic cancer and serve as the prognostic signature for modeling patient survival. 2022 , 13,	0
596	The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. 2022 ,	
595	The Pyroptosis-Related Gene Prognostic Index Associated with Tumor Immune Infiltration for Pancreatic Cancer. 2022 , 23, 6178	0
594	Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy. 12,	0
593	Development of a Prognostic Model Based on Pyroptosis-Related Genes in Pancreatic Adenocarcinoma. 2022 , 2022, 1-28	0
592	Integrated Analysis of Glutathione Metabolic Pathway in Pancreatic Cancer. 2022 , 10,	
591	Prognostic Factors in Resected Pancreatic Ductal Adenocarcinoma: Is Neutrophil-Lymphocyte Ratio a Useful Marker?.	
590	Diagnostic Significance of FNAB miRNA Expression in Papillary Thyroid Carcinoma. 2022 , 12, 1384	

589	A novel tool for predicting the risk of central lymph node metastasis in patients with papillary thyroid microcarcinoma: a retrospective cohort study. 2022 , 22,	0
588	Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer. 2022 , 114504	1
587	The Role of Thyroglobulin in Preoperative and Postoperative Evaluation of Patients With Differentiated Thyroid Cancer. 2022 , 13,	0
586	Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.	5
585	Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review. 2022 , 12, 48-55	
584	A multi-omics approach identifies pancreatic cancer cell extracellular vesicles as mediators of the unfolded protein response in normal pancreatic epithelial cells. 2022 , 11,	0
583	Gene Coexpression Network Characterizing Microenvironmental Heterogeneity and Intercellular Communication in Pancreatic Ductal Adenocarcinoma: Implications of Prognostic Significance and Therapeutic Target. 12,	
582	Diagnosis and Management of Pancreatic Neuroendocrine Tumors and Other Rare Pancreatic Neoplasms. 2021 , 1-27	
581	The Role of Surgery in Managing Primary and Metastatic Hepatopancreaticobiliary Cancers. 2022 , 431-443	
580	Involvement of Epigenomic Factors in Bile Duct Cancer. 2022 , 42, 202-211	
579	Cancer-Associated Fibroblasts Confer Gemcitabine Resistance to Pancreatic Cancer Cells through PTEN-Targeting miRNAs in Exosomes. 2022 , 14, 2812	3
578	Organoide als Meilenstein auf dem Weg zur personalisierten Therapie des Urothelkarzinoms: ein systematischer Review.	
577	Pancreatic cancer cells spectral library by DIA-MS and the phenotype analysis of gemcitabine sensitivity. 2022 , 9,	0
576	Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. 12,	1
575	Gallstones and risk of cancers of the liver, biliary tract and pancreas: a prospective study within two U.S. cohorts.	
574	The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318. Publish Ahead of Print,	0
573	Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 2022 ,	5
572	The Crosstalk Between Immune Infiltration, Circulating Tumor Cells, and Metastasis in Pancreatic Cancer: Identification of HMGB3 From a Multiple Omics Analysis. 13,	0

- 571 ABCA12 Promotes Proliferation and Migration and Inhibits Apoptosis of Pancreatic Cancer Cells Through the AKT Signaling Pathway. 13,
- 570 The Controversial Role of Vitamin D in Thyroid Cancer Prevention. **2022**, 14, 2593 1
- 569 The Role of Type 2 Diabetes in Pancreatic Cancer. **2022**,
- 568 Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease. **2022**, 12, 0
- 567 A single-cell atlas of tumor-infiltrating immune cells in pancreatic ductal adenocarcinoma. **2022**, 100258
- 566 Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review). **2022**, 61, 2
- 565 The Role of Diabetes Mellitus in the Malignant Pancreatic Cyst Neoplasm Diagnosis and Prognosis. Volume 14, 2091-2104
- 564 Eriodictyol induces apoptosis via regulating phosphorylation of JNK, ERK, and FAK/AKT in pancreatic cancer cells. **2022**, 65, 83-88 0
- 563 Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN- γ , TNF- α and PD-1/PD-L1 in comparison to established serum tumor markers. 0
- 562 Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer. 12,
- 561 It may not all be overdiagnosis: the potential role of environmental exposures in the thyroid cancer incidence increase. Publish Ahead of Print, 0
- 560 Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors. 12, 0
- 559 Emerging Role of CREB in Epithelial to Mesenchymal Plasticity of Pancreatic Cancer. 12, 0
- 558 Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival. **2022**, 13, 828-841 0
- 557 SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment. 12, 0
- 556 High Levels of DEAH-Box Helicases Relate to Poor Prognosis and Reduction of DHX9 Improves Radiosensitivity of Hepatocellular Carcinoma. 12, 0
- 555 Gene Differential Expression and Interaction Networks Illustrate the Biomarkers and Molecular Biological Mechanisms of Unsaponifiable Matter in Kanglaite Injection for Pancreatic Ductal Adenocarcinoma. **2022**, 2022, 1-19 0
- 554 The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment. 12, 0

- 553 Tumor suppressor microRNAs in gastrointestinal cancers: A mini-review. **2022**, 16, ○
- 552 Simultaneous Gemcitabine and Percutaneous CT-Guided Irreversible Electroporation for Locally Advanced Pancreatic Cancer. **2022**, 2022, 1-12 1
- 551 Endoscopic ultrasound as a reliable tool for assessment of pancreatic adenocarcinoma treatment: Example of in situ gene therapy. **2022**, 10, E910-E916
- 550 Thiosemicarbazones reprogram pancreatic cancer bidirectional oncogenic signaling between cancer cells and stellate cells to suppress desmoplasia. **2022**, 14, 1005-1017 ○
- 549 Pancreatic fistula and biliary fistula after laparoscopic pancreatoduodenectomy: 500 patients at a single institution. **2022**, ○
- 548 Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea. **2022**, 37, ○
- 547 Effects of Neoadjuvant Therapy on Pancreatic Ductal Adenocarcinoma Staging, Regression Scoring, and Patient Outcome: A Multi-Institutional Study.
- 546 Correlations of demographical and clinicopathological features with patient outcome of pancreatic ductal adenocarcinoma: A retrospective study (2010-2018) from a Libyan Cohort. **2022**,
- 545 Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. **2022**, 235, 342-349 ○
- 544 The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer. **2022**, 23, 7066 ○
- 543 Precision Approaches to Pancreatic Cancer Therapy: What Now and What Next?.
- 542 Hepatocellular Carcinoma.
- 541 Early enteral vs. oral nutrition after Whipple procedure: Study protocol for a multicentric randomized controlled trial (NUTRIWHI trial). 12, ○
- 540 Biomarkers for the Early Detection of Pancreatic Ductal Adenocarcinoma.
- 539 Descriptive, analytical and molecular epidemiology of pancreatic cancer. **2022**, 21, 90-103
- 538 Research advances of N6 -methyladenosine in diagnosis and therapy of pancreatic cancer. 2
- 537 Impact of Insurer on Papillary Thyroid Carcinoma Outcomes, Stage, and Treatment Modalities. 000348942211112
- 536 Identification of a costimulatory molecule-based signature to predict prognostic risk of pancreatic adenocarcinoma. **2022**, 15, 808-819

535	IFNA pathway drives the more aggressive phenotype of KRASG12D-mutant pancreatic ductal adenocarcinomas via IFNAR1/STAT3 activation.	
534	Multiple roles for cholinergic signaling in pancreatic diseases. 2022 , 28, 2910-2919	
533	Immunomodulatory antitumor effect of interferon-beta combined with gemcitabine in pancreatic cancer. 2022 , 61,	1
532	Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot.	3
531	Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients with Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase I Trial and Imaging-based Biomarker Validation. 2022 ,	1
530	Facts and Hopes in Immunotherapy of Pancreatic Cancer. OF1-OF12	3
529	Surgeon Thyroidectomy Case Volume Impacts Disease-free Survival in the Management of Thyroid Cancer.	
528	IGF1 receptor-targeted black TiO ₂ nanoprobe for MRI-guided synergetic photothermal-chemotherapy in drug resistant pancreatic tumor. 2022 , 20,	0
527	Diagnostic and Prognostic Roles of Thrombospondin-2 in Digestive System Cancers. 2022 , 2022, 1-10	
526	Pancreatic Cancer and the Obesity Epidemic: A Narrative Review. 2022 ,	0
525	A Genome-First Approach to Estimate Prevalence of Germline Pathogenic Variants and Risk of Pancreatic Cancer in Select Cancer Susceptibility Genes. 2022 , 14, 3257	0
524	Multimodal Therapies Against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches Towards Ultimate Nanomedicine Treatments. 2200079	2
523	The Value of Circulating Tumor Cells in the Prognosis and Treatment of Pancreatic Cancer. 12,	1
522	MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer.	1
521	Periplocin Induces Apoptosis of Pancreatic Cancer Cells through Autophagy via the AMPK/mTOR Pathway. 2022 , 2022, 1-13	
520	LncRNAs as epigenetic regulators of epithelial to mesenchymal transition in pancreatic cancer. 2022 , 13,	0
519	The combination of radiation therapy and complement C3a inhibition potentiate natural killer cell functions against pancreatic cancer.	
518	International cross sectional survey on ERCP training by the World Endoscopy Organisation.	

517	An exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: A multicenter cohort study. 2022 ,	2
516	Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma. 2022 , 14, 3494	1
515	GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer. 10, e12728	0
514	Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies. 2022 , 43, 101803	1
513	The mechanism and progress of ferroptosis in pancreatic cancer. 2022 , 124, 151919	1
512	Detection of actionable mutations in cytological specimens obtained by endoscopic ultrasound-guided fine needle aspiration with rapid onsite evaluation in pancreatic cancer. 2022 , 60, 152008	0
511	Inferior Survival Is Associated With Socioeconomic Deprivation in Hepatocellular Carcinoma. 2022 , 279, 228-239	0
510	The MD Anderson Cancer Center Moon Shots Program : A Global Priority. 2023 , 619-628	
509	Novel Gemcitabine-Re(I) Bisquinoliny Complex Combinations and Formulations With Liquid Crystalline Nanoparticles for Pancreatic Cancer Photodynamic Therapy. 13,	
508	Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma. 13,	
507	Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. 2022 , 2022, 1-10	
506	microRNA-497 prevents pancreatic cancer stem cell gemcitabine resistance, migration, and invasion by directly targeting nuclear factor kappa B 1.	1
505	Neoadjuvant chemo(radio)therapy in upfront resectable pancreatic cancer <u>Can we stratify patients better in the future?</u> . 1-2	
504	Standardization of MRI Screening and Reporting in Individuals With Elevated Risk of Pancreatic Ductal Adenocarcinoma: Consensus Statement of the PRECEDE Consortium.	1
503	Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection. 12,	
502	The Orexin receptors: Structural and anti-tumoral properties. 13,	0
501	Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry. 2022 , 10, e004638	0
500	Conditioned media of pancreatic cancer cells and pancreatic stellate cells induce myeloid-derived suppressor cells differentiation and lymphocytes suppression. 2022 , 12,	

- 499 Apigenin Targets MicroRNA-155, Enhances SHIP-1 Expression, and Augments Anti-Tumor Responses in Pancreatic Cancer. **2022**, 14, 3613 ○
- 498 Systematic Identification of the RNA-Binding Protein STAU2 as a Key Regulator of Pancreatic Adenocarcinoma. **2022**, 14, 3629 ○
- 497 Low-dose carbon monoxide suppresses metastatic progression of disseminated cancer cells. **2022**, 215831 ○
- 496 Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. **2022**, 28, 3637-3643 1
- 495 Trends in pancreatic cancer incidence, characteristics, and outcomes in Denmark 1980-2019: A nationwide cohort study. **2022**, 80, 102230
- 494 Genomic profiling amplifies the utility of endoscopic ultrasound-guided fine needle biopsy by identifying clinically applicable druggable mutations in pancreatic cancer. **2022**, 60, 152016 ○
- 493 Identification of hepatocellular carcinoma and paracancerous tissue based on the peak area in FTIR microspectroscopy. **2022**, 14, 3115-3124 ○
- 492 The molecular landscape of pancreatic ductal adenocarcinoma. **2022**, ○
- 491 Matairesinol Induces Mitochondrial Dysfunction and Exerts Synergistic Anticancer Effects with 5-Fluorouracil in Pancreatic Cancer Cells. **2022**, 20, 473 2
- 490 Delayed Gastric Emptying Does Not Influence Cancer-Specific Survival after Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. **2022**, 11, 4200
- 489 Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. **2022**, 12, 139-150
- 488 A genetic programming-based approach for classifying pancreatic adenocarcinoma: the SICED experience.
- 487 Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors. ○
- 486 An immune-related gene prognostic risk index for pancreatic adenocarcinoma. 13,
- 485 Histone Deacetylase Inhibitors Restore Cancer Cell Sensitivity towards T Lymphocytes Mediated Cytotoxicity in Pancreatic Cancer. **2022**, 14, 3709 ○
- 484 Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting. ○
- 483 Nardilysin-Regulated Scission Mechanism Activates Polo-like Kinase 3 to Suppress the Development of Pancreatic Cancer.
- 482 Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma.

- 481 Mechanistic and functional extrapolation of SET and MYND domain-containing protein 2 to pancreatic cancer. **2022**, 28, 3753-3766
- 480 Artificial intelligence for the detection of pancreatic lesions. 0
- 479 Research trends of artificial intelligence in pancreatic cancer: a bibliometric analysis. 12, 0
- 478 Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy. 0
- 477 The role, mechanism, and application of RNA methyltransferase METTL14 in gastrointestinal cancer. **2022**, 21, 1
- 476 Analysis of genomic alterations in cancer associated human pancreatic stellate cells. **2022**, 12,
- 475 Human microbiota colonization and pancreatic ductal carcinoma. 1-14
- 474 Neighborhood-Level Factors Contribute to Disparities in Hepatocellular Carcinoma Incidence in Texas. **2022**, 0
- 473 Geographic variation in attitudes regarding management of locally advanced pancreatic cancer. **2022**,
- 472 Identification of Candidate Therapeutic Target Genes and Profiling of Tumor-Infiltrating Immune Cells in Pancreatic Cancer via Integrated Transcriptomic Analysis. **2022**, 2022, 1-14
- 471 DNA Polymerase Theta Plays a Critical Role in Pancreatic Cancer Development and Metastasis. **2022**, 14, 4077 1
- 470 Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice—fifteen-year journey at a tertiary referral centre.
- 469 Utilization of Natural Language Processing Software to Identify Worrisome Pancreatic Lesions. 0
- 468 ASO Author Reflections: Natural Language Processing Aids in the Detection of Incidental Pancreatic Lesions in Cross-Sectional Imaging.
- 467 A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets. 1
- 466 Preoperative Risk Score for Early Mortality After Up-Front Pancreatic Cancer Surgery: A Nationwide Cohort Study.
- 465 Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in pancreatic cancer. **2022**, 22, 0
- 464 Targeted next generation sequencing of endoscopic ultrasound-guided through-the-needle-biopsies from pancreatic cystic lesions.. **2022**, 1

- 463 Carcinoma of unknown primary: Molecular tumor board-based therapy.
- 462 Clinical and Biological Activity of Chemo-immunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.
- 461 Current Screening Strategies for Pancreatic Cancer. **2022**, 10, 2056 0
- 460 Drug-loaded PCL electrospun nanofibers as anti-pancreatic cancer drug delivery systems. 2
- 459 Early diagnosis of pancreatic cancer: What strategies to avoid a foretold catastrophe. **2022**, 28, 4235-4248 2
- 458 Racial disparities in liver cancer: Evidence for a role of environmental contaminants and the epigenome. 12,
- 457 Construction of a Pyroptosis-Related Genes Signature to Improve the Prognostic Prediction and Therapeutic Drugs Selection in Patients with Pancreatic Cancer. Volume 15, 6387-6403 0
- 456 CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness. **2022**, 15, 4
- 455 BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer. 0
- 454 Clinical Outcome and Prognostic Factors of Pancreatic Adenosquamous Carcinoma Compared to Ductal Adenocarcinoma Results from the German Cancer Registry Group. **2022**, 14, 3946 0
- 453 Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. **2022**, 20, 887-897.e3 0
- 452 Estimation of porcine pancreas optical properties in the 600–1000 nm wavelength range for light-based therapies. **2022**, 12, 0
- 451 Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer. **2022**, 22,
- 450 RNA Modifications in Gastrointestinal Cancer: Current Status and Future Perspectives. **2022**, 10, 1918 0
- 449 An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer. 10,
- 448 Nicotinamide N-Methyltransferase as Promising Tool for Management of Gastrointestinal Neoplasms. **2022**, 12, 1173 2
- 447 Total laparoscopic pancreaticoduodenectomy with left posterior superior mesenteric artery first-approach and plexus-preserving circumferential lymphadenectomy: step-by-step technique with a surgical case report (with video). **2022**, 20,
- 446 Insight of pancreatic cancer: recommendations for improving its therapeutic efficacy - a narrative review. Publish Ahead of Print,

- 445 Drug-induced tumor-specific cytotoxicity in a whole tissue 'ex vivo' model of human pancreatic ductal adenocarcinoma. 12, 1
- 444 Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer. 12, 0
- 443 Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy?. 2022,
- 442 Abdominal obesity, rather than overall obesity, is a causal risk factor for pancreatic cancer.
- 441 Variation of Hepatocellular Carcinoma Treatment Patterns and Survival Across Geographic Regions in a Veteran Population. 0
- 440 A novel signature to predict thyroid cancer prognosis and immune landscape using immune-related LncRNA pairs. 2022, 15, 1
- 439 The Histopathology of Neoadjuvant-Treated (NAT) Pancreatic Ductal Adenocarcinoma. 2022,
- 438 Pancreatic cancer among solid organ transplant recipients in the United States.
- 437 Investigation and experimental validation of curcumin-related mechanisms against hepatocellular carcinoma based on network pharmacology. 2022, 23, 682-698 2
- 436 Single Cell Analysis of Cultivated Fibroblasts from Chronic Pancreatitis and Pancreatic Cancer Patients. 2022, 11, 2583 0
- 435 Normalization of the Tumor Marker and a Clear Resection Margin Affect Progression-Free Survival of Patients with Unresectable Pancreatic Cancer who have Undergone Conversion Surgery.
- 434 Exhaled breath condensate proteomic signatures potentially distinguish adenocarcinoma from benign cystic lesions of the pancreas. 2022, 70, 103361
- 433 Has the cancer-related death trend been changing in Turkey? An evaluation of the period between 2009 and 2019. 2022, 80, 102228
- 432 Tailoring radiotherapies and nanotechnology for targeted treatment of solid tumors. 2022, 472, 214757 2
- 431 Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma. 13, 0
- 430 Risk Analysis of Thyroid Cancer in China: A Spatial Analysis. 2022, 2, 577-592 0
- 429 Transcriptionally defined morphological subtypes of pancreatic ductal adenocarcinoma. 0
- 428 Proof of Principle of Combining Fluorescence-Guided Surgery with Photoimmunotherapy to Improve the Outcome of Pancreatic Cancer Therapy in an Orthotopic Mouse Model. 0

427	IgG+ Extracellular Vesicles Measure Therapeutic Response in Advanced Pancreatic Cancer. 2022 , 11, 2800	0
426	Lipid metabolism in pancreatic cancer: emerging roles and potential targets.	0
425	Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma Is Associated With Limited Lymph Node Yield but Improved Ratio. 2022 , 280, 543-550	0
424	Multiple cystic sphere formation from PK-8 cells in three-dimensional culture. 2022 , 32, 101339	0
423	The antitumor activity of hPRDX5 against pancreatic cancer and the possible mechanisms. 55,	0
422	Cáncer papilar de tiroides: ¿quánta extensa debe ser la cirugía según la Asociación Americana de Tiroides?. 2022 , 20, 295-301	0
421	Improved Pancreatic Tumor Detection by Utilizing Clinically-Relevant Secondary Features. 2022 , 139-148	0
420	Time interval from last visit to imaging diagnosis influences outcome in pancreatic adenocarcinoma: A regional population-based study on linked medico-administrative and clinical data. 2022 , 14, 175883592211132	0
419	Diagnosis and Management of Pancreatic Neuroendocrine Tumors and Other Rare Pancreatic Neoplasms. 2022 , 597-622	0
418	Intraoperative Radiation Treatment. 2022 , 569-578	0
417	Gastrointestinal Cancers: What Is the Real Board of Microenvironment and the Role of Microbiota-Immunity Axis?. 2022 ,	0
416	Automated biophysical classification of apoptotic pancreatic cancer cell subpopulations by using machine learning approaches with impedance cytometry. 2022 , 22, 3708-3720	2
415	Role of tumor cell sialylation in pancreatic cancer progression. 2022 ,	0
414	Targeting Oxidative Stress Specific NRF2 in Pancreatic Cancer Stem Cells. 2022 , 2021-2041	0
413	Pathogenesis, Epidemiology, and Prognosis of Pancreatic Adenocarcinomas. 2022 , 461-481	0
412	A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma. 2022 , 14, 175883592211195	1
411	Organoids. 2022 , 51, 608-616	0
410	A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence. 2022 , 14, 4128	1

409	ALK signaling drives tumorigenicity and chemoresistance of pancreatic ductal adenocarcinoma cells.	0
408	Laminarin Attenuates ROS-Mediated Cell Migration and Invasiveness through Mitochondrial Dysfunction in Pancreatic Cancer Cells. 2022 , 11, 1714	0
407	Preoperative Multiparametric Quantitative Magnetic Resonance Imaging Correlates with Prognosis and Recurrence Patterns in Pancreatic Ductal Adenocarcinoma. 2022 , 14, 4243	0
406	Lipid droplets are intracellular mechanical stressors that promote hepatocyte dedifferentiation.	0
405	Development and validation of a competing risk model for second primary pancreatic ductal adenocarcinoma: A population-based study. 9,	0
404	Comparing Survival after Resection of Pancreatic Cancer with and without Pancreatic Cysts: Nationwide Registry-Based Study. 2022 , 14, 4228	0
403	Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy. 2022 ,	0
402	Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma. 13,	0
401	Prognostic significance of the systemic immune inflammation index in patients with metastatic and unresectable pancreatic cancer. 9,	0
400	Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives. 2022 , 10, 2091	0
399	A pyroptosis-related gene signature for prognosis and immune microenvironment of pancreatic cancer. 13,	0
398	Functions and clinical applications of exosomes in pancreatic cancer.	0
397	Outcomes of using INTRABEAM mobile intraoperative radiotherapy system to treat locally advanced pancreatic cancer: case series and literature review.	0
396	Combating pancreatic cancer with ovarian cancer cells.	0
395	Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. 2022 , 64, 100864	0
394	Prediagnostic BMI trajectories in relation to pancreatic cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.	0
393	Delivering A Double Whammy: Targeting Stroma to Improve Immunotherapy Outcomes in Pancreatic Ductal Adenocarcinoma. 2022 ,	0
392	Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. 2022 , 12,	1

- 391 YY1 promotes pancreatic cancer cell proliferation by enhancing mitochondrial respiration. **2022**, 22, 0
- 390 A novel genomic instability-derived lncRNA signature to predict prognosis and immune characteristics of pancreatic ductal adenocarcinoma. 13, 0
- 389 Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients. **2022**, 14, 4447 1
- 388 Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer. **2022**, 23, 11521 0
- 387 Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies. **2022**, 27, 6307 0
- 386 Role of genetic testing in hepatic, pancreatic, and biliary cancers. **2022**, 44, 101844 0
- 385 Therapeutic potential of chrysin nanoparticle-mediation inhibition of succinate dehydrogenase and ubiquinone oxidoreductase in pancreatic and lung adenocarcinoma. **2022**, 27, 0
- 384 Prognostic value of glycolysis markers in pancreatic cancer: A systematic review and meta-analysis. 12, 0
- 383 A LETM2-Regulated PI3K-Akt Signaling Axis Reveals a Prognostic and Therapeutic Target in Pancreatic Cancer. **2022**, 14, 4722 0
- 382 Single Cell RNA Sequencing: A New Frontier in Pancreatic Ductal Adenocarcinoma. **2022**, 14, 4589 0
- 381 Supervised Exercise Therapy and Adjuvant Chemotherapy for Pancreatic Cancer: A Prospective, Single-Arm, Phase II Open-Label, Nonrandomized, Historically Controlled Study. Publish Ahead of Print, 0
- 380 Phospholipase A/acyltransferase 4 is a prognostic biomarker and correlated with immune infiltrates in pancreatic cancer. **2022**, 8, e10416 0
- 379 The Interplay Among Pancreatic Cancer, Cachexia, Body Composition, and Diabetes. **2022**, 0
- 378 Understanding the basis of major depressive disorder in oncological patients: Biological links, clinical management, challenges, and lifestyle medicine. 12, 0
- 377 Alginate-Based Nanosystems for Therapeutic Applications. **2022**, 2022, 1-11 0
- 376 Zinc Fingers and Homeoboxes 2 is Required for Diethylnitrosamine-induced Liver Tumor Formation in C57BL/6 Mice. 0
- 375 Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment. **2022**, 14, 4351 1
- 374 Multi-omics data integration for hepatocellular carcinoma subtyping with multi-kernel learning. 13, 0

- 373 FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer. 0
- 372 Serum angiopoietin 2 acts as a diagnostic biomarker for hepatocellular carcinoma: a meta-analysis of diagnostic test accuracy studies.. 0
- 371 Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review. **2022**, 0
- 370 Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers. 0
- 369 Clinical Prediction Models for Pancreatic Cancer in General and At-Risk Populations: A Systematic Review. **2022**, Publish Ahead of Print, 0
- 368 LINC00960 regulates cell proliferation and glycolysis in pancreatic cancer through the miR -326-3p/ TUFT1 / AKT/mTOR axis. 0
- 367 Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer. 13, 0
- 366 Oxidative Stress-Related LncRNAs Serve as a Biomarker of Prognosis for Pancreatic Cancer. 0
- 365 LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β -catenin from degradation. **2022**, 41, 0
- 364 Establishment of a human 3D pancreatic adenocarcinoma model based on a patient-derived extracellular matrix scaffold. **2022**, 1
- 363 On the Core Prescriptions and Their Mechanisms of Traditional Chinese Medicine in Hepatitis B, Liver Cirrhosis, and Liver Cancer Treatment. **2022**, 2022, 1-17 0
- 362 Pancreatic Cancer Detection on CT Scans with Deep Learning: A Nationwide Population-based Study. 1
- 361 Tissue metabolomics identified new biomarkers for the diagnosis and prognosis prediction of pancreatic cancer. 12, 0
- 360 Insilico Validation of Selected Natural Products as Multi-regulator of EZH2-PPAR Therapeutic Targets; A Hallmark for Prospective Restoration of Pancreatic Insulin Production and Cancer dysregulation. 0
- 359 Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma. **2022**, 15, 1199 1
- 358 Mechanisms of PDAC subtype heterogeneity and therapy response. **2022**, 0
- 357 Development of new bioactive molecules to treat breast and lung cancer with natural myricetin and its derivatives: A computational and SAR approach. 12, 2
- 356 The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma. 3

- 355 The FELIX Project: Deep Networks To Detect Pancreatic Neoplasms. ○
- 354 Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer. **2022**, 10, 9703-9713 ○
- 353 High Glucose Promotes Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance and Invasion through Modulating ROS/MMP-3 Signaling Pathway. **2022**, 2022, 1-19 ○
- 352 Global landscape of 2-hydroxyisobutyrylation in human pancreatic cancer. 12, ○
- 351 Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma. 12, 1
- 350 Rucaparib, a PARP inhibitor, enhances rapachone-induced pyroptosis in pancreatic cancer cells. ○
- 349 ITGB5 promotes innate radiation resistance in pancreatic adenocarcinoma by promoting DNA damage repair and the MEK/ERK signaling pathway. 12, ○
- 348 The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers. ○
- 347 Current trends in the diagnosis of pancreatic cancer. **2022**, 68, 363-370 ○
- 346 Zinc fingers and homeoboxes 2 is required for diethylnitrosamine-induced liver tumor formation in C57BL/6 mice. 1
- 345 The prognostic role of fatigue, depression and anxiety on postoperative outcomes after pancreatectomy for pancreatic cancer. A prospective observational study (FAT-PRO study). **2022**, ○
- 344 Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World. ○
- 343 Risk Factors and Genetic Predisposition. **2022**, 23-31 ○
- 342 Molecular Profiling and Precision Medicine for Pancreatic Cancer. **2022**, 255-267 ○
- 341 Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. **2022**, 1-33 ○
- 340 ENST00000438158 aids ultrasound for predicting lymph node metastasis and inhibits migration and invasion of papillary thyroid carcinoma cells. **2022**, ○
- 339 Mutations in lysine methyltransferase 2C and PEG3 are associated with tumor mutation burden, prognosis, and antitumor immunity in pancreatic adenocarcinoma patients. **2022**, 8, 205520762211336 ○
- 338 The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping. **2022**, 4, ○

- 337 Sociocultural influences on dietary behavior and meal timing among Native Hawaiian and Pacific Islander women at risk of endometrial cancer: a qualitative investigation. 0
- 336 Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer: A Critical Review and Practical Consideration. **2022**, 10, 2480 1
- 335 Drain fluid biomarkers for prediction and diagnosis of clinically relevant postoperative pancreatic fistula: A narrative review. 14, 1089-1106 0
- 334 An Exosomal miRNA Biomarker for the Detection of Pancreatic Ductal Adenocarcinoma. **2022**, 12, 831 1
- 333 Matrix mechanics, not hypoxia, modulate quiescin sulphydryl oxidase 1 (QSOX1) in pancreatic tumor cells. 0
- 332 Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. **2022**, 12, 1
- 331 Principles of Surgical Oncology. 1-12 0
- 330 Folate receptor-positive circulating tumor cells predict survival and recurrence patterns in patients undergoing resection for pancreatic cancer. 12, 0
- 329 Projection of Cancer Incidence and Mortality from 2020 to 2035 in the Korean Population Aged 20 Years and Older. 0
- 328 Systemic immune changes accompany combination treatment with immunotoxin LMB -100 and nab-paclitaxel. 0
- 327 Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer. **2022**, 14, 5302 0
- 326 Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. **2022**, 13, 0
- 325 Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project. 0
- 324 Exosomal DNAJB11 promotes the development of pancreatic cancer by modulating the EGFR/MAPK pathway. **2022**, 27, 0
- 323 A Cross-Sectional and Longitudinal Analysis of Pre-Diagnostic Blood Plasma Biomarkers for Early Detection of Pancreatic Cancer. **2022**, 23, 12969 0
- 322 Diet and Nutrition in the Etiology and Prevention of Cancer. 1-24 0
- 321 A novel cuproptosis-related gene signature for the prediction of liver cancer prognosis identified DLAT is a potential therapeutic target. 0
- 320 A New Hope for Liquid Biopsies: Early Detection of Pancreatic Cancer By Means of Protease Activity Detection in Serum Applying a Hierarchical Decision Structure. 0

- 319 Survivin Splice Variant 2¹ Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine. Volume 15, 1147-1160 ○
- 318 The Roles of microRNA miR-185 in Digestive Tract Cancers. **2022**, 8, 67 ○
- 317 Evaluation of the toxicity of *Caralluma europaea* (C.E) extracts and their effects on apoptosis and chemoresistance in pancreatic cancer cells. 1-18 3
- 316 Ultraviolet Light Exposure Decreases Thyroid Cancer Risk: A National Perspective. **2022**, 10, 2452 ○
- 315 Time series models show comparable projection performance with joinpoint regression: A comparison using historical cancer data from World Health Organization. 10, ○
- 314 NDUFA4 promotes cell proliferation by enhancing oxidative phosphorylation in pancreatic adenocarcinoma. ○
- 313 Pyruvate carboxylase promotes malignant transformation of papillary thyroid carcinoma and reduces iodine uptake. **2022**, 8, ○
- 312 In vitro and in silico characteristics of doxorubicin-loaded four polymeric-based polysaccharides-modified super paramagnetic iron oxide nanoparticles for cancer chemotherapy and magnetic resonance imaging. 1-14 ○
- 311 Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals. **2022**, 36, 929-942 ○
- 310 Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer. ○
- 309 Inhibition of Mitochondrial Redox Signaling with MitoQ Prevents Metastasis of Human Pancreatic Cancer in Mice. **2022**, 14, 4918 2
- 308 Neural Component of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. **2022**, 14, 5246 ○
- 307 Modeling Obesity-Driven Pancreatic Carcinogenesis: A Review of Current In Vivo and In Vitro Models of Obesity and Pancreatic Carcinogenesis. **2022**, 11, 3170 ○
- 306 Neoplasms of the Exocrine Pancreas. 1-20 ○
- 305 A novel cuproptosis-related gene signature for the prediction of liver cancer prognosis identified DLAT is a potential therapeutic target. ○
- 304 Nomogram for Predicting Distant Metastasis of Pancreatic Ductal Adenocarcinoma: A SEER-Based Population Study. **2022**, 29, 8146-8159 ○
- 303 Association between patient's age and the utility of prognostic markers after pancreaticoduodenectomy for pancreatic cancer. **2022**, ○
- 302 Cancer-derived small extracellular vesicles: emerging biomarkers and therapies for pancreatic ductal adenocarcinoma diagnosis/prognosis and treatment. **2022**, 20, 2

301	CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients. 2022 , 11, 3340	0
300	Predicting future cancer incidence by age, race, ethnicity, and sex. 2022 ,	0
299	Racial Disparity in Pathologic Response Following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancreatic Consortium.	0
298	Prognostic impact of postoperative infection in patients with pancreatic cancer: A multicenter cohort study. 2022 ,	0
297	Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort. 2022 , 14, 5413	0
296	Pancreatic cancer in a patient with vague abdominal pain. 2022 , 47, 10-12	0
295	FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope?. 2022 , 176, 168-170	0
294	Role of Neoplastic Markers in Pancreatic Adenocarcinoma. 2022 , 11, 6509	0
293	Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma. 1-24	0
292	The microbiota and aging microenvironment in pancreatic cancer: Cell origin and fate. 2022 , 1877, 188826	1
291	The association between diabetes mellitus of different durations and risk of pancreatic cancer: an Australian national data-linkage study in women. 2022 , 81, 102266	0
290	Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer. 2023 , 552, 215976	0
289	Simultaneous quantification of thyroid hormones using an ultrasensitive single-molecule fourplex nanoimmunosensor in an evanescent field. 2023 , 220, 114894	1
288	Outcomes and risks in palliative pancreatic surgery: an analysis of the German StuDoQ Pancreas registry. 2022 , 22,	0
287	Tumor suppressive and immune-stimulating roles of cholesterol 25-hydroxylase in pancreatic cancer cells.	1
286	Laparoscopic electrochemotherapy for the treatment of hepatocellular carcinoma: Technological advancement. 12,	1
285	Radiofrequency ablation remodels the tumor microenvironment and promotes neutrophil-mediated abscopal immunomodulation in pancreatic cancer.	0
284	Consortium bibliometric analysis of hotspots and frontiers of immunotherapy in pancreatic cancer.	0

- 283 The role of preoperative albumin and white blood cell count in surgical site infections following whipple surgery. **2022**, 12, 0
- 282 MS-5, a Naphthalene Derivative, Induces Apoptosis in Human Pancreatic Cancer BxPC-3 Cells by Modulating Reactive Oxygen Species. **2022**, 0
- 281 Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. **2022**, 5, 0
- 280 Identification of MYEOV-Associated Gene Network as a Potential Therapeutic Target in Pancreatic Cancer. **2022**, 14, 5439 0
- 279 Synthesis, biological evaluation and molecular docking of new triphenylamine-linked pyridine, thiazole and pyrazole analogues as anticancer agents. **2022**, 16, 0
- 278 Neoadjuvant therapy impact in early pancreatic cancer: Bioborderline vs. Non-bioborderline **2022**, 0
- 277 The role of LOXL2 induced by glucose metabolism-activated NF- κ B in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant pancreatic cancer. 0
- 276 Molecular subtyping based on TRP family and prognostic assessment for TRP-associated lncRNAs in pancreatic adenocarcinoma. **2022**, 22, 1
- 275 Review of the endocrine organ-like tumor hypothesis of cancer cachexia in pancreatic ductal adenocarcinoma. 12, 0
- 274 Differential roles of extracellular matrix proteins on primary and metastatic pancreatic cancer cells. 0
- 273 Evolution of thyroid cancer biomarkers: from laboratory test to patients' clinical management. **2022**, 1
- 272 Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis. **2022**, 15, 1368 1
- 271 Bioinformatic Analysis of the BCL-xL/BCL2L1 Interactome in Patients with Pancreatic Cancer. **2022**, 58, 1663 0
- 270 Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening. **2022**, 29, 8693-8719 1
- 269 Prognostic Impact of Positive Peritoneal Lavage Cytology on Resectable Pancreatic Body and Tail Cancer: A Retrospective Study. 0
- 268 Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma. **2022**, 11, 3482 1
- 267 Liposomal co-delivery system encapsulating celastrol and paclitaxel displays highly enhanced efficiency and low toxicity against pancreatic cancer. **2022**, 78, 103947 0
- 266 Finite element analysis to predict temperature distribution in the human neck with abnormal thyroid: A proof of concept. **2022**, 227, 107234 1

- 265 Association Between Family History and Risk of Pancreatic Cancer in Patients With BRCA1 and BRCA2 Pathogenic Variants. **2022**, 51, 733-738 ○
- 264 Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library. **2022**, 175395 ○
- 263 The role of TGF- β in the tumor microenvironment of pancreatic cancer. **2022**, ○
- 262 Tissue-Specific Human Extracellular Matrix Scaffolds Promote Pancreatic Tumour Progression and Chemotherapy Resistance. **2022**, 11, 3652 ○
- 261 Prognostic Value of NLR in Patients with Advanced Pancreatic Cancer. **2022**, 12, 10579-10585 ○
- 260 Outcomes of feeding jejunostomy after pancreaticoduodenectomy: A single-center experience. **2022**, 18, 444 ○
- 259 Prolonged complete response after neoadjuvant capecitabine-gemcitabine for a locally advanced pancreatic adenocarcinoma: A case report. **2022**, 25, 1945 ○
- 258 Pancreatic cancers. **2022**, 315-340 ○
- 257 Robust identification of common genomic biomarkers from multiple gene expression profiles for the prognosis, diagnosis, and therapies of pancreatic cancer. **2023**, 152, 106411 1
- 256 Expression of kinesin family member C1 in pancreatic ductal adenocarcinoma affects tumor progression and stemness. **2023**, 241, 154277 ○
- 255 Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/microsatellite instability high (MSI-high) endometrial carcinoma. **2023**, 169, 78-84 ○
- 254 Polymeric micelles assisted combinatorial therapy: Is it new hope for pancreatic cancer?. **2023**, 184, 111784 ○
- 253 mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LSL-KrasG12D/+Pdx-1-Cre murine models. **2023**, 554, 216020 ○
- 252 Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47 β and immune checkpoint inhibitors. **2023**, 28, 31-43 ○
- 251 Are Lymph Node Metastases Associated With Survival in Black Patients With Pancreatic Cancer?. **2023**, 284, 143-150 ○
- 250 Screening for Pancreatic Cancer: Current Status and Future Directions. 59-67 ○
- 249 Ductal Adenocarcinoma and Variants. **2022**, 41-59 ○
- 248 The Tumor Microenvironment in Pancreatic Cancer and Challenges to Immunotherapy. **2022**, ○

- 247 The application of the Glasgow prognostic score to predict the survival in patients with metastatic pancreatic carcinoma. 28, 406-412 ○
- 246 Dysregulation of HNF1B/Clusterin Axis Enhances Disease Progression in a Highly Aggressive Subset of Pancreatic Cancer Patients. ○
- 245 Methylation-sensitive high-resolution melting analysis of the USP44 promoter can detect early-stage hepatocellular carcinoma in blood samples. **2022**, 55, 553-558 ○
- 244 Epithelial and stromal co-evolution and complicity in pancreatic cancer. ○
- 243 Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. 1
- 242 Temporal Association of Total Serum Cholesterol and Pancreatic Cancer Incidence. **2022**, 14, 4938 ○
- 241 A multidomain fusion model of radiomics and deep learning to discriminate between PDAC and AIP based on 18F-FDG PET/CT images. ○
- 240 Circ_0007534 as new emerging target in cancer: Biological functions and molecular interactions. 12, ○
- 239 Targeted Delivery Polymeric Nanosystem Reinforced by Synergism of Embilin and RPI-1 for Therapeutics of Pancreatic Cancer. **2022**, 5, 18622-18636 ○
- 238 Gold Nanoparticles-Mediated Photothermal Therapy of Pancreas Using GATE: A New Simulation Platform. **2022**, 14, 5686 ○
- 237 Pancreatic ductal adenocarcinoma holds unique features to form an immunosuppressive microenvironment: a narrative review. **2022**, 5, 174-185 ○
- 236 Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and immune response in pancreatic cancer. **2022**, 22, ○
- 235 B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy. **2022**, 23, 15005 1
- 234 Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy. ○
- 233 Cancer-testis gene STK31 is regulated by methylation and promotes the development of pancreatic cancer. ○
- 232 Pancreatic Cancer 3D Cell Line Organoids (CLOs) Maintain the Phenotypic Characteristics of Organoids and Accurately Reflect the Cellular Architecture and Heterogeneity In Vivo. **2022**, 1, 168-183 1
- 231 Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. ○
- 230 Cost-Utility Analysis of a Supervised Exercise Intervention for Women with Early-Stage Endometrial Cancer. ○

229	Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy. 2022 , 14, 6179	0
228	Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study. 2023 , 15, 7	2
227	The Significance of Unsampld Microscopic Thyroid Carcinomas in Multinodular Goiter.	0
226	Value of thyroid cancer history in the prognosis of pancreatic cancer: a SEER population-based study.	0
225	The connection between innervation and metabolic rearrangements in pancreatic cancer through serine. 12,	0
224	Stress exacerbates pancreatic cancer both directly and indirectly by creating an immunosuppressive environment.	0
223	PPDPF Promotes the Development of Mutant KRAS-Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1. 2202448	0
222	Sex and gender differences in treatment intention, quality of life and performance status in the first 100 patients with periampullary cancer enrolled in the CHAMP study.	0
221	A Novel PiRNA Enhances CA19-9 Sensitivity for Pancreatic Cancer Identification by Liquid Biopsy. 2022 , 11, 7310	1
220	Increased expression of miR-194-5p through the circPVRL3/miR-194-5p/SOCS2 axis promotes proliferation and metastasis in pancreatic ductal adenocarcinoma by activating the PI3K/AKT signaling pathway. 2022 , 22,	1
219	Hemithyroidectomy in Papillary Thyroid Cancers: A Prospective, Single Institutional Surgical Audit and Contemplating on the Clinical Implications of 2015 American Thyroid Association Guidelines.	0
218	Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144.	0
217	The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. 2022 ,	0
216	Crosstalk between tumor acidosis, p53 and extracellular matrix regulates pancreatic cancer aggressiveness.	0
215	The WID-EC test for the detection and risk prediction of endometrial cancer.	0
214	Liquid biopsy leads to a paradigm shift in the treatment of pancreatic cancer. 28, 6478-6496	1
213	Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).	0
212	JNK inhibitor IX restrains pancreatic cancer through p53 and p21. 12,	0

211	From bench to bedside: Pursuing equity in precision medicine approaches to pancreatic cancer care. 12,	0
210	Association between type 2 diabetes and 5-year overall survival in early-stage pancreatic cancer: a retrospective cohort study. 10, e14538	0
209	Microbiota in the Natural History of Pancreatic Cancer: From Predisposition to Therapy. 2023, 15, 1	0
208	A Tumor Microenvironment Model of Pancreatic Cancer to Elucidate Responses toward Immunotherapy. 2201907	0
207	Adjuvant radiation therapy and health-related quality of life among older women with early-stage endometrial cancer: an analysis using the SEER-MHOS linkage.	0
206	NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer. 2022, 12,	0
205	Computational Exploration of Anti-cancer Potential of Flavonoids against Cyclin-Dependent Kinase 8: An In Silico Molecular Docking and Dynamic Approach.	1
204	Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS [®] and neoadjuvant treatment. 2022,	0
203	Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). 13,	0
202	Pancreatic Adenosquamous Carcinoma: A Rare Pathological Subtype of Pancreatic Cancer. 2022, 11, 7401	1
201	Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. 2022, 8, e12064	0
200	A visualized dynamic prediction model for survival of patients with geriatric thyroid cancer: A population-based study. 13,	0
199	Construction of a metabolism-related gene prognostic model to predict survival of pancreatic cancer patients. 2022, e12378	0
198	Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate.	0
197	Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. 2022, 14, 6223	1
196	Detection of pancreatic cancer with two- and three-dimensional radiomic analysis in a nationwide population-based real-world dataset. 2023, 23,	0
195	Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection. 9,	0
194	Cuproptosis-related lncRNAs signature as biomarker of prognosis and immune infiltration in pancreatic cancer. 14,	0

193	Design and synthesis of novel rigid dibenzo[b,f]azepines through ring closure technique as promising anticancer candidates against leukaemia and acting as selective topoisomerase II inhibitors and DNA intercalators. 2023 , 38,	0
192	Spatial Alignment of Organoids Tracking Subclonal Chemotherapy Resistance in Pancreatic and Ampullary Cancer. 2023 , 10, 91	0
191	Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma. 2023 , 13, 215	1
190	A retrospective preliminary study of intrapancreatic late enhancement as a noteworthy imaging finding in the early stages of pancreatic adenocarcinoma.	0
189	Circulating Monocytes Serve as Novel Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma Patients. 2023 , 15, 363	0
188	A four oxidative stress gene prognostic model and integrated immunity-analysis in pancreatic adenocarcinoma. 12,	0
187	NF- κ B/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer. 2023 , 14,	1
186	Race, Insurance, and Sex-Based Disparities in Access to High-Volume Centers for Pancreatectomy.	0
185	High expression of RNF169 is associated with poor prognosis in pancreatic adenocarcinoma by regulating tumour immune infiltration. 13,	0
184	Diagnostic and Prognostic Role of Extracellular Vesicles in Pancreatic Cancer: Current Evidence and Future Perspectives. 2023 , 24, 885	0
183	Target-Specific Nanoparticle Polyplex Down-Regulates Mutant Kras to Prevent Pancreatic Carcinogenesis and Halt Tumor Progression. 2023 , 24, 752	0
182	A Neural Network Model to Screen Feature Genes for Pancreatic Cancer.	0
181	Exploration of Patient-Derived Pancreatic Ductal Adenocarcinoma Ex Vivo Tissue for Treatment Response. 2023 , 12, 167	0
180	Development and validation of a novel ferroptosis-related lncRNA prognostic signature for pancreatic adenocarcinoma. 2023 , 27,	0
179	Effect of Having Concurrent Mutations on the Degree of Aggressiveness in Patients with Thyroid Cancer Positive for TERT Promoter Mutations. 2023 , 15, 413	0
178	Impact of Medicaid Expansion on Stage at Diagnosis for US Adults with Pancreatic Cancer: a Population-Based Study.	0
177	Transparency of clinical trials in pancreatic cancer: An analysis of availability of trial results from the ClinicalTrials.gov database. 12,	0
176	Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer. 2023 , 22,	0

- 175 Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma. **2023**, 23, ○
- 174 Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer . ○
- 173 Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma. **2023**, 12, 309-319 ○
- 172 Hyperglycemia predicts adverse prognosis in advanced pancreatic cancer patients. ○
- 171 Role of epigenetics in pancreatic ductal adenocarcinoma. ○
- 170 Rational design and development of novel NAE inhibitors for the treatment of pancreatic cancer. ○
- 169 Incidence and risk of pancreatic cancer in patients with chronic pancreatitis: defining the optimal subgroup for surveillance. **2023**, 13, ○
- 168 Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone conversion surgery. **2023**, 23, ○
- 167 Innate immunity in pancreatic cancer: Lineage tracing and function. 13, ○
- 166 Spatial genomics reveals a high number and specific location of B cells in the pancreatic ductal adenocarcinoma microenvironment of long-term survivors. 13, ○
- 165 Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART). **2023**, 30, 107327482211502 1
- 164 Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial. **2023**, 181, 155-165 ○
- 163 Complementary and alternative medicine mention and recommendations in pancreatic cancer clinical practice guidelines: A systematic review and quality assessment. **2023**, 12, 100921 ○
- 162 Obesity is Associated With Increased Risk for Adverse Postoperative Outcomes After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. **2023**, 284, 164-172 ○
- 161 Nanovesicles based drug targeting to control tumor growth and metastasis. **2023**, 7, 100083 ○
- 160 PDGFR α -targeted innovative imaging probe for pancreatic adenocarcinoma detection. **2023**, 255, 124225 ○
- 159 Effect of surgery on the survival of elderly patients with early stage pancreatic cancer: A propensity-matched analysis. **2022**, 3, 169-178 ○
- 158 The Power Setting of Focused Ultrasound for the Palliative Treatment of Advanced Pancreatic Cancer: A Study in an Ex Vivo Bovine Liver. **2023**, 13, 474 ○

157	Krüppel-like Factor 6 Suppresses the Progression of Pancreatic Cancer by Upregulating Activating Transcription Factor 3. 2023 , 12, 200	0
156	Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer.	1
155	Integrative study of mitochondrial dysfunction in skeletal muscle during pancreatic cancer cachexia.	0
154	Socioeconomic and Geographic Disparities in the Referral and Treatment of Pancreatic Cancer at High-Volume Centers.	0
153	Low-Dose Metformin Treatment Reduces In Vitro Growth of the LL/2 Non-small Cell Lung Cancer Cell Line. 2023 , 11, 65	0
152	A population-based study of synchronous distant metastases and prognosis in patients with PDAC at initial diagnosis. 13,	0
151	Identification and Validation of Potentially Clinically Relevant CpG Regions within the Class 2 Tumor Suppressor Gene SFRP1 in Pancreatic Cancer. 2023 , 15, 683	0
150	Chromatin-Accessible miRNA Regulons Driving Thyroid Tumorigenesis and Progression. Publish Ahead of Print,	1
149	MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. 2023 , 220,	0
148	Clinical and Biological Data in Patients with Pancreatic Cancer vs. Chronic Pancreatitis: A Single Center Comparative Analysis. 2023 , 13, 369	0
147	Establishment and validation of a nomogram to predict structural incomplete response in papillary thyroid carcinoma patients: a retrospective study. 2023 , 51, 030006052211498	0
146	Active Surveillance of Differentiated Thyroid Cancer Metastatic Cervical Lymph Nodes: A Retrospective Single-Center Cohort Study.	0
145	Evaluation and prognostic significance of tumor budding in pancreatic ductal adenocarcinomas. 2023 , 66, 38	1
144	Characterization of neuroendocrine regulation- and metabolism-associated molecular features and prognostic indicators with aid to clinical chemotherapy and immunotherapy of patients with pancreatic cancer. 13,	0
143	Identification of therapeutic targets and prognostic biomarkers among CC chemokines in the pancreatic adenocarcinoma microenvironment. 2023 ,	0
142	Bibliometric Analysis of Hotspots and Frontiers of Immunotherapy in Pancreatic Cancer. 2023 , 11, 304	0
141	Cribado de cáncer de páncreas en la práctica clínica: es el momento de la prevención. 2023 , 42, 234	0
140	Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer. 2023 , 15, 738	0

- 139 Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population-Based Study, 2000-2018. **2023**, 15, 870 ○
- 138 The Role of Noncoding RNA Antisense Transcript of the B-Cell Translocation Gene 3 Regulation of BTG3 in Pancreatic Ductal Adenocarcinoma Tumor Progression. **2023**, 98, 100700 ○
- 137 Mitochondrial Metabolism in Pancreatic Ductal Adenocarcinoma: From Mechanism-Based Perspectives to Therapy. **2023**, 15, 1070 ○
- 136 Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma. **2023**, 28, 1506 ○
- 135 Paraneoplastic Aquagenic Pruritus: A Case of Pancreatic Cancer. **2023**, ○
- 134 Dietary Factors and Pancreatic Cancer Risk: An Umbrella Review of Meta-Analyses of Prospective Observational Studies. **2023**, ○
- 133 UCHL3 promotes hepatocellular carcinoma cell migration by de-ubiquitinating and stabilizing Vimentin. **2023**, 13, ○
- 132 Combating pancreatic cancer with ovarian cancer cells. **2023**, 15, 2189-2207 ○
- 131 Construction of a pancreatic cancer prediction model for oxidative stress-related lncRNA. **2023**, 23, ○
- 130 The Impact of Bariatric Surgery on Pancreatic Cancer Risk: a Systematic Review and Meta-Analysis. **2023**, ○
- 129 Pancreatic cancer: Advances and challenges. **2023**, 186, 1729-1754 ○
- 128 Interactions between driver genes shape the signaling pathway landscape and direct hepatocellular carcinoma therapy. **2023**, ○
- 127 Berberine Induces Combined Cell Death in Gastrointestinal Cell Lines. **2023**, 24, 6588 ○
- 126 Development of a novel co-culture system using human pancreatic cancer cells and human iPSC-derived stellate cells to mimic the characteristics of pancreatic ductal adenocarcinoma in vitro. **2023**, 658, 1-9 ○
- 125 Self-nanoemulsifying drug delivery system for pancreatic cancer. **2023**, 190, 111993 ○
- 124 Correlation between hypoxia and HGF/c-MET expression in the management of pancreatic cancer. **2023**, 1878, 188869 ○
- 123 Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. **2023**, 68, 100939 ○
- 122 PTGES Expression Is Associated with Metabolic and Immune Reprogramming in Pancreatic Ductal Adenocarcinoma. **2023**, 24, 7304 ○

- 121 Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113). **2023**, 163, 110834 ○
- 120 Supervised learning on impedance cytometry data for label-free biophysical distinction of pancreatic cancer cells versus their associated fibroblasts under gemcitabine treatment. **2023**, 231, 115262 ○
- 119 Design, synthesis, and in-silico study of chromen-sulfonamide congeners as potent anticancer and antimicrobial agents. **2023**, 1283, 135190 ○
- 118 Familial pancreatic cancer. **2023**, 47, 102079 ○
- 117 Classification of Pancreatic Ductal Adenocarcinoma Using MALDI Mass Spectrometry Imaging Combined with Neural Networks. **2023**, 15, 686 ○
- 116 Tissue clearing and 3D reconstruction of digitized, serially sectioned slides provide novel insights into pancreatic cancer. **2023**, 4, 75-91 1
- 115 Using Google Trends and Wikipedia to Investigate the Global Public Interest in the Pancreatic Cancer Diagnosis of a Celebrity. **2023**, 20, 2106 ○
- 114 Peroxisomal trans-2-enoyl-CoA inhibits proliferation, migration and invasion of hepatocellular carcinoma cells. **2023**, 125, 152002 ○
- 113 CLINICAL VALUE OF GALECTIN-3 IN DIFFERENTIATING PAPILLARY THYROID CANCER FROM NODULAR GOITER. **2022**, 81, 21-26 ○
- 112 A Novel Liver X Receptor Inverse Agonist Impairs Cholesterol and Phospholipid Metabolism and Induces Apoptosis and Necroptosis in Pancreatic Ductal Adenocarcinoma Cells. **2023**, 2, 34-46 ○
- 111 Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. **2023**, 15, 900 ○
- 110 The diagnostic value of add-on thyroid cell block in the evaluation of thyroid lesions. 20, 3 ○
- 109 Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. ○
- 108 A Review on Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) of Pancreatic Lesions. **2023**, 13, 536 1
- 107 Upregulated GPRC5A disrupting the Hippo pathway promotes the proliferation and migration of pancreatic cancer cells via the cAMP-CREB axis. **2023**, 14, ○
- 106 Targeting chemoresistant senescent pancreatic cancer cells improves conventional treatment efficacy. **2023**, 4, ○
- 105 Gemcitabine promotes autophagy and lysosomal function through ERK- and TFEB-dependent mechanisms. **2023**, 9, ○
- 104 Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab. **2023**, 16, e251936 ○

103	Editorial: Surgical Advances in Pancreaticobiliary Diseases. 2023 , 12, 1268	0
102	TRANSCRIPTIONAL PROFILE OF HUMAN PANCREATIC ACINAR DUCTAL METAPLASIA. 2023 ,	0
101	Visualising disease trajectories from population-wide data. 3,	0
100	Genome-Wide Analysis of lncRNA-mRNA Co-Expression Networks in CD133+/CD44+ Stem-like PDAC Cells. 2023 , 15, 1053	0
99	The anticancer, anti-oxidant, and antibacterial activities of chitosan-lecithin-coated parthenolide/tyrosol hybrid nanoparticles. 1-15	1
98	Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise Evidence and Implications. 2023 , 13, 538-551	0
97	The risk of central nodal metastasis based on prognostic factors of the differentiated thyroid carcinoma: a systematic review and meta-analysis study.	0
96	The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralization. 2023 , 12, 14-21	0
95	Comparison of Invasive Pancreatic Ductal Adenocarcinoma versus Intraductal Papillary Mucinous Neoplasm: A National Cancer Database Analysis. 2023 , 15, 1185	0
94	Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response. 2023 , 12, 587	0
93	Disparities in primary pancreatic adenocarcinoma survival by Medicaid-status: A national population-based risk analysis. 2023 ,	0
92	Clinical Outcomes of EUS-Guided Choledochoduodenostomy for Biliary Drainage in Unresectable Pancreatic Cancer: A Case Series. 2023 , 59, 351	0
91	Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. gutjnl-2022-329371	0
90	microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer. 2023 , 15, 1230	1
89	Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma. 13,	0
88	The role of the multidisciplinary tumor board (MDTB) in the assessment of pancreatic cancer diagnosis and resectability: A tertiary referral center experience. 10,	0
87	Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans. 2023 , 115, 164-174	0
86	The Rise of Gastrointestinal Cancers as a Global Phenomenon: Unhealthy Behavior or Progress?. 2023 , 20, 3640	0

- 85 Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. **2023**, 4, ○
- 84 M6A-Related Long Non-Coding RNA Displays Utility in Predicting Prognosis, Portraying the Tumor Immune Microenvironment and Guiding Immunotherapy in Pancreatic Ductal Adenocarcinoma. **2023**, 11, 499 ○
- 83 Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients. **2023**, 18, e0281182 ○
- 82 Wogonin induces ferroptosis in pancreatic cancer cells by inhibiting the Nrf2/GPX4 axis. 14, ○
- 81 The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer [Results from a phase 1 study]. ○
- 80 CEACAM7 expression contributes to early events of pancreatic cancer. **2023**, ○
- 79 Positive Correlation between PMS2 Deficiency and PD-L1 Expression in Pancreatic Cancer. **2023**, 14, 74-90 ○
- 78 Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer. **2023**, 14, ○
- 77 RIOK3 promotes mTORC1 activation by facilitating SLC7A2-mediated arginine uptake in pancreatic ductal adenocarcinoma. ○
- 76 Comprehensive analysis of the prognosis of S100 family members and their relationship with tumor-infiltrating immune cells in human pancreatic adenocarcinoma. **2023**, 102, e32976 ○
- 75 Risks and benefits of pancreaticoduodenectomy in patients aged 80 years and over. **2023**, 408, ○
- 74 Amplification-Free, High-Throughput Nanoplasmonic Quantification of Circulating MicroRNAs in Unprocessed Plasma Microsamples for Earlier Pancreatic Cancer Detection. **2023**, 8, 1085-1100 ○
- 73 Expression and prognostic impact of DNA-PK in human lung cancer. **2023**, 102, e33143 ○
- 72 Association between thyroid cancer and cardiovascular disease: A meta-analysis. 10, ○
- 71 Histone Modifications Represent a Key Epigenetic Feature of Epithelial-to-Mesenchyme Transition in Pancreatic Cancer. **2023**, 24, 4820 ○
- 70 Clinical Features and Prognostic Impact of Pancreatic Ductal Adenocarcinoma without Dilatation of the Main Pancreatic Duct: A Single-Center Retrospective Analysis. **2023**, 13, 963 ○
- 69 The upregulation of keratocan promotes the progression of human pancreatic cancer. ○
- 68 A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer. ○

- 67 BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma. ○
- 66 Pancreatic cancer: a glimmer of hope. **2023**, 14, 5-10 ○
- 65 Lorazepam stimulates IL-6 production and is associated with poor survival outcomes in pancreatic cancer. ○
- 64 A Bitter Taste Receptor as a Novel Molecular Target on Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma. **2023**, 16, 389 ○
- 63 RAD51AP1 as an immune-related prognostic biomarker and therapeutic response predictor in hepatocellular carcinoma. ○
- 62 Necrosis as a strong independent prognostic factor required in the implementation of pathological reporting for pancreatic adenocarcinoma resection specimens. **2023**, 244, 154406 ○
- 61 PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial. **2023**, 4, 100972 ○
- 60 Bioinformatics-based construction of prognosis-related methylation prediction model for pancreatic cancer patients and its application value. 14, ○
- 59 Current Status and Perspective of Diagnosis for Pancreatic Diseases [Significance of Pancreatic Disease Screening. **2022**, 49, 618-626 ○
- 58 Quality of Life in Patients with Pancreatic Cancer [A Literature Review. **2023**, 20, 4895 ○
- 57 Pancreatic Cancer Surveillance in Carriers of a Germline Pathogenic Variant in CDKN2A. **2023**, 15, 1690 ○
- 56 Intra-arterial regional chemotherapy for pancreatic cancer (review). **2023**, 9, 16-25 ○
- 55 Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. **2023**, ○
- 54 Next-Generation Sequencing Analysis of Pancreatic Cancer Using Residual Liquid Cytology Specimens from Endoscopic Ultrasound-Guided Fine-Needle Biopsy: A Prospective Comparative Study with Tissue Specimens. **2023**, 13, 1078 ○
- 53 Targeting Tumor Microenvironment Akt Signaling Represents a Potential Therapeutic Strategy for Aggressive Thyroid Cancer. **2023**, 24, 5471 ○
- 52 Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma. **2023**, 12, 2211 ○
- 51 Co-delivery of gemcitabine and Triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer. **2023**, 636, 122844 ○
- 50 Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing. ○

- 49 Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma. 13,
- 48 Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?. **2023**, 11, 890
- 47 Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies. 13,
- 46 Validation of the Surgical Outcome Risk Tool (SORT) and SORT v2 for Predicting Postoperative Mortality in Patients with Pancreatic Cancer Undergoing Surgery. **2023**, 12, 2327
- 45 Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment.
- 44 The differential effects of sarcopenia and cachexia on overall survival for pancreatic ductal adenocarcinoma patients following pancreatectomy: A retrospective study based on a large population.
- 43 Anatomy-based approach to the thyroid examination. **2023**,
- 42 A Large-Scale Proteomics Resource of Circulating Extracellular Vesicles for Biomarker Discovery in Pancreatic Cancer.
- 41 The application of pancreatic cancer organoids for novel drug discovery. **2023**, 18, 429-444
- 40 The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients. **2023**, 14, 101474
- 39 Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. **2023**, 6, e234254
- 38 Human Microbiome Modulation: A Potential Therapeutic Strategy for Pancreatic Cancer. **2023**, 205-242
- 37 Comprehensive review on endoscopic ultrasound-guided tissue acquisition techniques for solid pancreatic tumor. 29, 1863-1874
- 36 Galectin-9 in Gastroenterological Cancer. **2023**, 24, 6174
- 35 Golgi-apparatus genes related signature for predicting the progression-free interval of patients with papillary thyroid carcinoma. **2023**, 16,
- 34 Anticancer Activity of Novel Difluorinated Curcumin Analog and Its Inclusion Complex with 2-Hydroxypropyl- β -Cyclodextrin against Pancreatic Cancer. **2023**, 24, 6336
- 33 FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer. gutjnl-2022-327927
- 32 Multi-omic characterization reveals a distinct molecular landscape in young-onset pancreatic cancer.

- 31 The role of LOXL2 induced by glucose metabolism-activated NF- κ B in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC. ○
- 30 A multimodal imaging study to highlight elastin-derived peptide pro-tumoral effect in a pancreatic xenograft model. ○
- 29 Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer. **2023**, 11, 1069 ○
- 28 Metabolomics-based discovery of XHP as a CYP3A4 inhibitor against pancreatic cancer. 14, ○
- 27 FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review. ○
- 26 Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report. 13, ○
- 25 Mitoxantrone and Mitoxantrone-Loaded Iron Oxide Nanoparticles Induce Cell Death in Human Pancreatic Ductal Adenocarcinoma Cell Spheroids. **2023**, 16, 2906 ○
- 24 Value of thyroid cancer history in the prognosis of pancreatic cancer: a SEER population-based study. **2023**, 13, ○
- 23 Survival Outcomes and Failure Patterns in Patients with Inoperable Non-Metastatic Pancreatic Cancer Treated with Definitive Radiotherapy. **2023**, 15, 2213 ○
- 22 Recent advances in targeted therapy for pancreatic adenocarcinoma. 15, 571-595 ○
- 21 Sex and gender differences in treatment intention, quality of life and performance status in the first 100 patients with periampullary cancer enrolled in the CHAMP study. **2023**, 23, ○
- 20 A Critical Review on Quercetin Bioflavonoid and its Derivatives: Scope, Synthesis, and Biological Applications with Future Prospects. **2023**, 104881 ○
- 19 Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. ○
- 18 Khasianine Affects the Expression of Sugar-Sensitive Proteins in Pancreatic Cancer Cells, Which Are Altered in Data from the Rat Model and Patients. ○
- 17 Clustering analysis and prognostic model based on PI3K/AKT-related genes in pancreatic cancer. 13, ○
- 16 NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer. ○
- 15 Disruption of desmoplastic stroma overcomes restrictions to T cell extravasation, immune exclusion and immunosuppression in solid tumors. ○
- 14 Preserved correlation matrices pinpoint extracellular matrix organization as a critical factor in pancreatic ductal adenocarcinoma. 12, 418 ○

- 13 Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy. **2023**, ○
- 12 Autophagy supports mitochondrial metabolism through the regulation of iron homeostasis in pancreatic cancer. **2023**, 9, ○
- 11 Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapy. ○
- 10 Advantage of patient-controlled epidural analgesia in patients undergoing laparoscopic surgery for pancreatic cancer: evidence from a retrospective study. ○
- 9 Gastrointestinal pan-cancer landscape of tumor matrix heterogeneity identifies biologically distinct matrix stiffness subtypes predicting prognosis and chemotherapy efficacy. **2023**, ○
- 8 Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. **2022**, 51, 1083-1091 ○
- 7 Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer. 14, ○
- 6 A Self-Assembly Combined Nano-Prodrug to Overcome Gemcitabine Chemo-Resistance of Pancreatic Tumors. ○
- 5 Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions. **2023**, ○
- 4 Should Positive Cytology Revealed by Intraoperative Lavage Preclude Radical Resection in Resectable Pancreatic Cancer?. **2022**, 51, 1263-1276 ○
- 3 Anti-Ro60 Antibodies Utility as a Diagnostic Indicator of Pancreatic Cancer. **2022**, 51, e121-e122 ○
- 2 Effect of Crude Extract of Clove Alcohol on the Biological Behaviour of PANC-1 Cells at 39°C. **2023**, 13, 273-281 ○
- 1 Multidisciplinary care for patients with HCC: a systematic review and meta-analysis. **2023**, 7, ○